document incorporate reference portion definitive proxy statement registrant annual meeting shareholder file day conclusion registrant fiscal year end december securities exchange commission pursuant regulation security exchange act amend incorporate reference iii annual report extent describe thereinbristolmyer squibb company index december item business acquisition divestiture license arrangement product intellectual property product exclusivity research development alliance marketing distribution customer competition pricing price constraint market access government regulation source availability raw material manufacturing quality assurance environmental regulation human capital management resource foreign operation bristol myers squibb website item risk factor item unresolved staff comment item property item legal proceeding item safety disclosure information executive officer item market registrant common stock stockholder matter item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum consolidate statement earning comprehensive lossincome consolidated balance sheet consolidate statement cash flow note financial statement item change disagreement accountant account financial disclosure item control procedure item information iii item director executive officer registrant item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction item auditor fee item exhibit financial statement schedule item summary signature summary abbreviate term exhibit index indicate brand name product trademark own bms specific trademark ownership information include exhibit index end item business general bristolmyers squibb company incorporate law state delaware august bristolmyer company successor new york business start bristolmyer company change bristolmyer squibb company result merger continue operate segment engage discovery development licensing manufacturing marketing distribution sale biopharmaceutical product global basis expect acquisition celgene myokardia position lead biopharmaceutical company expand oncology hematology immunology cardiovascular portfolio nearterm asset additional external partnership refer summary abbreviate term end term document principal strategy combine resource scale capability pharmaceutical company speed focus innovation biotech industry focus biopharmaceutical company discover develop deliver transformational medicine patient face disease area believe opportunity meaningful difference oncology solid tumor hematology immunology cardiovascular neurology priority continue renew diversify portfolio launch new product portfolio advance early mid latestage pipeline execute disciplined business development remain committed reduce debt return capital shareholder discussion strategy initiative refer item management discussion analysis financial condition result operationsstrategy compete worldwide researchbase drug company small research company generic drug manufacturer product sell worldwide primarily wholesaler distributor specialty pharmacy less extent directly retailer hospital clinic government agency manufacture product puerto rico significant manufacturing operation foreign country revenue come product follow therapeutic class hematology oncology cardiovascular immunology percentage revenue significant regioncountry follow year end december dollar millions united states europe rest world othera total revenue revenue include royalty alliancerelate revenue product sell bmss regional commercial organization acquisition divestiture license arrangement acquisition divestiture license arrangement allow focus resource growth opportunity drive great longterm value additional information relate acquisition divestiture license arrangement refer item management discussion analysis financial condition result operationsacquisition divestiture license arrangement item financial statement supplementary datanote acquisition divestiture license arrangement product intellectual property product exclusivity pharmaceutical product include chemicallysynthesize small molecule drug product produce biological process call biologics chimeric antigen receptor car tcell therapie small molecule drug typically administer orally form pill tablet drug delivery mechanism biologic typically administer patient injection intravenous infusion car tcell therapy administer patient intravenous infusion summary significant product include approve indication information alliance arrangement certain product refer alliance item financial statement supplementary datanote alliance revlimid revlimid lenalidomide oral immunomodulatory drug combination dexamethasone indicate treatment patient multiple myeloma revlimid single agent indicate maintenance therapy patient multiple myeloma follow autologous hematopoietic stem cell transplant revlimid receive approval indication hematological malignancy include lymphoma mds eliquis eliquis apixaban oral factor inhibitor indicate reduction risk strokesystemic embolism nvaf treatment dvtpe reduction risk recurrence follow initial therapy opdivo opdivo nivolumab biological product fully human monoclonal antibody bind nkt cell opdivo receive approval anticancer indication include bladder blood colon head neck kidney liver lung melanoma mesothelioma stomach opdivoyervoy regimen approve multiple market treatment nsclc melanoma mesothelioma rcc crc ongoing potentially registrational study opdivo tumor type disease area monotherapy combination yervoy anticancer agent pomalystimnovid pomalystimnovid pomalidomide small molecule administer orally modulate immune system biologically important target pomalystimnovid indicate patient multiple myeloma receive prior therapy include lenalidomide proteasome inhibitor demonstrate disease progression day completion therapy orencia orencia abatacept biological product fusion protein indicate adult patient moderately severely active psa reduce sign symptom certain pediatric patient moderately severely active polyarticular jia treatment agvhd combination calcineurin inhibitor methotrexate sprycel sprycel dasatinib oral inhibitor multiple tyrosine kinase indicate firstline treatment patient philadelphia chromosomepositive cml chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase cml resistance intolerance prior therapy include gleevec imatinib mesylate treatment child adolescent aged year year chronic phase philadelphia chromosomepositive cml yervoy yervoy ipilimumab biological product monoclonal antibody treatment patient unresectable metastatic melanoma abraxane abraxane paclitaxel albuminbound particle injectable suspension solventfree proteinbound chemotherapy product combine paclitaxel albumin proprietary nab technology platform treat breast cancer nsclc pancreatic cancer reblozyl reblozyl luspaterceptaamt biological product erythroid maturation agent indicate treatment anemia adult patient beta thalassemia require regular red blood cell transfusion treatment anemia failing erythropoiesis stimulate agent esa adult patient low intermediaterisk mds ring sideroblast require rbc transfusion empliciti empliciti elotuzumab biological product humanize monoclonal antibody treatment multiple myeloma abecma abecma idecabtagene vicleucel bcell maturation antigendirecte genetically modify autologous car cell therapy indicate treatment adult patient relapse refractory multiple myeloma prior line therapy include immunomodulatory agent proteasome inhibitor anticd monoclonal antibody zeposia zeposia ozanimod oral immunomodulatory drug treat moderately severely active relapse form multiple sclerosis include clinically isolate syndrome relapsingremitte disease active secondary progressive disease adult breyanzi breyanzi lisocabtagene maraleucel cddirecte genetically modify autologous car cell therapy indicate treatment adult patient relapse refractory large bcell lymphoma line systemic therapy include diffuse large bcell lymphoma specify highgrade bcell lymphoma primary mediastinal large bcell lymphoma follicular lymphoma grade inrebic inrebic fedratinib oral kinase inhibitor indicate treatment adult patient intermediate highrisk primary secondary post polycythemia vera postessential thrombocythemia myelofibrosis onureg onureg azacitidine oral hypomethylate agent incorporate dna rna indicate continued treatment adult patient aml achieve complete remission complete remission incomplete blood count recovery follow intensive induction chemotherapy able complete intensive curative therapy license number patent foreign country primarily cover product develop brand name trademark product consider overall protection patent trademark license intellectual property right material value act protect right infringement pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity product market exclusivity generally determine form intellectual property patent right hold innovator company regulatory form exclusivity innovative drug entitle patent key determinant market exclusivity brand pharmaceutical patent provide innovator right exclude practice invention relate medicine patent cover thing active ingredient use drug product pharmaceutical formulation drug delivery mechanism process intermediate useful manufacture product protection individual product extend vary period accordance expiration date patent country protection afford vary country country depend type patent scope coverage availability meaningful legal remedy country market exclusivity influence regulatory data protection exclusivity right develop country provide certain nonpatent incentive development medicine example japan certain country rdp exclusivity right offer incentive research medicine rare disease orphan drug medicine useful treat pediatric patient incentive provide market exclusivity period product expire patent term japan provide regulatory datum protection period time approval new drug regulatory agency rely innovators data approve competitor generic copy certain market patent protection form market exclusivity expire regulatory data protection particular importance regulatory form exclusivity prevent competitor gain regulatory approval prior expiration regulatory data protection exclusivity basis competitor safety efficacy datum drug drug identical market innovator patent right form exclusivity expire generic version medicine approve market substantial rapid decline sale original innovative product discussion impact generic competition business refer competition specific aspect law govern market exclusivity datum regulatory protection pharmaceutical vary country country follow summarize key exclusivity rule market represent significant sale united state key product protect patent vary term depend type patent filing date significant portion product patent life lose time take innovative company develop obtain regulatory approval new drug compensation lose patent term regulatory review period innovator depend number factor apply government restore lose patent term extend expiration date patent maximum term year provide extension cause patent effect year date drug approval company seek market innovative pharmaceutical submit complete set safety efficacy datum fda innovative pharmaceutical chemical product company file nda medicine biological product bla file type application receive certain period regulatory exclusivity nda bla compound designate orphan drug receive seven year exclusivity orphan drug indication period fda generally approve application drug product orphan use company earn month additional exclusivity drug specific clinical study conduct write request fda study use medicine treat pediatric patient submission fda prior loss basic exclusivity type application file affect regulatory datum protection exclusivity right discuss chemical product competitor seek launch generic substitute chemical innovative drug file anda fda anda generic manufacturer need demonstrate bioequivalence generic substitute approve nda drug anda rely safety efficacy datum previously file innovator nda innovator company require list certain patent cover medicine fda commonly know orange book absent successful patent challenge fda approve anda innovators list patent expire innovator market product year generic manufacturer file anda allege patent list orange book innovators nda invalid unenforceable infringe generic product allegation commonly know paragraph certification innovator decide file patent infringement suit generic manufacturer time time anda include paragraph certification file respect certain product evaluate andas casebycase basis warrant file suit generic manufacturer protect patent right medicine approve nda receive type regulatory data protection innovative chemical pharmaceutical product entitle year regulatory data protection fda approve generic substitute innovators patent challenge describe generic manufacturer file anda fourth year fiveyear regulatory datum protection period pharmaceutical drug product contain active ingredient previously approve nda approve example new formulation new route administration drug new indication basis new clinical study receive year regulatory data protection formulation route administration indication biologic product healthcare legislation enact create approval pathway biosimilar version innovative biological product previously exist prior time innovative biologic essentially unlimited regulatory exclusivity new regulatory mechanism fda approve product similar generic copy innovative biologic basis extensive datum require bla innovator market product year manufacturer file application approval biosimilar version innovator product application approval biosimilar version file year approval innovator product qualify innovative biological product receive year regulatory data protection mean fda approve biosimilar version year innovative biological product approve fda law provide mechanism innovator enforce patent protect innovative biological product biosimilar applicant challenge patent patent litigation begin early year innovative biological product approve fda increase likelihood generic biosimilar challenge innovators intellectual property increase risk loss innovator market exclusivity generic company increasingly seek challenge innovator basic patent cover major pharmaceutical product second statutory regulatory provision limit ability innovator company prevent generic biosimilar drug approve launch patent litigation ongoing result development possible predict length market exclusivity particular product certainty base solely expiration relevant patent current form regulatory exclusivity market biologic product include opdivo yervoy orencia reblozyl empliciti european union patent pharmaceutical product generally enforceable extended compensate patent term lose regulatory review process extension grant countrybycountry basis primary route use obtain marketing authorization pharmaceutical product centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum maa ema ema evaluate maa provide recommendation approve deny maa possible new chemical product obtain marketing authorization mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state obtain marketing authorization approval company obtain pricing reimbursement pharmaceutical product typically subject member state law certain country process place simultaneously product market country process complete company market new product pricing reimbursement procedure month year complete product marketing authorization file octobernovember subject regime year innovator receive community authorization medicinal product generic company file maa product health authority maa approved generic company commercialize product year elapse initial marketing authorization grant innovator possible extension year available innovator year marketing authorization obtain additional indication significant clinical benefit comparison exist treatment product file prior octobernovember year period regulatory data protection centralize procedure period year mutual recognition procedure depend member state contrast patent list regulatory authority generic version pharmaceutical product approve data protection expire regardless innovator hold patent cover drug possible innovator seek enforce patent generic competitor market product european patent system opposition procedure generic manufacturer challenge validity patent cover innovator product month grant general law treat chemicallysynthesize drug biologicallyderive drug respect intellectual property datum protection addition relevant legislation annexe relate biologic medicinal product ema issue guideline outline additional information provide biosimilar product know generic biologic order review application marketing approval japan japan medicines new chemical entity generally afford year regulatory data protection approve indication dosage patent pharmaceutical product enforceable generic copy receive regulatory approval regulatory data protection patent expiration patent japan extended compensate patent term lose regulatory review process general japanese law treat chemicallysynthesize biologicallyderive drug respect intellectual property market exclusivity rest world country outside japan wide variety legal system respect intellectual property market exclusivity pharmaceutical develop country utilize system similar develop country adopt patent law andor regulatory exclusivity law develop country formally adopt law order comply wto commitment take step implement law meaningful way enforcement wto action long process government assurance outcome assess likely future market exclusivity innovative drug develop country account formal legal right political factor follow chart show key product year early basic exclusivity loss patent right datum exclusivity currently estimate occur japan estimate minimum market exclusivity date sell pharmaceutical product country datum provide countrybycountry basis individual country revenue significant outside japan generally estimate minimum market exclusivity date table pertain end regulatory datum protection composition matter com patent expiration respective product patent term restoration ptr grant situation datum exclusivity patent protection competitor seek regulatory approval submit clinical study datum obtain marketing approval prior expiration regulatory data protection estimate minimum market exclusivity date product purpose business planning length market exclusivity product impossible predict certainty complex interaction patent regulatory form exclusivity inherent uncertainty patent litigation assurance particular product enjoy market exclusivity period time appear estimate exclusivity limit estimate estimate minimum market exclusivity date euk japan abecma idecabtagene vicleucel abraxane paclitaxela breyanzi lisocabtagene maraleucel eliquis apixabanb empliciti elotuzumab inrebic fedratinibc onureg azacitidine opdivo nivolumab orencia abatacepte pomalystimnovid pomalidomidef reblozyl luspaterceptaamtg revlimid lenalidomideh sprycel dasatinibi yervoy ipilimumab zeposia ozanimodj product footnote information currently market product country region indicate abraxane base settlement reach anticipate generic entry march generics enter market japan estimate minimum market exclusivity date base method use patent eliquis patent list fda orange book composition matter patent claim apixaban specifically expire formulation patent expiring challenge numerous generic company bms partner pfizer settle number generic company settle generic company continue litigate remain generic company remain generic company august district court district delaware decide challenge eliquis patent valid infringe remain generic company remain generic company appeal september court appeal federal circuit uphold decision respect patent term previously execute settlement agreement settle generic company permit date launch settle generic company patent april subject additional challenge sandoz limited sandoz teva pharmaceutical industries ltd teva limited respectively file lawsuit united kingdom france italy netherlands portugal republic ireland sweden seek revocation composition matter patent relate supplementary protection certificate trial schedule begin early refer item financial statement supplementary datanote legal proceeding contingency information inrebic ptr application pende grant estimate patent expiry estimate minimum market exclusivity date base regulatory datum protection exclusivity onureg estimate minimum market exclusivity date base seven year orphan drug exclusivity formulation patent cover onureg expire japan accord healthcare inc challenge formulation patent list fda orange book litigation ongoing formulation patent cover onureg patent pende opposition proceeding epo opposition division recently find formulation patent invalid decision appeal refer item financial statement supplementary datanote legal proceeding contingency information bms aware orencia biosimilar market japan formulation additional patent expire pomalyst currently expect generic entry prior quarter refer item financial statement supplementary datanote legal proceeding contingency information europe estimate minimum market exclusivity date base regulatory datum protection exclusivity japan estimate minimum market exclusivity date base method use patent reblozyl europe estimate minimum market exclusivity date base regulatory datum protection exclusivity ptr application method treatment patent pende grant estimate patent expiry spc application method treatment patent pende grant estimate patent expiry revlimid settlement natco pharma ltd natco partners affiliates natco grant volumelimite license sell generic lenalidomide commence march certain generic company grant volumelimite license sell generic lenalidomide begin confidential date march volumelimite license date provide natco addition natco generic company grant license sell generic lenalidomide volume limitation begin january licenses grant party market generic lenalidomide product prior expiry patent supplementary protection certificate spc right begin january major market european country france germany italy spain spc force begin february refer item financial statement supplementary datanote legal proceeding contingency information sprycel bms enter settlement agreement apotex inc apotex certain generic company patent cover certain polymorphic form dasatinib generic company launch generic dasatinib anda product september early certain circumstance epos opposition division uphold validity patent direct use dasatinib treat cml expire generic enter market indication enter market indication prior japan composition matter patent extend treatment nonimatinib resistant cml patent cover monohydrate form dasatinib expire refer item financial statement supplementary datanote legal proceeding contingency information zeposia ptr application pende grant estimate patent expiry estimate minimum market exclusivity date base regulatory datum protection exclusivity spc application pende grant estimate patent expiry estimate minimum market exclusivity date country base france germany italy spain research development critical longterm competitiveness concentrate effort follow disease area significant unmet medical need oncology include hematology cell therapy include multiple myeloma lymphoma chronic lymphocytic leukemia immunology include relapse multiple sclerosis psoriasis lupus rheumatoid arthritis inflammatory bowel disease cardiovascular include cardiomyopathy heart failure thrombotic disorder fibrotic disease specifically lung ipf liver nash continue analyze selectively pursue promising lead area pipeline include potential medicine modality include small chemically manufacture molecule large protein moleculesalso know biologicsand millamolecule antibody drug conjugate cellular therapy gene therapy addition discover develop new molecular entity look way expand value exist product new indication formulation provide additional benefit patient order new drug reach market industry practice government regulation foreign country provide determination drug effectiveness safety preclinical test control clinical evaluation clinical development potential new drug typically include phase phase phase iii clinical study design specifically support application regulatory approval particular indication assume study successful phase clinical study involve small number healthy volunteer patient suffer indicate disease test safety proper dosing phase clinical study involve large patient population investigate effect efficacy optimal dosage drug candidate phase iii clinical study conduct confirm phase result significantly large patient population long term provide reliable conclusive datum safety efficacy drug candidate regulatory approval typically base result phase iii clinical study times approval grant base datum early study consider registrational study significant program program include investigational compound phase iii development initial indication market product development additional indication formulation substantial component program strategy include expand portfolio market product hematology immunology opdivo combination yervoy agent secondline therapy new indication drug development time consume expensive risky process typically take fourteen year approximately half year spend phase iii latestage development average molecule discover pharmaceutical industry researcher prove medically effective safe approve medicine drug candidate fail stage process latestage product candidate fail receive regulatory approval accord kmr group base industry success rate approximately small molecule enter phase development fail achieve regulatory approval small molecule enter phase development failure rate approximately approximately phase iii later stage small molecule fail achieve approval biologic failure rate approximately phase development approximately phase development approximately phase iii later stage development total expense include cost discovery research preclinical development earlystage latestage clinical development drug formulation post commercialization medical support market product proportionate allocation enterprisewide cost upfront contingent milestone payment license acquire asset expense billion billion billion include license asset acquisition charge approximately billion billion million respectively expense include year expense result celgene acquisition occur november addition billion iprd charge recognize myokardia acquisition manage program product portfolio basis invest resource stage early discovery latestage development continually evaluate portfolio asset ensure appropriate balance earlystage latestage program support future growth company spend latestage development program represent approximately annual expense opdivo individual investigational compound market product represent expense drug discovery development work take place network stateoftheart facility worldwide continue investment exist site expansion manufacturing capability example expand lawrenceville new jersey site open new facility cambridge massachusetts plan addition support continue investment cell therapy portfolio expand manufacturing capability construction new stateoftheart cell therapy manufacturing facility deven massachusetts leiden netherlands supplement internal drug discovery development program acquisition alliance collaborative agreement help bring new molecular agent capability platform pipeline broad earlytomid stage pipeline unique compound clinical development pipeline build couple internal research development program distribute research development model focus identify support development disruptive innovative therapy outside company broad network external partnership management continue emphasize leadership innovation productivity quality strategy success activity list clinical study approve indication market product relate therapeutic area february list compound ultimately market product depend result clinical study competitive landscape potential product market reimbursement decision payer manufacturing process necessary produce potential product commercial scale factor assurance seek regulatory approval compound approval sought obtain assurance compound get approve commercially successful stage development determine intellectual property issue patent protection available investigational compound hematology phase phase phase iii approve indication additional indication additional indication additional indication revlimid opdivo opdivo opdivo multiple myeloma hematologic malignancy nonhodgkin lymphoma diffuse refractory hodgkin lymphoma mantle cell lymphoma breyanzi lisocel large bcell lymphoma empliciti revlimid mds mantle cell lymphoma nonhodgkin lymphoma follicular multiple myeloma multiple myeloma lymphoma abecma idecel pediatric hodgkin lymphoma reblozyl previously treat follicular lymphoma highrisk newlydiagnose multiple esa nave mds relapsedrefractory adult tcell myeloma primary testicular lymphoma anemia leukemialymphoma opdivo empliciti inrebic opdivo ela lop mse adrefractory multiple previously treat ruxolitinib advanced hodgkin lymphoma reblozyl onureg pomalystimnovid investigational compound nontransfusiondependent beta angioimmunoblastic tcell lymphoma multiple myeloma relatlimab thalassemia low risk mds relapsedrefractory multiple myeloma hematologic malignancy onureg abecma idecel aids relate kaposi sarcoma bet inhibitor post hma failure mds relapsedrefractory multiple hivnegative kaposi sarcoma nonhodgkin lymphoma breyanzi myeloma empliciti pomalystimnovid bet inhibitor diffuse large bcell lymphoma breyanzi relapsedrefractory multiple myeloma hematologic malignancy transplant noneligible diffuse large bcell lymphoma empliciti revlimid bcma adc lchronic lymphocytic leukemia transplant eligible relapsedrefractory multiple myeloma relapsedrefractory multiple follicular lymphoma marginal sprycel myeloma zone lymphoma cml bcma tce pediatric bcell acute pediatric lymphoblastic leukemia relapsedrefractory multiple refractory cml myeloma primary cns lymphoma bcma nex high grade bcell lymphoma reblozyl transfusiondependent betathalassemia relapsedrefractory multiple myeloma abecma idecel mds previously treat esa gprcd car highrisk newlydiagnose multiple myeloma inrebic relapsedrefractory multiple myeloma relapsedrefractory multiple myeloma onureg gspt celmod relapsedrefractory multiple postinduction acute myeloid leukemia relapsedrefractory acute myeloid myeloma maintenance leukemia breyanzi antisirp diffuse large bcell lymphoma nonhodgkin lymphoma abecma idecel lsd inhibitor investigational compound relapsedrefractory multiple myeloma relapsedrefractory nonhodgkin lymphoma iberdomide nex relapsedrefractory multiple myeloma relapsedrefractory nonhodgkin lymphoma celmod iberdomide relapsedrefractory multiple myeloma nonhodgkin lymphoma bet inhibitor bms nke hematologic malignancy relapsedrefractory multiple myeloma cdxcd nonhodgkin lymphoma cka celmod hematologic malignancy ror car hematologic malignancie bcma nke relapsedrefractory multiple myeloma oncology phase phase phase iii approve indication additional indication additional indication additional indication opdivo opdivo opdivo opdivo metastatic melanoma solid tumor solid tumor glioblastoma gastric opdivo yervoy crc hcc adjuvant melanoma solid tumor pan tumor tmb high head neck adjuvant bladder pediatric head neck locally advanced adjuvant esophagealgastroesophageal opdivo yervoy esophageal mesothelioma solid tumor highrisk nonmuscle invasive previously treat advanced rcc investigational compound metastatic castrationresistant bladder cancer previously treat gastric cancer japan china motolimod prostate adjuvant gastric previously treat metastatic head neck scchn opdivo cdk inhibitor adjuvant hcc previously treat metastatic melanoma relatlimab neoadjuvant erher breast adjuvant melanoma previously treat metastatic msihigh crc solid tumor opdivo relatlimab adjuvant rcc previously treat metastatic nonsquamous nsclc nit tni igd tam nit probody rdu lao ldt esleukin bia odt ylt vca lhi eta lde ivi tyr mmrt evd ose mot rou elo iau nsclc solid tumor esophageal rcc bet inhibitor gastric previously treat metastatic msihigh crc solid tumor hcc previously treat hcc antisirp investigational compound intermediate hcc opdivo cabozantinib solid tumor antictla crc msihigh metastatic rcc cdxpsca solid tumor adjuvant melanoma yervoy solid tumor antictla probody adjuvant rcc adjuvant melanoma antiil solid tumor nsclc egfr mutant metastatic melanoma solid tumor antitigit unresectable nsclc abraxane lidd tumor til yrs miv aelatlimab rit idn uma ors dol ntu ibo nli les ina asive bladder taa slly ticd rastatic nsclc tgf inhibitor extensive stage sclc cancer nsclc solid tumor bet inhibitor opdivo bempegaldesleukin pancreatic solid tumor melanoma unresectable pancreatic solid tumor farletuzumaberibulin adc adjuvant melanoma anticcr solid tumor muscle invasive bladder cancer solid tumor rhu eous nivolumab rcc oit lid sific solid tumor cap rvoy farletuzumaberibulin adc metastatic rcc solid tumor mage tcebispecific solid tumor investigational compound subcutaneous nivolumab rhuph advanced rcc immunology phase phase phase iii approve indication investigational compound investigational compound additional indication orencia tyk inhibitor branebrutinib zeposia active polyarticular jia autoimmune disease rheumatoid arthritis crohns disease early rheumatoid arthritis tlr inhibitor sjgren disease jia intravenous autoimmune disease systemic lupus erythematosus jia subcutaneous inhibitor atopic dermatitis psoriatic arthritis autoimmune disease deucravacitinib investigational compound auto injector ilcd crohn disease deucravacitinib intravenous autoimmune disease lupus nephritis psoriasis subcutaneous anticd systemic lupus erythematosus psoriatic arthritis acute graft versus host disease autoimmune disease ulcerative colitis cendakimab zeposia afimetoran discoid lupus erythematosus eosinophilic esophagitis relapse multiple sclerosis cutaneous lupus erythematosus iberdomide ulcerative colitis systemic lupus erythematosus cendakimab atopic dermatitis afimetoran systemic lupus erythematosus spr modulator atopic dermatitis inhibitor ankylose spondylitis cardiovascular phase phase phase iii approve indication investigational compound additional indication additional indication eliquis factor xia inhibitor eliquis eliquis stroke prevention atrial fibrillation thrombotic disorder pediatric heart disease vte prevention pediatric venous thromboembolism prevention orthopedic cardiac myosin inhibitor surgery hypertrophic cardiomyopathy venous thromboembolism treatment romk inhibitor heart failure investigational compound mavacamten investigational compound nonobstructive hypertrophic mavacamten cardiomyopathy obstructive hypertrophic heart failure preserve cardiomyopathy ejection fraction obstructive hypertrophic danicamtiv cardiomyopathy septal reduction therapy eligible genetic dilate cardiomyopathy milvexian thrombotic disorder farelaxin heart failure fibrotic disease phase phase investigational compound investigational compound nme hsp fibrosis nonalcoholic steatohepatitis lpa antagonist pulmonary fibrosis neuroscience phase investigational compound faahmgll dual inhibitor neuroscience antitau neuroscience btk inhibitor neuroscience eifb activator neuroscience covid phase phase investigational compound sarscov mab duo covid therapy prevention orencia covid treatment note pipeline exclude clinical collaboration development partnership opdivo yervoy relatlimab ono collaboration ono include early stage compound empliciti abbvie bempegaldesleukin nektar cabozantinib exelixis inc eliquis pfizer factor xia inhibitor janssen pharmaceuticals inc hsp nitto denko corporation cdxpsca gemoab monoclonals gmbh abecma ide cel seventy bio reblozyl merck ahr ikena oncology adc triphase accelerator immune tolerance anokion sarscov mab duo rockefeller university tigit bispecific agenus farletuzumaberibulin adc eisai rhuph halozyme antitau prothena corporation plc eifb activator evotec mage tce bispecific immatic trial explore combination partnerrun study follow potential registrational study readout anticipate opdivoyervoy hematology asset tumor trial time asset disease trial time opdivo yervoy hcc cmdw abecma multiple myeloma karmma chronic lymphocytic opdivo yervoy periadjuvant nsclc cmt transcendcll leukemia breyanzi opdivo yervoy crpc cmdx follicular lymphoma transcendfl opdivo yervoy adj hcc cmdx mds esa nave command reblozyl opdivo adj rcc myelofibrosis independence opdivo periadjuvant mibc opdivo adj nsclc anvil rcc melanoma bempegaldesleukin bladder opdivo nktr neoadj cisineligible bempegaldesleukin mibc immunology cardiovascular asset disease trial time asset disease trial timing moderate severe zeposia yellowstone mavacamten srt valor crohns disease deucravacitinib psa cendakimab eoe ccee alliance enter alliance arrangement party development commercialization specific product drug candidate therapeutic area focus alliance structure codevelopment cocommercialization license joint venture arrangement arrangement include upfront payment option payment develop commercialize specific asset technology payment developmental regulatory salesbase performance milestone royalty cost reimbursement profit sharing equity investment provision alliance arrangement lessen investment risk compound lead revenue generating product reduce profitability market product profit share royalty payment actively pursue arrangement view alliance important complement discovery development commercialization activity alliance arrangement contain customary early termination provision follow material breach bankruptcy product safety concern arrangement typically provide termination bms cause notice require early termination generally range immediately notice day receipt notice termination immediately notice generally available party file voluntary bankruptcy petition material safety issue arise product medical riskbenefit incompatible welfare patient continue develop commercialize product termination notice period generally available involuntary bankruptcy petition file dismiss material breach party occur cure bms terminate cause bms right terminate cause exercisable specify period time elapse alliance agreement sign alliance typically contain provision provide party right terminate alliance typically retain right party product intellectual property alliance terminate loss right product market sell pursuant alliance material result operation loss cash flow cause loss right material financial condition liquidity alliance agreement structure terminate specific date product patent expiration date expiry date profit sharing payment typically expiration date royalty payment typically cease loss market exclusivity include patent expiration refer item financial statement supplementary datanote alliance information significant alliance agreement alliance agreement marketing distribution customer promote appropriate use product directly healthcare professional organization doctor nurse practitioner physician assistant pharmacist technologist hospital pbms mco provide information appropriate use product consumer directtoconsumer print radio television digital advertising promotion addition sponsor general advertising educate public innovative medical research corporate mission discussion regulation promotion marketing pharmaceutical refer government regulation field sale medical organization explain risk benefit approve use product medical professional work gain access product formulary reimbursement plan list recommend approve medicine product include medicare plan provide information clinical profile product marketing sale prescription pharmaceutical limit approve use particular product continue develop scientific datum information potential additional use product provide information scientific exchange scientific congress share information product appropriate way include development publication response unsolicited inquiry doctor medical professional mcos operation include marketing sale organization product marketing organization support sale force responsible sell product market organization focus certain class customer manage care entity certain type marketing tool digital consumer communication sale force focus communicate information new approve product use approve use establish product promotion physician increasingly target physician specialist treat patient need medicine product sell principally wholesaler specialty distributor specialty pharmacy less extent directly distributor retailer hospital clinic government agency revlimid pomalyst distribute united states primarily contract pharmacy lenalidomide rem pomalyst rem program respectively proprietary mandatory riskmanagement distribution program tailor specifically provide safe appropriate distribution use revlimid pomalyst internationally revlimid imnovid distribute mandatory riskmanagement distribution program tailor meet local authority specification provide product safe appropriate distribution use program vary country depend country design riskmanagement program product sell hospital retail pharmacy refer item financial statement supplementary datanote revenue gross revenue large pharmaceutical wholesaler percentage global gross revenue business dsas substantially direct wholesaler distributor customer allow monitor wholesaler distributor inventory level require wholesaler distributor maintain inventory level month demand dsa include large wholesaler expire june subject certain termination provision nonus business significantly direct customer information available direct customer product level inventory correspond movement information reliability thirdparty demand information vary widely limit direct customer sale channel inventory report reliably gather report inventory level customer number country outside contract distributor support certain product service provide distributor vary market include distribution logistic regulatory pharmacovigilance andor sale advertising promotion competition market compete generally broad base highly competitive compete worldwide researchbase drug company small research company limit therapeutic focus generic drug manufacturer important competitive factor include product efficacy safety ease use price demonstrate costeffectiveness marketing effectiveness product label customer service new product process sale product impact new study indicate competitor product safe effective treat disease particular form disease product revenue impact additional labeling requirement relate safety convenience impose product fda similar regulatory agency different country competitor introduce new product process therapeutic cost advantage product subject progressive price reduction decrease volume sale advancement treat cancer therapy continue evolve rapid pace product particularly opdivo operate highly competitive marketplace addition compete market share product approve indication lung cancer melanoma face increase competition exist compete product receive fda approval additional indication new agent receive fda approval enter market furthermore therapy combine different product product exist chemotherapy target therapy treatment investigate potential expand approval anticipate product continue experience intense competition competitive challenge face generic pharmaceutical manufacturer regulatory approval process exempt generic costly timeconsuming clinical study demonstrate safety efficacy allow generic manufacturer rely safety efficacy innovator product result generic pharmaceutical manufacturer typically invest far researchbase pharmaceutical company price product significantly lower brand product accordingly brand product lose market exclusivity normally face intense price competition generic form product expiration loss market exclusivity product lose major portion product revenue short period time expiration exclusivity rate revenue decline product vary country general decline market rapid develop country observe rapid decline number country decline develop country tend rapid develop country rate revenue decline expiration exclusivity historically influence product characteristic example drug large patient population prescribed key primary care physician tend experience rapid decline drug specialized area medicine oncology drug complex manufacture sterile injectable product usually experience slow decline simple manufacture certain country outside patent protection weak nonexistent compete generic version shortly launch innovative product addition generic pharmaceutical company introduce generic product exclusivity expire resolution relate patent litigation information market exclusivity refer product intellectual property product exclusivity believe longterm competitive position depend success discover develop innovative costeffective product serve unmet medical need ability manufacture product efficiently market effectively highly competitive environment pricing price constraint market access medicine price base number factor include value scientific innovation patient society context overall health care spend economic factor impact health care system ability provide appropriate sustainable access necessity sustain investment innovation platform address unmet medical need central price clinical value innovation bring market current landscape alternative treatment option goal ensure appropriate patient access innovation sustain investment creative platform continue explore new pricing approach ensure patient access medicine enhance patient access medicine priority focus offer creative tiere pricing reimbursement support patient assistance program optimize access protect innovation advocate sustainable healthcare policy infrastructure leverage advocacypayer input utilize partnership appropriate improve access care supportive service vulnerable patient partnership demonstration project important factor pricing medicine depend government regulation subject increase international domestic effort government implement strengthen measure regulate pharmaceutical market access product pricing payment require provide discount purchase pharmaceutical product federal state healthcare program federal government official legislator continue face intense pressure public manage perceive high cost pharmaceutical respond pursue legislation rule claim reduce cost drug federal government stakeholder require comply recently enact state law seek additional transparency cost prescription drug monitor effort state seek additional rebate limit state spend drug light budget pressure international federal state legislative regulatory development create new constraint ability set price andor impact market access certain area discussion pricing pressure risk refer iitem risk factorsproduct industry operational risksincreased pricing pressure restriction abroad continue negatively affect revenue profit margin growth consolidation mcos pbm optum uhc cvs health cvs express script esi major factor healthcare marketplace mcos pbms consolidate few large entity enhance purchasing strength importance half population participate version manage care mco include medical insurance company medical plan administrator healthmaintenance organization medicare prescription drug plan alliance hospital physicians physician organization pbms party support formulary management contracting mco successfully compete formulary position mcos pbms demonstrate product offer medical benefit cost advantage compare form care exclusion product formulary lead sharply reduce usage patient population consequently pharmaceutical company compete aggressively product include new product introduce compete product market product later develop competitor possible company compete inclusion base unique feature product great efficacy well patient ease use few effect low overall cost therapy important factor product demonstrate few therapeutic advantage compete inclusion base primarily price generally universally successful major product include mco pbm formulary market outside operate environment governmentmandate costcontainment program market significant portion fund healthcare service determination pricing reimbursement pharmaceutical product subject direct government control point care government significant power large single payer result product face restrict access public private payer subject assessment comparative value effectiveness exist standard care government place restriction physician prescription level patient reimbursement emphasize great use generic drug andor enact acrosstheboard price cut rebate scheme method cost control countries example government regulate price new product launch direct price control international price comparison control profit andor reference pricing markets germany government set pricing restriction launch pricing freedom subsequently limit company face significant delay market access new product year elapse new medicine available patient market additionally member states regularly impose new additional cost containment measure pharmaceutical volume discount cost cap cost sharing increase excess prior year cost individual product aggregate market level spending clawback free product portion expect therapy period existence price differential different national pricing reimbursement law lead potential significant parallel trade flow government regulation pharmaceutical industry subject extensive global regulation regional country state local agency federal food drug cosmetic act federal statute regulation state statute regulation include newly enact state law regulate drug price transparency rebate drug spending law regulation foreign government govern vary degree test approval production labeling distribution postmarket surveillance advertising dissemination information promotion product lengthy process laboratory clinical testing datum analysis manufacture development regulatory review necessary require governmental approval extremely costly significantly delay product introduction give market promotion marketing manufacturing distribution pharmaceutical product extensively regulate major world market addition operation subject complex federal state local foreign environmental occupational safety law regulation anticipate law regulation affect manufacture sale current product introduction new product continue require substantial scientific technical effort time expense significant capital investment fda particular importance jurisdiction virtually activity impose requirement cover testing safety effectiveness manufacturing labeling marketing advertising postmarkete surveillance product case fda requirement increase time money necessary develop new product bring market regulatory review process resource intensive undertake fda pharmaceutical manufacturer improvement efficiency process significant impact bring new therapy patient quickly fda employ tool facilitate development certain drug expedite certain application include fast track designation breakthrough therapy designation priority review accelerate approval incentive orphan drug develop rare disease example recent year fda oncology center excellence oce establish project test novel approach efficient regulatory review oncology drug realtime oncology review pilot program assessment aid assessment aid pilot program fda approve opdivoyervoy give cycle platinumdoublet chemotherapy firstline treatment adult patient metastatic recurrent nsclc egfr anaplastic lymphoma kinase genomic tumor aberration approval achieve month priority review pdufa date august develop framework concurrent review supplemental oncology application multiple approval authority oce initiate project orbis project orbi early approval australian therapeutic good administration tga health canada singapore health sciences authority receive combination opdivoyervoy give cycle platinumdoublet chemotherapy fda mandate drug manufacture package label conformity cgmp establish fda comply cgmp regulation manufacturer continue expend time money effort production recordkeeping quality control ensure product meet applicable specification requirement ensure product safety efficacy fda periodically inspect drug manufacturing facility ensure compliance applicable cgmp requirement failure comply statutory regulatory requirement subject possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse event use product report fda result imposition market restriction label change product removal product approval withdraw compliance regulatory requirement maintain problem concern safety efficacy occur follow approval federal government extensive enforcement power activitie pharmaceutical manufacturer include authority withdraw delay product approval commence action seize prohibit sale unapproved noncomplye product halt manufacture operation compliance cgmp impose seek injunction voluntary recall civil monetary criminal penalty restriction prohibition sale withdrawal approval product market materially adversely affect business financial condition result operation cash flow marketing authorization product subject revocation applicable governmental agency addition modification enhancement approve product change manufacturing location circumstance subject additional fda approval receive subject lengthy application process distribution pharmaceutical product subject pdma federal food drug cosmetic act regulate activity federal state level pdma implement regulation state permit require registration manufacturer distributor provide pharmaceutical manufacturer distributor place business state state permit adopt regulation limit distribution product sample license practitioner pdma impose extensive licensing personnel recordkeeping packaging quantity labeling product handle facility storage security requirement intend prevent sale pharmaceutical product sample product diversion fda amendment act impose additional obligation pharmaceutical company delegate enforcement authority fda area drug safety key element legislation fda authority require company conduct postmarkete safety study drug impose certain safety relate drug labeling change iii mandate risk mitigation measure education healthcare provider restrict distribution medicine require company publicly disclose datum clinical study prereview television advertisement marketing practice pharmaceutical manufacturer subject federal state healthcare law protect integrity government healthcare program office inspector general oig oversee compliance applicable federal law connection payment product government fund program primarily medicaid medicare law include federal antikickback statute criminalize knowingly offer value induce recommendation order purchase product service reimburse government healthcare program oig issue series guidance segment healthcare industry include compliance program guidance pharmaceutical manufacturer include recommendation pharmaceutical manufacturer minimum adhere phrma code voluntary industry code marketing practice subscribe phrma code implement compliance program address requirement set forth guidance compliance healthcare law failure comply healthcare law subject administrative legal proceeding include action federal state government agency action result imposition civil criminal sanction include fine penalty injunctive remedy impact materially adversely affect business financial condition result operation cash flow subject jurisdiction federal state regulatory enforcement department agency federal trade commission department justice department health human service license drug enforcement administration procure produce control substance subject possible administrative legal proceeding action organization action result imposition civil criminal sanction include fine penalty injunctive administrative remedy healthcare industry subject governmentimposed regulation authorize price price control continue impact total revenue participate state government medicaid program certain qualify federal state government program discount rebate provide participate state local government entity participate federal government program specify discount certain federal government entity significant department defense department veterans affair entity receive minimum discount base define nonfederal average manufacturer price purchase result affordable care act reconciliation bill contain package change healthcare bill continue experience additional financial cost certain change business example require provide discount brandname drug patient fall medicare coverage gap refer donut hole pay annual nontaxdeductible fee federal government base allocation market share brand drug sale certain government program include medicare medicaid department veterans affairs department defense tricare annual fee impose pharmaceutical manufacturer billion activity outside subject regulatory requirement govern testing approval safety effectiveness manufacturing labeling marketing product regulatory requirement vary country country fda approval obtain product approval product comparable regulatory authority country outside case obtain prior marketing product country approval process rigorous country country time require approval long shorter require approval country assure product approve country discussion rebate program refer item management discussion analysis financial condition result operation gtn adjustment critical accounting policy source availability raw material general purchase raw material component supply require manufacturing product open market product purchase raw material component supply source source available single source approve source available require obtain raw material supply particular source attempt possible mitigate potential risk associate raw material component supply inventory management alternative source strategy discussion source refer manufacture quality assurance discussion particular product manufacture quality assurance operate manage manufacturing network consist internal external resource manner permit improve efficiency maintain flexibility reallocate manufacturing capacity pharmaceutical manufacturing process complex highly regulate vary widely product product give shift add manufacturing capacity lengthy process require significant capital expenditure regulatory approval manage operate flexible manufacturing network minimize unnecessary product transfer inefficient use manufacturing capacity discussion regulatory impact manufacturing refer government regulation significant biologic cell therapy pharmaceutical manufacturing facility locate puerto rico ireland switzerland require significant ongoing capital investment maintenance compliance increase regulatory requirement example fda approve large scale multi product bulk biologic manufacturing facility deven massachusetts continue capital investment facility addition expect continue modification exist manufacturing network meet complex processing standard require grow portfolio particularly biologic cell therapy biologic manufacturing involve complex process traditional pharmaceutical operation example complete new largescale biologic manufacturing facility cruiserath ireland approve fda december january cell therapy product candidate market product include breyanzi abecma invest manufacturing network include facility bothell washington summit new jersey deven massachusetts thirdparty manufacturer regulatory requirement product involve technically sophisticated manufacturing process require specialized raw material example manufacture clinical commercial use sterile product biologic product car product particularly complex involve highly specialized manufacturing technology result slight deviation point production process lead production failure recall addition manufacture site rely party manufacture supply portion active product ingredient drug substance necessary manufacture product opdivo eliquis sprycel yervoy reblozyl inrebic abraxane pomalystimnovid expand use thirdparty manufacturer drug product finish good manufacturing continue shift thirdparty manufacturer supply mature brand respect revlimid thalomid operate manufacturing facility zofingen switzerland produce active product ingredient revlimid thalomid contract thirdparty manufacturer provide backup active product ingredient revlimid thalomid maintain stable supply product variety action include inventory management maintenance additional quantity material possible design provide reasonable level ingredient hold party supplier manufacturing operation interrupt certain supply arrangement extend multiple year commit amount expect near longterm demand requirement subject change additional protection case step maintain approve backup source available need example capability manufacture opdivo internally arrangement thirdparty manufacturer meet demand connection acquisition divestiture license collaboration arrangement distribution agreement certain product certain circumstance enter agreement agree supply product party intend continue enter arrangement agreement future addition liability arise failure supply product agreement arrangement agreement require invest facility manufacture nonstrategic product case divestiture distribution arrangement result additional regulatory filing obligation cause interruption manufacture strategic product success depend great measure customer confidence quality product integrity datum support safety effectiveness product quality arise total commitment quality part operation include research development purchasing facility maintenance planning manufacturing warehouse logistic distribution maintain record demonstrate quality integrity datum technical information production process control production process involves establish specification standard raw material component ingredient equipment facility manufacturing method operation packaging material labeling perform test stage production process raw material drug substance final product product sample hold stability ensure product meet regulatory requirement conform standard test involve chemical physical analyse microbiological testing combination analyse quality control testing provide business unitsite thirdparty laboratory quality assurance group routinely monitor manufacturing procedure system subsidiary thirdparty supplier ensure quality compliance requirement meet environmental regulation facility operation subject extensive foreign law regulation relate environmental protection human health safety include govern discharge pollutant air water use management disposal hazardous radioactive biological material waste cleanup contamination pollution control permit require operation permit subject modification renewal revocation issue authority environment occupational health safety sustainability group monitor operation world provide overview regulatory requirement oversee implementation standard compliance incur operating capital cost matter ongoing basis material addition invest project reduce resource use energy water believe substantial compliance applicable environmental health safety requirement permit require operation incur additional cost include civil criminal fine penalty cleanup cost thirdparty claim property damage personal injury violation liabilitie law current facility operation year time operator facility generate store dispose substance waste consider hazardous federal state andor foreign environmental law include cercla result soil groundwater certain facility contaminate require significant expenditure investigate control remediate contamination case provide compensation andor restoration damage natural resource currently involve investigation remediation current facility identify prp applicable law environmental condition approximately waste disposal reprocess facility operate party investigation andor remediation activity ongoing face liability cercla federal state foreign law entire cost investigation remediation contaminate site natural resource damage regardless fault ownership time disposal release addition certain site bear remediation responsibility pursuant contractual obligation generally thirdparty operator site involve multiple prps liability expect apportion base nature hazardous substance dispose party site number financially viable prps additional information matter refer item financial statement supplementary datanote legal proceeding contingency human capital management resource believe employee world embody mission discover develop deliver innovative medicine help patient prevail disease unyielde focus patient define culture demographic december approximately employee country approximately employee locate exclude puerto rico locate outside supplement employee population independent contractor contingent worker temporary workforce support need average tenure employee approximately year people strategy people heart soul globally unify culture people strategy design inspire individual encourage team work patient community invest workforce extensive program policy initiative describe accelerate personal development collaboration service patient believe investment competitive advantage recruit future workforce accelerate innovation strive match diverse knowledge skill capabilitie talented employee community business need follow program policy initiative encompass objective measure continue focus people strategy diversity equity inclusion culture inclusion foster diverse mosaic people seek mirror patient community worldwide create agile responsive work environment diversity people unique perspective experience help achieve patientfocuse mission business objective believe inclusive culture encourage pursue innovative idea develop leadership capability gain valuable experience shape exciting career implement measure provide accountability continually increase diversity commitment attract diverse talent include train workforce diversity source strategy partner external local national organization develop supply diverse talent united negro college fund inc prospanica ascend inc woman color pharma ongoing investment people business resource group pbrg represent key lever use support acquisition development retention diverse talent business objectives career advancement development need employee maintain pbrg chapter worldwide member network learn skill participate learn development event contribute business objective tangible way pbrg sponsor member leadership team lead fulltime dedicated leader report directly member leadership team pbrg include black organization leadership development bristol myers squibb network woman cultivate leadership innovation millennial disability advancement workplace network pride alliance organization latino achievement pan asian network veteran community network august bms bristol myers squibb foundation announce independently invest million year series commitment health equity diversity inclusion currently focus key priority address health disparity increase clinical trial diversity expand supplier diversity program expand puerto rico employee give program increase workforce diversity executive level october bristol myers squibb foundation partner national medical fellowship american association cancer research announce group physicians select diversity clinical trial career development program earlystage investigator communityoriente clinical trialist train program announce intend expand diversity workforce leadership double blackafrican american hispaniclatino representation executive level end increase representation woman remain area focus management commit achieve gender parity executive level globally end achieve gender parity global bms employee population career growth development offer broad range professional training education career advancement leadership development employee program design help employee find purpose pursue passion achieve aspiration accelerate business performance stimulate work assignment structure learning opportunity pbrg sponsor program diverse work experience employee access expansive library resource cover wide range special interest topic multiple language variety learning development resource million learning activity complete employee consultant partner commit cultivate growth manager senior leader virtual inclassroom learn new experienced manager senior leader tuition reimbursement available globally eligible employee initiation desire development participate accredit educational program employee encourage stretch assignment maximize learn experience employee engagement routinely conduct confidential employee engagement survey global workforce provide feedback employee satisfaction engagement cover variety topic company culture value execution strategy diversity inclusion individual development survey result review executive officer board director analyze area progress opportunity company level function level individual manager use survey result implement action activity intend increase wellbee employee believe employee engagement initiative competitive pay benefit program career growth development opportunity help increase employee satisfaction tenure reduce voluntary turnover employee health commit protect workforce community patient ensure continue supply lifesave medicine focus direct ensure employee temporary contractor visitor site work safely prioritize health safety employee covid pandemic continue supply medicine patient drive strong business performance sciencebase company social responsibility help reduce spread pandemic vaccination require generally employee puerto rico subject local regulation limit restrict vaccine mandate encourage january approximately employee region vaccinate covid local regulation condition exus jurisdiction limit restrict vaccine mandate commit implement similar requirement market possible request medical religious accommodation consider individual basis total reward provide highly competitive benefit compensation work life offering reflect total reward strategy enable empower energy talent workforce deliver business strategy transform patient live science competitive pay benefit program aim attract retain incentivize diverse talented employee executive capable thriving lead business highly complex competitive environment benefit plan program necessarily vary country include choice health coverage include medical pharmacy dental vision pretax saving spending account financial protection life insurance supplemental health insurance personal coverage protection financial saving wellbee highly competitive saving plan financial wellbeing service similarly work life offering encourage growth recognition tuition reimbursement living life well wellbeing platform bravo global recognition program encourages team peer peer individual recognition align value onsite fitness center select location employee assistance program provide support welcome nurture family member pay parental leave care new child bridge parent leave ease transition new parent work adoptionsurrogacy reimbursement fertilityinfertility benefit support travel mother pay family care leave assist employee manage life workday child elder pet care resource commuter account pay sick time provide employee opportunity recharge community vacation holiday annual pay volunteer day pay bereavement leave pay military leave pay military family care leave addition offer market competitivebase salary overall total reward package annual incentive recognize reward company performance individual result longterm equity incentive spur employee focus longterm value creation respect executive substantial proportion pay variable atrisk base financial operational result deliver form equity support alignment executive compensation plan creation longterm value shareholder target equitybase grant vest condition facilitate retention critical personnel refer item management discussion analysis financial condition result operationseconomic market factorscovid information human capital management action response covid pandemic foreign operation significant operation outside conduct subsidiary distributor international operation subject certain risk inherent conduct business abroad include limited currency fluctuation possible nationalization expropriation price exchange control counterfeit product limitation foreign participation local enterprise restrictive governmental action international business subject governmentimpose constraint include law price reimbursement use product bristol myers squibb website internet website address wwwbmscom website available free charge annual quarterly current report include amendment report soon reasonably practicable electronically file material furnish material sec pursuant section securities exchange act amended exchange act document available secs website wwwsecgov information relate corporate governance bristol myers squibb include principle integrity code ethic senior financial officer code business conduct ethic director collectively code corporate governance guideline information concern executive committee board director include board committee committee charter transaction bristol myers squibb security director executive officer available website usour company leadership investor caption print stockholder request waiver code director executive officer material amendment code business conduct ethic director code ethic senior financial officer post promptly website information relate stockholder service include dividend reinvestment plan direct deposit dividend available website investorsshareholder service caption addition information sustainability program available website ussustainability caption forego information website content convenience information contain connected website deem incorporate reference file sec incorporate reference certain information part definitive proxy statement annual meeting shareholder proxy statement sec allow disclose important information refer manner refer information proxy statement available website investorssec filing caption day end fiscal year item risk factor risk uncertainty describe significantly negatively affect business operation financial condition operate result include component financial result cash flow prospect reputation credit rating future cause trading price common stock decline significantly additional risk uncertainty presently know risk currently consider immaterial impair business operation financial condition operate result cash flow follow discussion risk factor contain forwardlooke statement discuss item management discussion analysis financial condition result operationsspecial note forwardlooke statement product industry operational risk increase pricing pressure restriction abroad continue negatively affect revenue profit margin product continue subject increase pressure portfolio pharmaceutical market access pricing control discount change tax importation law restriction region world result low price low reimbursement rate small population payer reimburse negatively impact revenue profit margin include federal state law regulation aim regulate pricing reimbursement pharmaceutical product include potential penalty increase price rate inflation new discount fund redesign medicare benefit government negotiationsprice control establish maximum allow pricereimbursement rate change law regulation federal healthcare program medicare medicaid modify federal antikickback statute discount safe harbor accelerate generic drug approval process grant additional authority governmental agency manage drug utilization negotiate drug price include implementation regulation issue federal government authorize state private party develop implement program import certain prescription drug canada sell american rescue plan act eliminate medicaid prescription drug rebate cap start january expand utilization drug pricing program iii competition relate placement applicable commercial medicare formularie change income tax law result increase income tax expense include increase taxation international operation change trade law world include drug importation law rule practice mcos institutional governmental purchaser take action control cost shift cost burden manufacturer include action result exclusion product unfavorable placement product mco formulary vii change federal pharmaceutical coverage reimbursement policy practice include potential impact infrastructure investment job act pass senate august thing require certain manufacturer drug payable medicare provide rebate government discard portion drug december final rule issue center medicare medicaid services cm calculation average manufacturer price good price medicaid rebate address copay assistance product line extension topic previously issue rule address inclusion sale territory calculation average manufacturer price good price begin january viii increase scrutiny drug manufacturer include additional review bms celgene house oversight reform committee reimbursement delay government price erosion mechanism europe country result deflation pharmaceutical product pricing increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary xii collection delay failure pay governmentfunde public hospital outside xiii developments technology andor industry practice impact reimbursement policy practice thirdparty payer xiv inhibit market access real perceive difference value proposition product compare compete product expect market access constraint pharmaceutical pricing control discount restriction acute continue negatively affect future revenue profit margin additionally early health resource services administration hrsa finalize regulation pricing methodology provide guideline civil monetary penalty issue know intentional manufacturer overcharge cover entity effective date regulation january follow effective date manufacturer find knowingly intentionally overcharge cover entity subject significant monetary penalty course past year celgene receive inquiry hrsa limited distribution network revlimid pomalyst thalomid compliance program broad integration strategy alignment distribution model post acquisition celgene corporation recently announce beginning march recognize designate contract pharmacy location hospital lack entityowne pharmacy believe comply continue comply applicable legal requirement additional legal legislative change respect program cause update approach significant change sale pricing practice regard distribution drug program material change payer channel mix adverse effect revenue profitability addition require pay penalty applicable regulation adverse effect revenue profitability experience difficulty delay development commercialization new product ability replace revenue product lose patent protection directly dependent ability successfully commercialize new product timely manner common pharmaceutical industry bms expect sale key brand product like revlimid pomalyst sprycel abraxane decline loss market exclusivity product consequently future success highly dependent pipeline new product high rate failure inherent research development process new drug result high risk fund invest research program generate financial return compound product appear promise development fail reach market expected optimal timeframe example november fda extended review nda mavacamten announce new pdufa action date april fda early set pdufa action date january addition product extension additional indication approve furthermore product indication approve fdas accelerate approval program contingent verification description clinical benefit confirmatory study study successful example july announced voluntarily withdraw market indication opdivo nivolumab single agent patient hepatocellular carcinoma hcc previously treat sorafenib opdivo grant indication fda accelerated approval program action withdraw indication take consultation fda accordance standard procedure evaluate accelerate approval meet postmarketing requirement broad industrywide evaluation develop commercialize new compound product involve inherent risk uncertainty include efficacy safety concern finding superior safety efficacy compete product delay deny regulatory approval include result difficulty enrol patient complete clinical trial timely manner iii delay challenge produce product commercial scale excessive cost manufacture product failure enter implement optimal alliance development andor commercialization new product change regulatory approval process cause delay denial new product approval preclusion commercialization intellectual property issue dispute party vii failure certain market obtain reimbursement commensurate level innovation clinical benefit present product unable predict change law regulatory policy occur affect business particularly pipeline new product example partial federal government shutdown halt work federal agency employee late december late january extend government shutdown result reduction delay fda activity include respect ongoing clinical program manufacture product product candidate product approval regulatory approval delay especially common product expect rem program require fda address significant riskbenefit issue expect certain future key product distribute primarily rem program inability bring product market significant delay expect approval relate launch date new product negatively impact revenue earning addition certain acquire pipeline program cancel believe commercial prospect reduce recognize material noncash impairment charge program finally lose key molecule intermediary compound library natural manmade disaster act sabotage negatively impact product development cycle provide assurance product development approve launch product launch commercially successful maintain continuous flow successful new product successful new indication exist product sufficient cover substantial research development cost replace sale lose profitable product lose market exclusivity displace compete product therapie failure short term long term material adverse effect business result operation cash flow financial condition prospect public announcement datum clinical study competitor news development relate competitor product latestage compound cause significant volatility stock price depend datum result adverse impact business financial condition result operation development key latestage product candidate delay discontinued clinical study meet primary endpoint stock price decline significantly adverse impact business financial condition result operation focus effort resource disease area high unmet need focus portfolio investor place heighten scrutiny product latestage compound experienced setback continue development clinical study example october announce phase latticeuc study evaluating deucravacitinib firstinclass oral selective tyrosine kinase tyk inhibitor compare placebo moderate severe ulcerative colitis meet primary efficacy endpoint clinical remission week secondary efficacy endpoint additionally obtain latestage compound prioritize brand portfolio hematology immunology acquisition celgene meet expectation announcement datum clinical study competitor news development relate competitor product latestage compound opdivo continue cause significant volatility stock price depend news result adverse impact business financial condition result operation furthermore announcement negative unexpected datum discontinuation development key latestage product candidate delay anticipate timeline file regulatory approval significant advancement competitor continue cause stock price decline significantly adverse impact business financial condition result operation assurance datum clinical study support filing regulatory approval key product candidate prove effective effective compete product approve product commercially successful approve indication indication key product approve fda accelerate approval program continue approval contingent verification description clinical benefit confirmatory trial withdraw lose market exclusivity product early expect pharmaceutical biotechnology industry majority innovative product commercial value realize market exclusivity period country market exclusivity expire generic version approve market biosimilar introduce compete product usually substantial rapid decline product revenue market exclusivity product base patent right certain regulatory form exclusivity scope patent right vary country country dependent availability meaningful legal remedy country failure obtain maintain patent intellectual property right limitation use loss right result rapid loss sale affect product material country include certain member state basic patent protection product exist certain country historically offer right obtain specific type patent andor licensor file country addition patent environment unpredictable validity enforceability patent predict certainty addition manufacturer innovative drug generic drug manufacturer able design product own license patent compete result alternative technology absent relevant patent protection product datum exclusivity period expire generic alternative version approve market generic biosimilar product manufacturer group seek financial gain increasingly seek challenge patent expire face earlierthanexpecte competition product time patent cover key product likely continue subject validity enforceability infringement challenge patent litigation postgrant review patent office proceeding confident strength intellectual property right possible generic drug company successfully challenge right launch generic version drug prior expiration intellectual property right addition order avoid uncertainty expense litigation reason decide enter settlement generic manufacturer permit generic market entry prior expiration intellectual property right example expect generic drug company market generic version revlimid major european market expiration intellectual property right particular result patent settlement expect generic entry revlimid united kingdom begin january european country supplemental protection certificate force begin february similarly follow patent settlement certain company grant volumelimite license sell generic lenalidomide commence march case manufacturer seek regulatory approval submit clinical study datum obtain marketing approval choose launch generic product risk expiration applicable patent andor final resolution relate patent litigation addition country allow manufacturer manufacture sell generic product negatively impact protection afford company lowerprice generic biosimilar bms biologic product compete biologic negatively impact volume price addition congress fda take step promote development approval generic drug biosimilar biologic example december congress enact legislation intend facilitate generic company access drug sample section consolidate appropriation act provide generic biosimilar developer private right action obtain sufficient quantity drug sample reference product manufacturer order conduct testing necessary obtain approval generic biosimilar product law potential adverse impact business assurance particular product enjoy market exclusivity time period appear estimate disclose assume provide financial guidance certain novel approach treatment disease chimeric antigen receptor car cell therapy present significant challenge risk development novel approach treatment disease acquisition november celgene junos car cell therapy program include breyanzi lisocel abecma idecel present new challenge risk unique nature genetic modification patient cell vivo certain virus reengineer cell ultimately treat disease include obtain regulatory approval fda regulatory agency limit experience development cellular therapy involve genetic modification patient cell develop deploy consistent reliable process limit contamination engineering patient cell vivo infuse genetically modify cell patient develop process safe administration cellular therapy include longterm followup patient receive cellular therapy source additional clinical approve commercial supply material manufacture process potential car product use reengineered cell potential cancer treatment recent development broadly accept regulatory patient medical community able satisfactorily establish safety efficacy reliability therapie health authority approval demonstrate potential advantage effect compare exist future therapy regulatory requirement govern gene cell therapy product change frequently continue change future furthermore certain payment model impact financial feasibility make car cell therapy available certain market certain treatment site limit patient access date product involve genetic modification patient cell approve commercial sale safety profile cellular therapy adversely influence public perception adversely influence willingness subject participate clinical trial approve physician payer subscribe novel treatment approach fail overcome challenge significant adverse event report similar therapy development novel treatment approach hampered delay adversely affect future anticipate revenue andor profitability relate therapeutic program addition face difficulty manufacture car cell therapy adversely affect future anticipate revenue andor profitability relate car cell therapy experience difficulty delay disruption manufacture distribution sale product face intense competition manufacturer expect increase market penetration lowerprice generic product future growth bms dependent market access uptake expansion market brand new product introduction new indication product extension copromotional activity alliance partner competition keen lose exclusivity market brand lowerpriced generic product increasingly penetrate market generic challenge product arise time patent prevent emergence generic competition product example receive adverse litigation decision country eliquis composition matter patent relate supplementary protection certificate challenge item financial statement supplementary datanote legal proceeding contingency able prevent generic apixaban product introduce country prior estimate minimum market exclusivity date country patent protection significantly weak united states political social pressure push legislation measure promote use generic biosimilar product addition face competition new product enter market particularly new product lower price superior efficacy benefit safety risk profile actual perceive iii technological advantage product convenient use well insurance coverage reimbursement level effective marketing program andor differentiate factor hard product compete face intense competition external partnership joint venture acquisition target help develop bring new product market business combination competitor major thirdparty payer increase competition product unable compete successfully competitor product marketplace material negative impact revenue earning experience difficulty delay disruption manufacture distribution sale product product supply relate patient access future negatively impact difficulty delay disruption manufacture distribution sale product difficulty delay disruption include product seizure recall force closing manufacture plant failure failure vendor supplier comply cgmp applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture iii manufacturing quality assurancequality control supply problem governmental approval delay failure supplier include sole source single source supplier provide necessary raw material supply finish good reasonable timeframe require quality failure thirdparty manufacturer supply bulk active finished product time construction regulatory approval delay new facility expansion exist facility include intended support future demand biologic product opdivo vii failure meet new emerge regulation require product track distribution channel unique identifier verify authenticity supply chain viii manufacturing distribution issue include limit manufacturing capacity change type product produce biologic physical limitation business interruption disruption supply chain continuity include market force recent stress global logistic natural disaster hurricane global disease outbreak covid act war terrorism unforeseeable unavoidable event materially impact facility critical supplier addition manufacturing process novel cellbase therapy car cell therapy evolve process complicate expensive approach take current future competitor ability source raw material supply manufacture car cell therapy develop consistent reliable manufacturing process distribution network attractive cost good impact future anticipate revenue gross profit car cell therapy furthermore face challenge source raw material supply clinical approve commercial manufacture logistical shipment delay factor control prevent delay delivery product candidate market product patient additionally require maintain complex chain identity custody respect patient material material enter move manufacturing process result slight deviation point production process car cell therapie material car cell therapy result loss product regulatory remedial action adversely affect future anticipate revenue andor profitability relate car cell therapy encounter difficulty integrate celgene business operation fully realize project benefit acquisition celgene ultimate success acquisition celgene ability realize anticipate benefit acquisition include expect cost saving avoidance synergy innovation opportunitie operational efficiency depend thing effective integrate bristol myers squibb celgene operation product employee process integrate large number manufacture operational administrative system achieve consistency combine company include respect human capital management portfolio rationalization finance accounting system sale operation product distribution pricing system methodology cybersecurity system compliance program internal control process integration complex costly timeconsuming process difficulty integration operation occur adversely affect business include way cause failure meet demand product adversely affect ability meet financial reporting obligation inconsistency standard control procedure policy adversely affect ability maintain relationship customer supplier distributor alliance partner creditor clinical trial investigator manager clinical trial event outside control include change regulation law economic trend adversely affect ability realize expect benefit acquisition regulatory intellectual property litigation tax legal compliance risk litigation claim infringement intellectual property adversely affect future revenue operate earning certain subsidiary future involve legal proceeding include patent litigation claim patent invalid unenforceable andor cover product generic drug manufacturer party seek damage andor injunctive relief compensate allege infringement patent commercial activity resolve intellectual property infringement claim costly time consuming require enter license agreement available commercially reasonable term successful claim patent intellectual property infringement subject significant damage injunction prevent manufacture sale use affect product product event material adverse effect profitability financial condition adverse outcome legal matter negatively affect business current future lawsuit claim proceeding government investigation preclude delay commercialization product adversely affect operation profitability liquidity financial condition possible insurance recovery available legal matter include intellectual property dispute adverse decision litigation include product safety liability consumer protection commercial case iii antibribery regulation foreign corrupt practice act bribery act include compliance ongoe reporting obligation government result settlement recall withdrawal pharmaceutical product force closing manufacture plant allege failure fulfill obligation supply contract government customer agreement relate business product pricing promotional matter vii lawsuit claim assert investigation violation security antitrust federal state pricing consumer protection datum privacy law regulation viii environmental health safety sustainability matter include regulatory action response climate change tax liability result assessment tax authority subject variety international law regulation currently subject number government law regulation future subject new government law regulation cost compliance law regulation negative result noncompliance adversely affect business operating result financial condition company law regulation control regulate key aspect business include limited market access pricing control discount tax liability return paymentsiii import trade restriction intellectual property protection enforcement good practice guideline regulation accounting standard vii datum storage privacy particularly viii requirement report payment value transfer healthcare professional compliance antibribery anticorruption practice country addition healthcare industry highly regulate subject frequent substantial change including result new judicial governmental decision example fda indicate undertake industrywide review indication receive accelerate approval confirmatory study meet primary endpoint specific company december announce withdraw opdivo nivolumab indication treatment patient sclc disease progress platinumbase chemotherapy line therapy grant accelerated approval action take consultation fda accordance standard procedure evaluate accelerate approval meet postmarketing requirement broad industrywide evaluation anticipate continue congressional interest modify provision affordable care act particularly give rule texas azar invalidate law unconstitutional revenue generate health insurance exchange medicaid expansion affordable care act material impact change law similar recent administration action expect limited future replacement modification repeal affordable care act adversely affect business financial result particularly legislation reduce incentive employersponsored insurance coverage predict future federal state legislative administrative change relate healthcare reform affect business change tax regulation negatively impact earning subject income taxis country globally change tax law regulation occur recently tax cut job act reduce tax rate introduce broad complex change result numerous new regulation interpretation significant judgment require determine company tax liability company tax return periodically examine tax authority face continue face audit challenge apply tax law regulation ultimate resolution tax matter result payment great amount accrue negative impact provision income taxis addition future earning negatively impact change tax legislation include change tax rate tax base limit phasingout eliminate deduction tax credit increase tax certain excess income intellectual property revise tax law interpretation domestic foreign jurisdiction change rule earning repatriation change tax law country notably july october oecdg inclusive framework agree general rule redefine jurisdictional taxation right global minimum tax detail implementation rule expect implement material impact tax provision result operation failure party meet contractual regulatory obligation adversely affect business rely supplier vendor outsource partner alliance partner party research develop manufacture commercialize promote sell product manage certain marketing human resource finance datum business unit functional service meet contractual regulatory obligation party pose number risk perform standard legal requirement example relation outsource significant clinical development activity innovative medicine contract research organization produce reliable result iii perform timely manner maintain confidentiality proprietary information incur significant cyberattack business disruption subject government order mandate require priority government set aside preexist commercial order vii dispute arise respect ownership right technology develop partner viii disagreement cause delay termination research development commercialization product result litigation arbitration party locate market subject political social risk corruption infrastructure problem natural disaster addition country specific privacy datum security risk give current legal regulatory environment failure critical party meet obligation include future royalty milestone payment adequately deploy business continuity plan event crisis andor satisfactorily resolve significant disagreement address factor material adverse impact operation result addition party violate allege violate law regulation include local pharmaceutical code foreign corrupt practice act bribery act eus general data protection regulation similar law regulation performance obligation possible suffer financial reputational harm negative outcome include possible legal consequence product labeling change market product result negative impact revenue profit margin regulatory authority need change label pharmaceutical product include product market year change result additional datum postmarkete study headtohead study adverse event report study identify biomarker objective characteristic indicate particular response product therapy study postmarkete experience produce important additional information product new information add product label affect riskbenefit profile lead potential recall withdrawal decline revenue product liability claim additional information study identify portion patient population nonresponsive medicine high risk adverse reaction label change base study limit patient population study provide additional information sponsor sponsor competitor insurance company government institution mcos scientist investigator interested party additional safety efficacy information study assist healthcare provider identify good patient population product negatively impact revenue inventory return limit patient population go forward additionally certain study result especially headtohead study affect product formulary listing adversely affect revenue illegal distribution sale party counterfeit unregistered version product steal product negative impact revenue earning reputation business party illegally distribute sell counterfeit version product meet rigorous manufacturing testing standard patient receive counterfeit drug product divert authorized market risk number dangerous health consequence reputation business suffer harm result counterfeit drug sell brand divert product prevalence counterfeit medicine industrywide issue variety factor include adoption ecommerce increase covid pandemic greatly enhance consumer ability obtain prescription medical treatment internet lieu traditional brick mortar pharmacy internet expose patient great risk prefer vehicle dangerous counterfeit offer scam anonymity afford counterfeiter theft inventory warehouse plant intransit properly store later sell unauthorized channel adversely impact patient safety reputation business addition diversion product authorize market channel result reduced revenue negatively affect profitability increase use social medium platform present risk challenge increase use social medium communicate company news event inappropriate andor unauthorized use certain medium vehicle cause brand damage information leakage lead legal implication include improper collection andor dissemination personally identifiable information employee patient healthcare professional stakeholder addition negative inaccurate post comment social network website damage reputation brand image goodwill disclosure nonpublic company sensitive information workforce intentional unintentional external medium channel lead information loss information technology cybersecurity risk dependent information technology system infrastructure face certain risk include cybersecurity breach datum leakage rely extensively information technology system network service include internet site data host processing facility tool physical security system hardware software technical application platform manage host provide andor thirdpartie vendor assist conduct business significant breakdown invasion corruption destruction interruption critical information technology system infrastructure workforce authorize access system unauthorized person negatively impact operation everincrease use evolution technology include cloudbase computing create opportunity unintentional dissemination intentional destruction modification confidential information store thirdparty provider system portable medium storage device experience business interruption theft confidential information reputational damage industrial espionage attack malware cyberattack compromise system infrastructure lead datum leakage internally thirdparty provider covid pandemic continue progress observe increase cybersecurity incident industry predominantly ransomware social engineering attack government entity subject cyberattack cyberthreat landscape evolve attack grow frequency sophistication intensity nature attack risk remain undetected period time aggregate impact operation financial condition material date target cyberattack expect continue cybersecurity threat rapidly evolve sophistication prevalent industry invest industry appropriate protection monitor practice datum reduce risk continue monitor system ongoing basis current potential threat maintain cyber insurance insurance sufficient cover financial legal business reputational loss result interruption breach system assurance continue effort prevent breakdown breach thirdparty provider database system adversely affect business strategic business development employee attraction retention risk failure execute business strategy adversely impact growth profitability strategy focus deliver innovative transformational medicine patient focus set disease area unable successfully execute strategy negatively impact future result operation market capitalization connection strategy process integrate celgene myokardia ability successfully integrate celgene myokardia impact result operation able achieve cost saving expect negatively impact operate margin earning result addition unable consistently maintain adequate pipeline internal program transaction party support future revenue growth competition pharmaceutical company acquisition product licensing opportunity intense able locate suitable acquisition target license partner reasonable price successfully execute transaction unable support grow market product successfully execute launch newly approve product advance latestage pipeline manage change operating model evolution manage cost effectively operate result financial condition negatively impact depend key product revenue cash flow earning derive majority revenue earning key product expect revlimid eliquis opdivo represent significant percentage revenue earning cash flow year reduction revenue product adversely impact earning cash flow major product subject issue loss patent protection significant change demand formulary access change material product liability unexpected effect regulatory proceeding negative publicity supply disruption manufacturing operation thirdparty supplier significant advancement compete product incur adverse impact business financial condition result operation trading price stock thirdparty royalty represent significant percentage pretax income operate cash flow enter arrangement entitle potential royalty party outlicense intellectual property commercialization right salesbase contingent proceed relate divestiture business arrangement minimal continue involvement contribute financial success activity royalty continue represent significant percentage pretax income include royalty relate divestiture diabete business include transfer certain future royalty right pertain amylin onglyza farxiga product sale outlicense intellectual property merck patent infringement settlement pretax income generate royalty approximately billion pretax income adversely affect royalty stream decline future period failure effectively manage acquisition divestiture alliance joint venture portfolio action adversely impact future result addition business asset acquire future underperform able successfully integrate exist business occurrence number unexpected factor prevent substantially delay consummation anticipate acquisition divestiture merger acquire inlicense number asset expect continue support pipeline compound product obtain licensing acquisition future revenue profit cash flow acquire company product technology pipeline candidate materialize low product uptake delay miss pipeline opportunity inability capture expect synergy result cost saving avoidance increase competition safety concern regulatory issue supply chain problem factor control substantial difficulty cost delay result integrate acquisition include manufacturing distribution sale marketing promotion information technology activity policy procedure process control compliance iii tax consideration acquire debt equity security consideration business development activity connection joint venture acquisition value security fluctuate depreciate value control company acquire security connection collaborative arrangement result limited ability determine management operational decision internal control compliance policy result additional financial reputational risk successful separate underperform nonstrategic asset gain loss divestiture lose operating income asset affect earning divestiture result continued financial exposure divest business guarantee financial arrangement continue supply service arrangement potential litigation follow transaction arrangement nonperformance result obligation impose material adverse effect competitive position cash flow result operation financial condition reputation particular divested otezla connection obtain regulatory approval acquisition celgene ftc determines violate consent order agree connection divestiture ftc seek civil penalty reputation adversely affect incur asset impairment charge related acquisition divestiture reduce earning value allocate certain asset substantially impair number factor control new revise accounting standard rule interpretation result change recognition income expense materially adversely affect financial result execution implementation acquisition divestiture alliance joint venture portfolio action successful adversely impact financial condition cash flow result operation substantial debt incur finance cash portion celgene myokardia acquisition assurance able expand business development capacity commit reduce debt pursue strategic transaction opportunity future require obtain additional equity debt financing result increase leverage andor downgrade credit rating failure attract retain highly qualified workforce affect ability successfully develop commercialize product success largely dependent continue ability attract retain highly qualified scientific technical management workforce include people expertise clinical governmental regulation commercialization connection celgene acquisition integrate unique corporate culture maintain employee morale face increase competition limit pool qualified individual numerous pharmaceutical biotechnology company university government entity research institution company seek enter healthcare space company industry sure able retain quality talent cost materially increase market liquidity credit risk significant additional indebtedness incur connection celgene myokardia acquisition negative consequence acquisition celgene myokardia increase debt result additional interest expense reduce financial flexibility continue capital investment develop new product declare future dividend adverse change global economic political condition adversely affect profitability global economic political risk pose significant challenge company growth profitability difficult mitigate generate approximately revenue outside revenue earning cash flow expose risk strengthen dollar inflation instance inflation factor significantly increase business cost adversely affect revenue profitability exposure customer credit risk europe south america market include government guarantee hospital receivables market payment receive time significant operation europe include manufacture distribution result operation negatively impact member country exit eurozone monetary union particular exit occur january create uncertainty affect business operation impact research commercial general business operation include approval supply product require change legal entity structure addition currently uncertainty phase libor july united kingdom regulator regulate libor announce intention phase libor rate end march ice benchmark administration capacity administrator usdlibor announce intends extend publication usd libor oneweek twomonth tenor june notwithstanding extension joint statement key regulatory authority call bank cease enter new contract use usdlibor reference rate soon practicable later december alternative reference rate committee steering committee comprise large financial institution propose replace usdlibor new index calculate shortterm repurchase agreement secure overnight financing rate sofr time consensus exist rate rate accept alternative libor impossible predict extent bank continue provide libor submission administrator libor onemonth threemonth sixmonth month usd libor rate continue publish june issue variable rate debt base libor undertake interest rate swap contain variable element base libor enter certain agreement amend certain agreement rely sofr alternative interest rate method libor predict impact agreement amendment sofr sofr appear preferred replacement rate usd libor time financial market coalesce alternative benchmark rate method libor different sofr need renegotiate agreement negatively impact renegotiated term adversely affect interest rate result high borrowing cost predict addition phase replacement libor cause disruption credit market lead downgrade current credit rating increase future borrowing cost cost capital impair ability access capital credit market term commercially acceptable adversely affect liquidity capital resource finally business operation adversely affect political volatility conflict crise individual country region include terrorist activity war guarantee pay dividend repurchase stock declaration time dividend fall discretion board director board decision depend factor include financial condition earning capital requirement debt service obligation industry practice legal requirement regulatory constraint factor board deem relevant reduction elimination dividend payment dividend program adversely affect stock price addition time decide buy share market adversely affect stock price amend bylaw designate court chancery state delaware sole exclusive forum certain lawsuit stockholder limit stockholder ability obtain judicial forum find favorable lawsuit costly stockholder bring lawsuit effect discourage lawsuit amend bylaw provide consent write selection alternative forum court chancery state delaware full extent permit law sole exclusive forum derivative action proceeding bring behalf action assert claim breach fiduciary duty owe director officer employee stockholder creditor constituent iii action assert claim arise pursuant provision general corporation law state delaware amend restate certificate incorporation amend bylaw action assert claim director officer employee govern internal affair doctrine provide event court chancery state delaware lack jurisdiction action proceed sole exclusive forum action proceed state federal court state delaware bylaw provide person entity purchase acquire hold interest share capital stock deem notice consent forum selection provision court chancery state delaware court chancery jurisdiction state federal court state delaware full authority allow law issue antisuit injunction enforce forum selection clause preclude suit forum forum selection provision intend apply action bring securities act securities act amended exchange act section exchange act create exclusive federal jurisdiction suit bring enforce duty liability create exchange act rule regulation thereunder section security act create concurrent jurisdiction federal state court suit bring enforce duty liability create security act rules regulation thereunder accordingly forum selection provision amend bylaw relieve duty comply federal security law rule regulation thereunder stockholder deem waive compliance law rule regulation forum selection provision bylaw limit stockholder ability bring claim judicial forum find favorable dispute director officer employee discourage lawsuit respect claim stockholder deem waive compliance federal security law rule regulation thereunder addition stockholder bring claim court chancery state delaware face additional litigation cost pursue claim particularly reside near delaware believe risk court decline enforce forum selection provision contain amend bylaw low court find provision inapplicable unenforceable respect specify type action proceeding incur additional cost associate resolve action jurisdiction harm business operating result financial condition general risk covid pandemic affecting business material adverse effect covid pandemic affect operate business response covid pandemic international federal state local public health governmental authority take continue number action limit spread covid address relate disruption global economy begin covid pandemic see change demand product drive low patient start visit covid pandemic continue impact revenue result operation far significantly impact negative impact covid pandemic extend assume timeline result worse expect extent impact depend future development ultimate duration severity spread covid variant strain globally effectiveness outreach vaccines effectiveness federal state local international government mitigation action pandemic impact global economy change behavior patient medical professional time resumption normal operation development affect healthcare delivery medicine patient experience significant manufacturing supply issue covid possible experience issue future negatively impact business result operation instance experience scarcity certain raw material component result influx covid vaccine order receive priority treatment vendor similarly highly contagious variant covid create material staffing shortage manufacture site disrupt supply product possible experience supply chain interruption result quarantine shelterinplace governmental order policy travel restriction airline cargo capacity route reduction addition natural disaster potentially disruptive event occur current pandemic deplete safety stock level experience manufacture supply distribution issue restart inperson interaction customerface field personnel health care setting number market determine long safe engage inperson interaction likely return remote model engagement transition negative impact business possible longerlaste shift interaction field personnel health care professional anticipate negative impact business result operation addition impact covid enrollment clinical trial stabilize continue experience delay initiation enrollment patient clinical trial new variant covid able fully mitigate delay negatively impact time pipeline development program expect future revenue andor cash flow addition experience additional delay difficulty enrol patient clinical trial andor delay difficulty ongoing fully enrol clinical trial negatively impact time pipeline development program expect future revenue andor cash flow prolong clinical trial delay potentially significant negative effect business particularly new competitive product enter market clinical trial result competitor product affect value proposition product delay difficulty clinical development potentially lead material impairment intangible asset include approximately billion intangible asset december addition research early development activity perform laboratory resume suspend period time negatively impact advancement early pipeline asset plan mitigate impact able fully mitigate breadth future pipeline opportunity adversely affect predict reasonably estimate impact potential longterm change healthcare industry covid example potential shift payer channel mix change patient coverage current economic crisis able reliably estimate impact result operation give highly variable uncertain situation possible change healthcare system impose additional burden clinical trial increase cost sponsor clinical trial lead additional delay difficulty complete clinical trial experience additional pricing pressure andor increase governmental regulation face additional risk impact covid supplier vendor outsource partner alliance partner party rely research develop manufacture commercialize copromote sell product manage certain marketing sell human resource finance business unit functional services example thirdparty provider suffer limited solvency pandemic negatively impact operating model business possible estimate potential impact time covid pandemic increase volatility financial market foreign currency exchange interest rate addition facing continue face potential negative consequence stem covid pandemic include limited increase cyber threat partner phishe social engineering malware attack delay plan integration milestone ability collect receivable possible covid exacerbate risk describe time predict extent negative impact covid pandemic business financial condition result operation andor cash flow item unresolved staff comment item property principal executive office locate east street floor new york lease manufacturing administration storage distribution facility approximately site worldwide believe manufacturing property combination thirdparty manufacturer good operating condition provide adequate production capacity current project operation believe property subject material encumbrance easement restriction detract materially value impair use operation business information manufacturing property refer item businessmanufacture quality assurance significant manufacturing location geographic area follow december manufacturing united states europe total item safety disclosure applicable information executive officer list information executive officer february executive officer elect board director initial term continue board meeting follow annual meeting shareholder elect oneyear term successor elect executive officer serve discretion board director current position age employment history past year giovanni caforio chief executive officer director company chairman board chief executive officer present chairman board chief executive officer member leadership team christopher boerner phd president head commercial executive vice president chief commercialization officer president head international market member leadership team present executive vice president chief commercialization officer david elkins group vice president chief financial officer consumer consumer medicine executive vice president chief financial officer johnson johnson member leadership team worldwide vice president chief financial officer consumer product medical device corporate function johnson johnson chief financial officer celgene present executive vice president chief financial officer samit hirawat executive vice president head oncology development novartis executive vice president chief medical officer global drug present executive vice president chief medical officer global drug development development member leadership team sandra leung present executive vice president general counsel executive vice president general counsel member leadership team greg meyers corporate vice president chief information officer motorola solutions executive vice president chief digital technology officer group chief information digital officer syngenta group member leadership team present executive vice president chief digital technology officer elizabeth mily manage director barclays investment bank executive vice president strategy business development present executive vice president strategy business development member leadership team ann powell senior vice president chief human resource officer executive vice president chief human resource officer present executive vice president chief human resource officer member leadership team karen santiago lead enable function finance transformation senior vice president corporate controller present senior vice president corporate controller louis schmukler president global product development supply executive vice president president global product development senior vice president president global product development supply supply present executive vice president president global product development supply member leadership team rupert vessey bch frcp dphil president research early development celgene executive vice president research early development present executive vice president research early development member leadership team paul von autenrie senior vice president chief information officer executive vice president chief information officer present executive vice president chief information officer member leadership team michelle weese founderchief executive officer stratigence inc executive vice president corporate affairs general secretary north america danone member leadership team present executive vice president corporate affairs item legal proceeding information pertain legal proceeding find item financial statement supplementary datanote legal proceeding contingency incorporate reference item market registrant common stock stockholder matter bristol myers squibb common stock trade new york stock exchange symbol bmy holder common stock number record holder common stock january number record holder base actual number holder register book date base information provide shareowner service transfer agent include holder share street name person partnership association corporation entity identify security position listing maintain depository trust company equity compensation plan information information require item contain proxy statement head item vote uponitem advisory vote approve compensation name executive officersequity compensation plan information information incorporate reference performance graph follow graph compare cumulative total stockholder return common share cumulative total stockholder return company list standard poor index index composite peer group major pharmaceutical company comprise abbvie amgen astrazeneca biogen gilead glaxosmithkline johnson johnson lilly merck novartis pfizer roche sanofi graph assume investment december common share index stock peer group company include reinvestment dividend year end december stock price performance follow graph necessarily indicative future stock price performance bristol myers squibb peer group issuer purchase equity security follow table summarize surrender equity security month end december total number share approximate dollar value purchase share total number average price pay publicly announce purchase period share purchaseda sharea programsb programsb dollar million share datum october november december month end december include share repurchase publicly announce program share common stock surrender company satisfy tax withholding obligation connection vest award longterm incentive program board director authorize repurchase billion common stock june increase authorization repurchase common stock additional billion october board director approve new share repurchase program authorize repurchase additional billion common stock november increase authorization repurchase common stock approximately billion february board director approve increase billion total outstanding share repurchase authorization january december board director approve increase billion billion respectively share repurchase authorization remain share repurchase capacity program approximately billion december refer item financial statementsnote equity information share repurchase program item reserve item management discussion analysis financial condition result operation management discussion analysis financial condition result operation provide supplement read conjunction consolidate financial statement relate note include enhance understanding result operation financial condition cash flow comparison result omit incorporate reference year end december item management discussion analysis financial condition result operation file february executive summary bristolmyers squibb company global biopharmaceutical company mission discover develop deliver innovative medicine help patient prevail disease refer summary abbreviate term end term document obtain approval new medicine additional indication formulation currently market medicine major market japan include regulatory approval breyanzi abecma hematology malignancy approval cell therapy portfolio support continue investment cell therapy portfolio expand manufacturing capability construction new stateoftheart cell therapy manufacturing facility deven massachusetts leiden netherlands continue momentum immunooncology portfolio additional approval opdivo opdivoyervoy indication adjuvant bladder gastric cancer gastroesophageal junction cancer esophageal adenocarcinoma rcc return growth opdivo portfolio immunology expand fda approval zeposia treatment adult moderately severely active important opportunity deucravacitinib tyk inhibitor treatment psoriasis immunemediate disease bolster lead cardiovascular franchise add mavacamten acquisition myokardia fda accept nda mavacamten patient symptomatic obstructive hcm assign revise pdufa goal date april revenue increase eliquis opdivoyervoy recently launch new product revlimid foreign exchange gaap ep compare gaap loss share primarily iprd charge result myokardia asset acquisition specify item include low unwind inventory purchase price adjustment income relate equity investment contingent value right iii internal transfer certain intangible asset streamline legal entity structure subsequent celgene acquisition result tax benefit tax charge adjust specify item nongaap eps increase high revenue partially offset high expense support product launch overall portfolio highlight follow table summarize financial information year end december dollar million share datum total revenue dilute earningsloss share gaap nongaap nongaap financial measure include nongaap earning relate eps information adjust exclude specify item represent certain cost expense gain loss item impact comparability financial result detail list specify item information reconciliation nongaap financial measure refer nongaap financial measure economic market factor covid response covid pandemic international federal state local public health governmental authority take continue number action limit spread covid address relate disruption global economy continue experience impact revenue covid primarily low new patient start patient visit pandemic significantly impact result operation situation remain dynamic difficult reasonably assess predict extent negative impact covid pandemic business financial condition result operation cash flow future financial operational impact covid pandemic bms depend future development ultimate duration severity spread covid variant strain globally effectiveness outreach vaccines effectiveness federal state local international government mitigation action pandemic impact global economy change behavior patient medical professional time resumption normal operation development affect healthcare delivery medicine patient iitem risk factorsgeneral risksthe covid pandemic affecting business material adverse effect covid pandemic affect global healthcare system major economic financial market adopt procedure focus ensure continued supply medicine patient protect health wellbeing safety workforce workplace community maintain steadfast commitment protect workforce community patient ensure continue supply lifesave medicine sciencebase company social responsibility help reduce spread virus vaccination require generally employee puerto rico subject local regulation limit restrict vaccine mandate encourage january approximately employee region vaccinate covid request medical religious accommodation consider individual basis local regulation condition exus jurisdiction limit restrict vaccine mandate commit implement similar requirement market possible return worker office continue assess need require weekly asymptomatic testing mask wear physical distancing colleague onsite facility puerto rico workforce safe conduct regular deep cleaning site manufacture site remain open pandemic support site personnel take thoughtful phase approach bring rest workforce plus site world guide follow principle serve need patient customer prioritize health safety follow medical advice government direction lead compassion flexibility model key learning single approach fit site market timeline circumstance vary globe monitor local condition government direction closely adjust plan appropriate supply medicine support patient physician advocacy group important element keep promise patient family healthcare provider ensure supply chain robust carefully manage clinical commercial supply chain team proactively mitigation plan ensure product reach market clinical site patient past month thank effort see significant disruption clinical commercial supply chain pandemic recognize remain challenge time know patient face additional hardship exist patient support program available help eligible patient prescribe bristol myers squibb medicine lose employment health insurance covid pandemic program eligible patient provide certain bristol myers squibb medicine free puerto rico personnel currently require vaccinate interact customer vendor people clinical trial site continue employ remote interaction appropriate ensure continue support healthcare professional patient care access medicine global market clinical trial research work health authority investigator protect trial participant personnel bms clinical trial site ensure regulatory compliance integrity science provide clinical trial investigator overarch principle guidance conduct bms clinical trial worldwide light covid take account guidance health authority applicable governmental action product continue subject increase pressure portfolio pharmaceutical market access pricing control discount change tax importation law restriction region world result low price low reimbursement rate small population payer reimburse negatively impact result operation include intangible asset impairment charge operate cash flow liquidity financial flexibility example congress currently consider number different proposal potentially allow government set negotiate price prescription drug include benchmarking price price pay country penalize manufacturer price increase inflationary measure iii redesign benefit new pocket limit patient new mandate discount manufacturer change income tax law result increase income tax expense include increase taxation international operation outcome congressional action remain highly uncertain addition oecd recently reach agreement global minimum tax pursuant country expect implement change tax law update international tax treaty risk factor company risk factor item include iitem risk factorsproduct industry operational risksincreased pricing pressure restriction abroad continue negatively affect revenue profit margin change tax regulation negatively impact earning significant product pipeline approval follow summary significant approval receive product date approval fda approval orencia prevention agvhd combination calcineurin inhibitor orencia december methotrexate adult pediatric patient year age old undergo hematopoietic stem cell transplantation match allelemismatche unrelated donor japans ministry health labour welfare approval opdivo treatment cancer opdivo december unknown primary japans ministry health labour welfare approval opdivo firstline treatment opdivo november unresectable advanced recurrent gastric cancer combination chemotherapy japans ministry health labour welfare approval opdivo adjuvant treatment opdivo november esophageal cancer zeposia november approval zeposia treatment adult moderately severely active approval opdivo combination fluoropyrimidine platinumbase combination chemotherapy firstline treatment adult patient hernegative advanced metastatic gastric opdivo october gastroesophageal junction esophageal adenocarcinoma tumor express pdl combine positive score japans ministry health labour welfare approval opdivo line gastric cancer opdivo september adjuvant esophageal cancer japans ministry health labour welfare approval opdivo treatment pediatric patient opdivo august recurrent refractory classical hodgkin lymphoma japans ministry health labour welfare approval combination therapy opdivo opdivo august cabometyx treatment unresectable metastatic rcc fda approval opdivo adjuvant treatment patient urothelial carcinoma high risk opdivo august recurrence undergo radical resection regardless prior neoadjuvant chemotherapy nodal involvement pdl status approval abecma treatment adult patient relapse refractory multiple myeloma abecma august receive prior therapy include immunomodulatory agent proteasome inhibitor anticd antibody demonstrate disease progression therapy approval opdivo adjuvant treatment adult patient esophageal gastroesophageal opdivo july junction cancer residual pathologic disease follow prior neoadjuvant chemoradiotherapy approval opdivo plus yervoy treatment adult patient mismatch repair deficient opdivoyervoy june microsatellite instabilityhigh metastatic crc prior fluoropyrimidinebase combination chemotherapy approval onureg maintenance therapy adult patient aml achieve complete remission complete remission incomplete blood count recovery follow induction therapy onureg june consolidation treatment candidate include choose proceed hematopoietic stem cell transplantation approval opdivo plus yervoy firstline treatment adult unresectable malignant opdivoyervoy june pleural mesothelioma zeposia fda approval zeposia treatment adult moderately severely active japans ministry health labour welfare approval opdivo yervoy combination therapy opdivoyervoy firstline treatment unresectable advanced recurrent malignant pleural mesothelioma product date approval fda approval opdivo adjuvant treatment patient completely resect esophageal opdivo gastroesophageal junction cancer residual pathologic disease neoadjuvant chemoradiotherapy fda approval opdivo combination chemotherapy patient advance metastatic gastric opdivo april cancer gastroesophageal junction cancer esophageal adenocarcinoma regardless pdl expression status approval opdivo combination cabometyx firstline treatment patient opdivo april advance rcc fda approval abecma treatment adult patient relapse refractory multiple myeloma abecma march prior line therapy include immunomodulatory agent proteasome inhibitor anti monoclonal antibody japans ministry health labour welfare approval breyanzi treatment patient breyanzi march relapse refractory large bcell lymphoma relapse refractory follicular lymphoma approval inrebic treatment diseaserelate splenomegaly symptom adult patient inrebic february primary myelofibrosis postpolycythaemia vera myelofibrosis postessential thrombocythaemia myelofibrosis janu associate kinase inhibitor nave treat ruxolitinib fda approval breyanzi treatment adult patient relapse refractory large bcell breyanzi february lymphoma line systemic therapy fda approval opdivo combination cabometyx firstline treatment patient opdivo january advance rcc following summary significant approval receive january japan ministry health labour welfare approve abecma treatment adult patient relapse refractory multiple myeloma receive prior therapy refer product pipeline development development market product latestage pipeline early strategy principal strategy combine resource scale capability pharmaceutical company speed focus innovation biotech industry focus biopharmaceutical company discover develop deliver transformational medicine patient face disease area believe opportunity meaningful difference oncology solid tumor hematology immunology cardiovascular neurology priority continue renew diversify portfolio launch new product portfolio advance early mid latestage pipeline execute disciplined business development remain committed reduce debt return capital shareholder develop new medicine follow core therapeutic area oncology priority certain tumor type hematology opportunity broaden franchise potentially sustain leadership position multiple myeloma iii immunology priority relapse multiple sclerosis psoriasis psoriatic arthritis lupus inflammatory bowel disease cardiovascular disease fibrotic disease priority lung liver continue advance wave innovative medicine invest significantly pipeline internally business development activity expand oncology hematology immunology portfolio nearterm asset additional external partnership invest oncology portfolio pursue monotherapy combination approach advance wave early asset explore new collaboration opportunity therapeutic area focus remain focused wellresourced cancer development program seek broaden use opdivo early line therapy expand new tumor accelerate wave oncology mechanism develop treatment option refractory oncology patient strengthen portfolio opportunity relatlimab fix dose combination nivolumab treatment melanoma expand opportunity adjuvant melanoma lung liver crc hematology opportunity launch new medicine nearterm additional pipeline opportunity long term broad effort continue address unmet medical need multiple myeloma work multiple modality mechanism action cereblon modulator celmod tcell engager car tcell therapy cancer continue advance early stage portfolio immunology cardiovascular neuroscience disease strengthen partnership diverse group company academic institution new expand research activity believe differentiate internal external focus contribute advance pipeline potentially transformational medicine immunology deucravacitinib selective tyk opportunity medicine treat multiple immunemediate disease fda accept nda deucravacitinib treatment adult moderate severe plaque psoriasis set pdufa goal date september expand portfolio cardiovascular disease alliance partnership janssen advance nextgeneration antithrombotic medicine milvexian additionally acquisition myokardia add mavacamten potential firstinclass medicine treat underlying cause obstructive hcm fda accept nda mavacamten indication assign revise pdufa goal date april commercial model successful revenue key brand continue grow demonstrate strong execution strategy continue drive adoption opdivo expand additional indication tumor type monotherapy combination yervoy anticancer agent eliquis continue grow leverage good class clinical profile extensive real world datum number novel oral anticoagulant total prescription globally revlimid pomalyst transform treatment multiple myeloma gain deep understanding mechanism action revlimid pomalyst leverage knowledge intentionally design novel celmod agent iberdomide improve early treatment able leverage lead capability hematological malignancy robust pipeline provide opportunity longterm growth offset impact future patent expire revlimid pomalyst build continue success key brand remain strongly commit orencia sprycel optimistic future growth nearterm opportunity reblozyl inrebic zeposia onureg breyanzi abecma operating model transformation commercial infrastructure leverage potential growth expect growth inline new product portfolio enable offset expect decline revlimid abraxane product revenue loss market exclusivity operating model continue evolve successful focus commercial manufacturing resource key brand market strengthen capability tumor biology patient selection new biomarker deliver lean administrative function streamline manufacture network reflect importance biologic current future portfolio evolution operating model focus maintain discipline approach marketing sell administrative expense enable deliver necessary strategic financial operational flexibility invest high priority opportunity portfolio celgene acquisition restructuring activity expect realize approximately billion synergy result cost saving avoidance integration effort general administrative manufacturing procurement streamline company pricing information technology infrastructure look ahead continue implement biopharma strategy drive growth key brand execute product launch invest diverse innovative pipeline aid strategic business development focus prioritize market increase investment biologic manufacturing capability maintain culture continuous improvement acquisition divestiture license arrangement significant acquisition divestiture license arrangement summarize refer item financial statement supplementary datum note alliance note acquisition divestiture license arrangement information agenu obtain global exclusive license agenu proprietary bispecific antibody program agen block tigit additional target agen currently phase clinical trial eisai commence exclusive global strategic collaboration eisai codevelopment cocommercialization morab selective folate receptor alpha antibodydrug conjugate investigate endometrial ovarian lung breast cancer morab currently phase iii clinical trial solid tumor prothena exercise option global neuroscience research development collaboration exclusive rights prx antitau antibody specifically target area microtubule bind region potential treatment alzheimer disease prx currently phase clinical trial rockefeller university obtain global exclusive license develop manufacture commercialize rockefeller universitys novel monoclonal antibody duo treatment neutralize sarscov virus treatment potentially prevention covid phase clinical trial assess dose subcutaneous formulation assess safety complete rockefeller university enrollment initiate phase study nih activ protocol network site phase enrollment complete august topline datum expect quarter result operation regional revenue composition change revenue follow year end december dollar million change foreign exchangeb united states europe rest world othera total revenue include royalty alliancerelate revenue product sell regional commercial organization foreign exchange impact derive apply prior period average currency rate current period revenue united states revenue increase eliquis recently launch new product revlimid opdivoyervoy average net selling price increase approximately compare period year ago europe europe revenue increase eliquis revlimid opdivoyervoy foreign exchange partially offset low demand mature brand average net selling price low compare period year ago rest world rest world revenue increase opdivoyervoy pomalystimnovid eliquis partially offset low revenue abraxane manufacturing delay mature brand average net selling price low compare period year ago single country outside contribute total revenue business typically seasonal gtn adjustment recognize revenue net gtn adjustment describe critical accounting policy activity end reserve balance significant category gtn adjustment follow year end december rebate chargeback medicaid return discount dollar million cash discount medicare rebate adjustment total balance january provision relate sale current period prior period payment return foreign currency translation balance december reconciliation gross product sale net product sale significant category gtn adjustment follow year end december change dollar million gross product sale gtn adjustment chargeback cash discount medicaid medicare rebate rebate return discount adjustment total gtn adjustment net product sale gtn adjustment percentage nonus reduction provision product sale prior period result change estimate million million respectively reduction provision primarily related eliquis coverage gap discount gtn adjustment primarily function product sale volume regional payer channel mix contractual legislative discount rebate gtn adjustment percentage increase primarily high government channel mix high gtn adjustment percentage product revenue year end december change dollar million revlimid nonus eliquis nonus opdivo nonus pomalystimnovid nonus orencia nonus sprycel nonus yervoy nonus abraxane nonus reblozyl nonus empliciti nonus abecma nonus zeposia nonus breyanzi nonus year end december change dollar million inrebic nonus onureg nonus mature brand nonus total revenue nonus change excess revlimid lenalidomide oral immunomodulatory drug combination dexamethasone indicate treatment patient multiple myeloma revlimid single agent indicate maintenance therapy patient multiple myeloma follow autologous hematopoietic stem cell transplant revenue increase high average net selling price high demand international revenue increase high demand foreign exchange impact exclude foreign exchange impact revenue increase certain party grant volumelimite license sell generic lenalidomide begin march license grant party market generic lenalidomide product prior expiry patent supplementary protection certificate right begin january major market european country france germany italy spain supplementary protection certificate force begin february japan estimate minimum market exclusivity date base composition matter patent expire july global revenues revlimid expect decline approximately billion billion eliquis apixaban oral factor inhibitor indicate reduction risk strokesystemic embolism nvaf treatment dvtpe reduction risk recurrence follow initial therapy revenue increase high demand majority eliquis patient enter coverage gap fourth quarter result low revenue second half year international revenue increase high demand foreign exchange impact exclude foreign exchange impact revenue increase september bristol myers squibbpfizer alliance announce court appeal federal circuit affirm district court august decision find composition matter patent formulation patent cover eliquis valid infringed give decision early generic manufacturer permit launch apixaban product april subject additional challenge follow expiration regulatory exclusivity eliquis europe generic manufacturer seek market generic version eliquis europe prior expiration patent lead additional infringement invalidity action involve eliquis patent file country europe believe innovative science eliquis strength intellectual property defend infringement refer item financial statementsnote legal proceeding contingenciesintellectual property information opdivo nivolumab fully human monoclonal antibody bind nkt cell approve anticancer indication include bladder blood crc head neck rcc hcc lung melanoma mpm stomach opdivoyervoy regimen approve multiple market treatment nsclc melanoma mpm rcc crc gastric esophageal cancer ongoing potentially registrational study opdivo tumor type disease area monotherapy combination yervoy anticancer agent revenue increase high demand multiple therapy include opdivoyervoy combination nsclc opdivocabometyx combination kidney cancer opdivo gastric esophageal cancer high average net selling price partially offset decline secondline eligibility tumor indication increase competition international revenue increase high demand foreign exchange impact partially offset low average net selling price exclude foreign exchange impact revenue increase pomalystimnovid pomalidomide proprietary distinct small molecule administer orally modulate immune system biologically important target pomalystimnovid indicate patient multiple myeloma receive prior therapy include lenalidomide proteasome inhibitor demonstrate disease progression day completion therapy revenue increase high average net selling price high demand international revenue increase high demand foreign exchange impact partially offset low average net selling price exclude foreign exchange impact revenue increase orencia abatacept fusion protein indicate adult patient moderately severely active psa indicate reduce sign symptom certain pediatric patient moderately severely active polyarticular jia revenue increase high demand international revenue remain consistent foreign exchange impact offset low demand exclude foreign exchange impact revenue decrease estimate minimum market exclusivity date previously base method use patent expire formulation additional patent expire orencia biosimilar market japan sprycel dasatinib oral inhibitor multiple tyrosine kinase indicate firstline treatment patient philadelphia chromosomepositive cml chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase cml resistance intolerance prior therapy include gleevec imatinib mesylate treatment child adolescent aged year year chronic phase philadelphia chromosomepositive cml revenue remain consistent high demand offset low average net selling price international revenue decrease low demand result increase generic competition certain indication low average net selling price partially offset foreign exchange impact exclude foreign exchange impact revenue decrease yervoy ipilimumab monoclonal antibody treatment patient unresectable metastatic melanoma opdivoyervoy regimen approve multiple market treatment nsclc melanoma mpm rcc crc revenue increase high demand primarily opdivoyervoy combination nsclc high average net selling price international revenue increase high demand foreign exchange impact partially offset low average net selling price exclude foreign exchange impact revenue increase abraxane paclitaxel albuminbound particle injectable suspension solventfree proteinbound chemotherapy product combine paclitaxel albumin proprietary nab technology platform treat breast cancer nsclc pancreatic cancer revenue increase high average net selling price high demand international revenue decrease manufacturing delay low demand result generic competition partially offset foreign exchange impact exclude foreign exchange impact revenue decrease expect manufacturing delay international continue quarter base settlement reach anticipate generic entry begin march generics enter market japan estimate minimum market exclusivity date base method use patent global revenue abraxane expect decline approximately start reblozyl luspaterceptaamt erythroid maturation agent indicate treatment anemia adult patient beta thalassemia require regular red blood cell transfusion treatment anemia fail esa adult patient low intermediaterisk mds ring sideroblast require rbc transfusion revenue increase high demand primarily launch reblozyl april treatment adult patient mds previously treat esa empliciti elotuzumab humanized monoclonal antibody treatment multiple myeloma abecma idecabtagene vicleucel bcell maturation antigendirecte genetically modify autologous car cell therapy indicate treatment adult patient relapse refractory multiple myeloma prior line therapy include immunomodulatory agent proteasome inhibitor anticd monoclonal antibody abecma launch zeposia ozanimod oral immunomodulatory drug treat relapse form multiple sclerosis include clinically isolate syndrome relapsingremitte disease active secondary progressive disease adult treat moderately severely active adult zeposia launch june breyanzi lisocabtagene maraleucel cddirecte genetically modify autologous car cell therapy indicate treatment adult patient certain type relapse refractory large bcell lymphoma line systemic therapy breyanzi launch april inrebic fedratinib oral kinase inhibitor indicate treatment adult patient intermediate highrisk primary secondary postpolycythemia vera postessential thrombocythemia myelofibrosis inrebic launch august onureg azacitidine oral hypomethylate agent incorporate dna rna indicate continued treatment adult patient aml achieve complete remission complete remission incomplete blood count recovery follow intensive induction chemotherapy able complete intensive curative therapy onureg launch september mature brand include brand include lose exclusivity major market otc brand royalty revenue international revenue decrease low demand low average net selling price result generic competition estimate endus demand pursuant sec consent order describe sec consent order monitor level inventory hand wholesaler distribution channel outside direct customer distribution channel obligate disclose product level inventory excess month hand expect demand subject minimis exception estimate level inventory distribution channel excess month hand follow product material result operation date indicate abraxane month inventory hand internationally distribution channel september compare month inventory hand june ongoing business transition distributor avert forecast order latin america generally determine month hand estimate inventory level product hand outmovement provide large wholesaler account approximately total gross sale product year end december factor influence estimate include generic competition seasonality product wholesaler purchase light increase wholesaler list price new product launch new warehouse opening wholesaler new customer stocking wholesaler addition estimate calculate thirdparty datum impact recordkeeping process revlimid pomalyst distribute primarily contract pharmacy lenalidomide rem pomalyst rem program respectively proprietary riskmanagement distribution program tailor specifically provide safe appropriate distribution use revlimid pomalyst internationally revlimid imnovid distribute mandatory riskmanagement distribution program tailor meet local authority specification provide product safe appropriate distribution use program vary country depend country design riskmanagement program product sell hospital retail pharmacy nonus business significantly direct customer information available direct customer product level inventory correspond movement information reliability thirdparty demand information vary widely limit direct customer sale channel inventory report influence demand information exist available develop variety methodology estimate datum include historical sale direct customer thirdparty market research datum relate prescription trends endus demand give difficulty inherent estimate thirdparty demand information evaluate methodology estimate direct customer product level inventory calculate month hand ongoing basis change necessary factor affect estimate include generic competition seasonality product price increase new product launch new warehouse opening direct customer new customer stocking direct customer expect direct customer purchase governmental bidding situation information require estimate month hand direct customer distribution channel nonus business year end december available prior filing disclose product level inventory excess month hand expect demand subject minimis exception quarterly report form expense year end december change dollar million cost product solda marketing sell administrative research development iprd charge myokardia acquisition amortization acquire intangible asset incomeexpense net total expense exclude amortization acquire intangible asset cost product sell cost product sell include material internal labor overhead cost own manufacturing site thirdparty product supply cost supply chain cost manage global manufacturing supply organization cost product sell include royalty profit share certain excise taxis foreign currency hedge settlement gain loss impairment charge cost product sell typically vary period result product mix volume particularly royaltie profit share less extent change foreign currency price inflation cost attribute manufacturing site exit impairment charge cost product sell exclude amortization acquire intangible asset cost product sell decrease billion primarily lower unwind inventory purchase price adjustment billion low impairment acquire market product right million partially offset high profit sharing royalty eliquis revenue growth expiration sprycel copromotion fee million high product manufacture relate cost marketing sell administrative marketing sell administrative expense primarily include salary benefit cost thirdparty professional marketing fee outsource fee shipping handling cost advertising product promotion cost expense manage regional commercialization organization global enable function finance legal information technology human resource certain expense share alliance partner base contractual agreement marketing sell administrative expense remain unchanged primarily high advertising promotion expense cost support new product launch offset cash settlement myokardia unvested stock awards million acceleration charitable give million research development research development activity include research early discovery preclinical clinical development drug formulation medical support market product expense include salary benefit cost thirdparty grant fee pay clinical research organization supply upfront contingent milestone payment license asset acquisition investigational compound iprd impairment charge proportionate allocation enterprisewide cost allocation include facility information technology employee stock compensation cost appropriate cost certain expense share alliance partner base contractual agreement expense typically vary period number reason include time license asset acquisition charge iprd impairment charge research development expense increase million primarily high cost associate overall portfolio impact significant charge summarize significant charge include research development expense follow year end december dollar millions eisai upfront collaboration fee agenu upfront license fee prothena optin license fee dragonfly upfront license fee milestone bluebird collaboration fee forbius asset acquisition cormorant milestone milestone license asset acquisition charge iprd impairment inventory purchase price accounting adjustment employee compensation charge site exit cost research development significant charge license acquisition charge relate obtain right investigational compound develop company acquisition cost include initial upfront payment additional contingent payment substantive development regulatory milestone achieve prior regulatory approval refer item financial statement supplementary datanote alliance note acquisition divestiture license arrangement information charge iprd impairment charge relate orvacel program study potential treatment hematologic fibrotic disease refer item financial statement supplementary datanote goodwill intangible asset information charge employee compensation charge result cash settlement myokardia unvested stock award site exit cost result celgene integration activity iprd charge myokardia acquisition iprd charge represent cost iprd asset acquire transaction business combination myokardia acquisition account asset acquisition substantially fair value gross asset acquire exclude cash defer taxis allocate single asset mavacamten iprd charge relate myokardia transaction present separately significance charge amortization acquire intangible asset amortization intangible asset primarily relate revlimid pomalystimnovid market product right obtain celgene acquisition amortization acquire intangible asset increase million additional product approval incomeexpense net incomeexpense net change billion primarily contingent value right equity investment item discuss component incomeexpense net follow year end december dollar million interest expense royalty license income equity investment gain integration expense contingent consideration loss debt redemption provision restructure litigation settlement transition service fee investment income divestiture gain intangible asset impairment reversion excise tax incomeexpense net royalty licensing income include diabete business royalty keytruda royalty tecentriq royalty upfront licensing fee milestone product obtain commercial approval refer item financial statement supplementary datanote acquisition divestiture license arrangement information equity investment gain include fair value adjustment investment readily determinable fair value observable price change investment readily determinable fair value result primarily initial public offering thirdparty acquisition entity hold ownership interest share income equity method investment primarily fair value adjustment attribute limited partnership refer item financial statement supplementary datanote financial instrument fair value measurement information integration expense primarily include consulting fee implement celgene integration initiative relate process system contingent consideration primarily include fair value adjustment result change trade price contingent value right issue celgene acquisition contractual obligation pay contingent value right terminate january fda approve lisocel jcar december loss debt redemption result early redemption billion longterm debt obligation provision restructuring include exit cost primarily related celgene acquisition plan achieve approximately billion annualize pretax cost saving relate celgene acquisition plan track achieve annualize pretax cost saving approximately billion detailed restructuring activity refer item financial statement supplementary datanote restructure information litigation settlement include bms share patentinfringement settlement relate roche group pdl antibody tecentriq investment income decrease primarily low interest rate reversion excise tax result transfer retiree medical plan asset company income taxis year end december dollar millions earningsloss income taxis provision income taxis effective tax rate impact specify item effective tax rate exclude specify item tax impact attribute specify item primarily low jurisdictional tax rate attribute unwind inventory purchase price adjustment intangible asset amortization iprd impairment charge contingent value right fair value adjustment taxable deductible internal transfer intangible asset billion income tax benefit recognize revaluation tax basis certain intangible asset internally transfer streamline legal entity structure subsequent celgene acquisition million defer tax charge result internal transfer certain intangible asset streamline legal entity structure subsequent celgene acquisition additional million gilti tax charge finalization otezla divestiture tax consequence tax authority recognize increase effective tax rate exclude specify item favorable discrete tax adjustment approximately million primarily result finalization prior year tax return partially offset jurisdictional earning mix refer item financial statement supplementary datanote income taxis additional information nongaap financial measure nongaap financial measure nongaap earning relate eps information adjust exclude certain cost expense gain loss specify item evaluate individual basis item adjust consider quantitative qualitative aspect typically follow characteristic highly variable difficult project unusual nature significant result particular period indicative future operating result similar charge gain recognize prior period likely reoccur future period include amortization acquire intangible asset include product right generate significant portion ongoing revenue recur intangible asset fully amortize unwind inventory purchase price adjustment iii acquisition integration expense restructuring cost accelerated depreciation impairment property plant equipment intangible asset charge income result upfront contingent milestone payment connection acquisition licensing thirdparty intellectual property right vii divestiture gain loss viii stock compensation result accelerate vest celgene award certain retentionrelate employee compensation charge relate celgene transaction pension legal contractual settlement charge equity investment contingent value right fair value adjustment include adjustment attribute limited partnership equity method investment amortization fair value adjustment debt acquire celgene exchange offer item defer current income taxis attribute item adjust consider individual impact overall tax expense deductibility jurisdictional tax rate certain significant tax item exclude impact result internal transfer intangible asset streamline legal entity structure subsequent celgene acquisition gilti tax charge finalization otezla divestiture provide international revenue priority product exclude impact foreign exchange calculate foreign exchange impact convert currentperiod local currency financial result prior period average currency rate compare adjust amount currentperiod result reconciliation non gaap measure comparable gaap measure include exhibit form file february incorporate reference nongaap information intend portray result baseline performance supplement enhance management analyst investor overall understand underlying financial performance facilitate comparison current past future period example nongaap earning ep information indication baseline performance item consider reflective ongoing result addition information primary indicator use basis evaluate performance allocate resource set incentive compensation target planning forecast future period information intend consider isolation substitute net earning dilute eps prepared accordance gaap comparable similarly title measure present company possible difference method item adjust encourage investor review financial statement publiclyfile report entirety rely single financial measure specify item follow year end december dollar million inventory purchase price accounting adjustment intangible asset impairment employee compensation charge site exit cost cost product sell employee compensation charge site exit cost marketing sell administrative license asset acquisition charge iprd impairment inventory purchase price accounting adjustment employee compensation charge site exit cost research development iprd charge myokardia acquisition amortization acquire intangible asset interest expensea contingent consideration royalty license income equity investment gain integration expense provision restructure litigation settlement reversion excise tax divestiture gain loss debt redemption incomeexpense net increase pretax income income taxis item income taxis attribute otezla divestiture income taxis attribute internal transfer intangible asset income taxis increase net earning include amortization purchase price adjustment celgene debt reconciliation gaap nongaap follow year end december dollar million share datum net earningsloss attributable bms diluted eps calculation gaap specify item net earning attributable bms diluted eps calculation nongaap weightedaverage common share outstanding diluted gaap incremental share attributable sharebased compensation plan weight average common share outstanding diluted nongaap dilute earningsloss share attributable bms gaap dilute eps attributable specify item dilute eps attributable bms nongaap financial position liquidity capital resource net debt position follow december dollar million cash cash equivalent marketable debt security current marketable debt security noncurrent total cash cash equivalent marketable debt security shortterm debt obligation longterm debt net debt position liquidity capital resource regularly assess anticipate work capital need debt leverage level debt maturity capital expenditure requirement dividend payout potential share repurchase future investment acquisition order maximize shareholder return efficiently finance ongoing operation maintain flexibility future strategic transaction regularly evaluate capital structure ensure financial risk adequate liquidity access low cost capital efficiently manage lead issuance additional debt security repurchase debt security prior maturity issuance repurchase common stock believe exist cash cash equivalent marketable debt security cash generate operation require issuance commercial paper sufficient satisfy anticipate cash need year include dividend capital expenditure milestone payment work capital restructuring initiative business development repurchase common stock debt maturity approximately billion debt repurchase redemption tender offer share repurchase program authorize board director allow repurchase share specific timing number share repurchase determined management discretion vary base market condition security law limitation factor share repurchase program obligate repurchase specific number share specific expiration date suspend discontinue time repurchase effect combination open market repurchase privately negotiate transaction transaction structure investment banking institution derivative transaction rely rule rule exchange act outstanding share repurchase authorization program billion december board director approve increase share repurchase authorization common stock billion january billion december repurchase approximately million share common stock billion remaining share repurchase capacity share repurchase program approximately billion december refer item financial statement supplementary datanote equity additional information february execute accelerated share repurchase asr agreement repurchase aggregate billion common stock asr agreement fund cash onhand expect settle second quarter total number share repurchase asr agreement base volumeweighted average price common stock term asr transaction discount subject adjustment pursuant term condition asr agreement dividend payment billion billion dividend authorize quarterly basis board director commercial paper program issue maximum billion unsecured note maturity day date issuance commercial paper borrowing outstanding december purchase aggregate principal billion certain debt security approximately billion cash series tender offer redemption billion note mature repay december separate revolve credit facility total billion consist day billion facility expire january threeyear billion facility expire january fiveyear billion facility extend september july respectively borrowing outstanding revolve credit facility december january enter fiveyear billion facility expire january extendable annually year consent lender facility provide customary term condition financial covenant provide backup liquidity commercial paper borrowing concurrently entry facility commitment exist fiveyear billion facility terminate threeyear billion facility day billion facility expire accordance term january investment portfolio include marketable debt security subject change fair value result interest rate fluctuation market factor investment policy establishe limit time maturity investment institution policy require investment enter corporate financial institution meet high credit quality standard refer item financial statement supplementary datum note financial instrument fair value measurement information capital expenditure annual capital expenditure approximately million million million expect approximately billion continue capital expenditure connection expansion cell therapy manufacturing capability research development facilityrelate activity contractual obligation offbalance sheet arrangement normal course business enter contract commitment obligate payment future information obligation relate debt income taxis lease arrangement provide item financial statement supplementary datanote income taxis note financial instrument fair value measurement note lease respectively commit aggregate billion potential contingent future research development milestone payment party inlicense asset acquisition development program include earlystage milestone billion milestone achieve phase iii clinical study latestage milestone billion milestone achieve post phase iii clinical study payment generally payable achievement certain developmental regulatory milestone specific timing predict certain agreement provide salesbased milestone aggregate billion obligate pay achievement certain sale level addition royalty certain manufacturing development commercialization obligation connection alliance arrangement practicable estimate obligation refer item financial statement supplementary datanote alliance information alliance offbalance sheet arrangement material reasonably likely material financial condition result operation credit rating current longterm shortterm credit rating assign moodys investor service prime respectively stable longterm credit outlook current longterm shortterm credit rating assign standard poor respectively negative longterm credit outlook longterm rating reflect agency opinion low default risk somewhat susceptible adverse effect change circumstance economic condition shortterm rating reflect agency opinion good extremely strong capacity timely repayment credit rating downgrade affect interest rate debt incur fair market value exist debt ability access capital market generally cash flow follow discussion cash flow activity year end december dollar million cash flow provide byused operating activity invest activity financing activity operate activity cash flow operating activity represent cash receipt disbursement activity invest financing activity operate cash flow derive adjust net earning noncontrolle interest noncash operating item gain loss attribute invest financing activity change operate asset liability result time difference receipt payment cash transaction recognize result operation result change cash operating activity reflect time cash collection customer alliance partner payment supplier alliance partner employee customer discount rebate tax payment ordinary course business billion change cash flow operating activity compare primarily high cash collection time payment ordinary course business low celgene restructure integration payment million cash settlement myokardia unvested stock award million partially offset reversion postretirement plan asset million investing activity cash requirement invest activity include cash acquisition manufacturing facilityrelate capital expenditure purchase marketable security original maturity great day time purchase proceed business divestiture include royalty sale maturity marketable security sale equity investment upfront contingent milestone license arrangement billion change cash flow investing activity compare low license asset acquisition payment billion primarily result myokardia acquisition high proceed sale equity investment approximately billion partially offset change marketable debt security hold billion financing activity cash requirement financing activity include cash pay dividend repurchase common stock repay longterm debt borrowing reduce proceed exercise stock option issuance longterm debt borrowing billion change cash flow financing activity compare primarily debt issuance approximately billion partially fund myokardia acquisition high debt repayment billion include series tender offer redemption high share repurchase billion sec consent order previously disclose august enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter settlement reach consent copy attach exhibit quarterly report form period end september term consent agree subject certain define exception limit sale product sell direct customer include wholesaler distributor hospital retail outlet pharmacie government purchaser base expect demand amount exceed approximately month inventory hand make timely public disclosure change practice agree consent certain measure implement include establish formal review certification process annual quarterly report file sec establish business risk disclosure group retain outside consultant comprehensively study help reengineer accounting financial reporting process publicly disclose sale incentive offer direct customer purpose induce purchase product excess expect demand ensure budget process give appropriate weight input come adequately document process establish companywide policy concern sale direct customer purpose comply consent include adoption procedure monitor limit sale direct customer accordance term consent procedure include governance process escalate appropriate management level potential question concern compliance policy timely resolution question concern addition compliance policy monitor regular basis maintain dsas pharmaceutical wholesaler account nearly gross revenue current term dsas wholesaler customer provide weekly information respect month hand productlevel inventory outmovement product large wholesaler currently account approximately gross revenue inventory information receive wholesaler internal information estimate month hand product level inventory wholesaler estimate month hand product inventory level businesss wholesaler customer large wholesaler extrapolate month hand calculate large wholesaler contrast nonus business significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely accordingly rely variety method estimate month hand product level inventory business unit believe abovedescribe procedure provide reasonable basis ensure compliance consent recently issue accounting standard recently issue accounting standard refer item financial statement supplementary datanote accounting policy recently issue accounting standard critical accounting policy preparation financial statement require use estimate assumption affect report amount asset liability report amount revenue expense critical accounting policy significantly affect financial condition result operation require difficult subjective complex judgment need estimate effect matter inherently uncertain uncertainty actual result vary estimate revenue recognition accounting policy revenue recognition substantial impact report result rely certain estimate revenue recognize follow step model identify customer contract identify contract performance obligation iii determine transaction price allocate transaction price performance obligation recognize revenue performance obligation satisfied revenue reduce gtn sale adjustment discuss involve significant estimate judgment consider legal interpretation applicable law regulation historical experience payer channel mix medicare medicaid current contract price applicable program unbilled claim processing time lag inventory level distribution channel estimate assess period adjust require revise information actual experience follow category gtn adjustment involve significant estimate judgment information obtain external source refer item financial statement supplementary datanote revenue discussion analysis significant category gtn sale adjustment chargeback cash discount business participate program government entity significant department defense department veteran affair party include cover entity drug pricing program pricing product extend wholesaler list price participate entity entity purchase product wholesaler low program price wholesaler charge difference acquisition cost low program price account receivable reduce estimate unprocessed chargeback claim attributable sale typically week time lag certain country customer offer cash discount incentive prompt payment generally approximate invoice sale price account receivable reduce estimate cash discount time sale discount typically take customer month medicaid medicare rebate business participate state government medicaid program qualify federal state government program require discount rebate participate state local government entity discount rebate provide program include medicaid rebate accrual medicaid rebate extend drug manage medicaid plan estimate unpaid unbilled rebate present liability rebate discount offer manage healthcare organization manage prescription drug program medicare advantage prescription drug plan cover medicare drug benefit pay point service discount cms medicare beneficiarie coverage gap estimate unpaid unbilled rebate discount present liability rebate return discount adjustment gtn sale adjustment include sale return program base applicable law regulation individual nonus country rebate offer manage healthcare organization less extent nonus program include different pricing scheme cost cap volume discount outcomebase pricing scheme pricing clawback base sale individual company aggregation company participate specific market estimate unpaid unbilled rebate discount present liability estimate return establish product determine consider historical experience factor include level inventory distribution channel estimate shelf life product recall product discontinuance price change competitive product introduction generic product introduction competitive new product low demand follow loss market exclusivity estimate return new product determine consider historical sale return experience similar product product line similar therapeutic area andor similar distribution model estimate level inventory distribution channel project demand estimate product return present liability use information external source information external source estimate gtn adjustment estimate inventory wholesaler base project prescription demand base sale product historical inventory experience analysis thirdparty information include write oral information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum internal information inventory information receive wholesaler product recordkeeping process exclude inventory hold intermediary sell retailer hospital continue practice combine retail mail prescription volume retailequivalent basis use methodology internal demand forecast use information external source identify prescription trend patient demand average selling price estimate subject inherent limitation estimate rely thirdparty information certain thirdparty information form estimate reflect limitation include lags date thirdparty information generate date receive thirdparty information longlive asset intangible asset valuation significant purchase price celgene acquisition allocate intangible asset include acquire market product right iprd asset intangible asset billion december billion december identifiable intangible asset measure respective fair value acquisition date engage independent thirdparty valuation firm assist determine fair value asset acquisition date fair value asset estimate discount cash flow model model require use follow significant estimate assumption identification product candidate sufficient substance require separate recognition estimate revenue operate profit relate commercial product product candidate eligible patient price market share estimate future revenue probability success unapproved product candidate additional indication commercial product resource require complete development approval product candidate time regulatory approval exclusivity appropriate discount rate product market participant income tax rate allocation expect synergies product believe estimate preliminary fair value assign intangible asset acquire reasonable estimate assumption consider fact circumstance acquisition date impairment amortization longlive asset include intangible asset longlive asset include intangible asset property plant equipment review impairment event change circumstance indicate carry asset recoverable annually iprd intangible asset highly vulnerable impairment charge particularly newly acquire asset recently launch product iprd asset initially measure fair value reduction expectation valuation potentially lead impairment common potential risk leading impairment include change competitive landscape early expect loss market exclusivity pricing reduction adverse regulatory change clinical study result delay failure obtain regulatory approval initial follow indication unanticipate development cost inability achieve expect synergy result cost saving avoidance high operating cost change tax law macroeconomic change complexity estimate fair value intangible asset connection impairment test similar initial valuation carrying value longlive asset exceed fair value asset write fair value expectation future cash flow subject change base near longterm production volume margin generate asset potential alternative future use estimate useful life longlive asset subjective require significant judgment patent life future plan external market factor longlive asset periodically review change fact circumstance result reduction estimate useful life asset require acceleration depreciation amortization impairment charge million recognize cost product sell carry value inrebic regulatory approval milestone exceed project undiscounted cash flow asset additionally impairment charge million record research development expense relate iprd asset refer item financial statement supplementary datanote goodwill intangible asset discussion analysis impairment charge goodwill goodwill represent excess consideration transfer estimate fair value net asset acquire business combination goodwill billion december assess goodwill balance single reporting unit annually event change circumstance indicate carry value goodwill recoverable determine impairment asset exist extent impairment goodwill review impairment assess qualitative factor include compare market capitalization carry value asset event circumstance require interim evaluation include unexpected adverse business condition economic factor unanticipate technological change competitive activity act government court income taxis valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment defer tax asset billion december net valuation allowance billion billion december net valuation allowance billion federal net operating loss carryforward million december carryforward acquire result certain acquisition subject limitation section internal revenue code net operating loss carryforward expire vary amount begin foreign state net operating loss carryforward expire vary amount begin certain amount unlimited life prior mead johnson splitoff follow transaction occur internal spinoff mead johnson share own conversion mead johnson class share class share iii conversion mead johnson company limited liability company transaction splitoff mead johnson exchange offer qualify taxexempt transaction internal revenue code base private letter ruling receive internal revenue service relate conversion mead johnson class share class share outside legal opinion certain assumption representation covenant mead johnson rely future conduct business matter affect tax treatment exchange example current tax law generally create presumption exchange taxable mead johnson shareholders engage transaction result great change stock ownership year period begin year exchange offer establish exchange offer plan series relate transaction effect change ownership internal spinoff exchange offer determine qualify tax exempt transaction transaction subject tax exchange taxable sale market value addition negative basis excess loss account ela exist investment stock mead johnson prior transaction receive opinion outside legal counsel effect likely eliminate ela transaction taxable income respect ela tax law area complex possible internal spinoff exchange offer tax exempt internal revenue code internal revenue service assert additional taxable income period respect ela expose additional taxis occur base understand internal revenue code opinion outside legal counsel tax reserve million establish reduce gain disposal mead johnson include discontinued operation agree certain tax relate indemnity mead johnson set forth tax sharing agreement include certain taxis relate business prior completion initial public offering create restructure facilitate ipo mead johnson agree indemnify potential tax effect result breach certain representation discuss certain transaction relate acquisition mead johnson stock asset liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know discussion income taxis refer item financial statement supplementary datanote accounting policy recently issue accounting standardsincome taxis note income taxis contingency normal course business subject contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter recognize accrual contingency probable liability incur loss reasonably estimate estimate subject uncertainty difficult predict actual result vary estimate discussion contingency refer item financial statement supplementary datanote accounting policy recently issue accounting standardscontingencie note income taxis note legal proceeding contingency product pipeline development program manage portfolio basis early discovery latestage development include balance earlystage latestage program support future growth late stage program phase iii development include investigational compound initial indication additional indication formulation market product spending program represent approximately annual expense year opdivo investigational compound market product represent great expense year late stage development program potentially impact revenue earning year regulatory approval obtain product successfully commercialize follow development market product latestage pipeline product indication date development announce fda approval opdivo adjuvant treatment patient urothelial carcinoma august high risk recurrence undergo radical resection regardless prior neoadjuvant chemotherapy nodal involvement pdl status approval base phase iii checkmate trial ono alliance partner opdivo japan announce submission supplemental application bladder opdivo expand use adjuvant therapy resect urothelial cancer partial change approve march item manufacturing marketing approval application base result global phase iii checkmate ono trial announce ema validate type variation application opdivo adjuvant treatment march patient surgically resect highrisk muscleinvasive urothelial carcinoma application base result phase iii checkmate trial ono alliance partner opdivo japan announce japan ministry health labour welfare approve opdivo expand use firstline treatment unresectable advanced recurrent november gastric cancer combination chemotherapy partial change approve item manufacture marketing approval approval base result phase iii checkmate ono trial ono alliance partner opdivo japan announce japan ministry health labour welfare approve opdivo adjuvant treatment esophageal cancer partial change approve november item manufacturing marketing approval approval base result phase iii checkmate ono trial announce approval opdivo combination fluoropyrimidine platinumbase combination chemotherapy firstline treatment adult patient hernegative advanced metastatic gastric october gastroesophageal junction esophageal adenocarcinoma tumor express pdl combine positive score approval base result phase iii checkmate trial opdivo announce approval opdivo adjuvant treatment adult patient esophageal july gastroesophageal junction cancer residual pathologic disease follow prior neoadjuvant gastric esophageal chemoradiotherapy approval base result phase checkmate trial cancer announce fda approval opdivo adjuvant treatment patient completely resect esophageal gastroesophageal junction cancer residual pathologic disease receive neoadjuvant chemoradiotherapy approval base result phase iii checkmate trial announce fda approval opdivo combination combination fluoropyrimidine platinum contain chemotherapy treatment patient advance metastatic gastric cancer april gastroesophageal junction cancer esophageal adenocarcinoma regardless pdl expression status approval base phase iii checkmate trial announce positive topline result phase iii checkmate trial evaluate treatment opdivo plus chemotherapy opdivo plus yervoy patient unresectable advanced metastatic escc opdivo plus chemotherapy meet primary secondary endpoint overall survival patient tumor april express pdl allrandomize patient population primary endpoint progression free survival pdl population opdivo plus yervoy meet primary secondary endpoint overall survival population primary endpoint progression free survival pdl population meet announce consultation fda withdraw indication opdivo hcc follow treatment sorafenib opdivo grant accelerated approval indication base tumor hcc july response phase iii checkmate trial checkmate confirmatory randomize study opdivo versus sorafenib firstline set achieve statistical significance primary endpoint overall survival prespecified analysis product indication date developments ono alliance partner opdivo japan announce japan ministry health labour welfare approve opdivo treatment pediatric patient recurrent refractory classical hodgkin lymphoma september hodgkin lymphoma partial change approve item manufacture marketing approval approval base result phase penguin trial announce phase iii checkmate trial meet primary endpoint improve eventfree survival patient resectable stage iiia nsclc prespecifie interim analysis opdivo plus nsclc november chemotherapy show statistically significant clinically meaningful improvement eventfree survival compare chemotherapy give surgery opdivo ono alliance partner opdivo japan announce japans ministry health labour welfare approve combination therapy opdivo cabometyx treatment unresectable august metastatic rcc partial change approve item manufacture marketing approval approval base result phase iii checkmateer trial rcc announce approval opdivo combination cabometyx firstline treatment adult april advanced rcc approval base result phase iii checkmateer trial announce fda approval opdivo combination cabometyx firstline treatment january patient advance rcc approval base phase iii checkmateer trial announce approval opdivo plus yervoy treatment adult patient mismatch repair crc june deficient dmmr microsatellite instabilityhigh mcrc prior fluoropyrimidinebase combination chemotherapy approval base result phase checkmate trial announce new sixandahalf year datum phase iii checkmate trial demonstrate durable melanoma improvement survival firstline opdivo plus yervoy therapy opdivo monotherapy versus yervoy patient advanced melanoma announce fda accept sbla opdivo combination yervoy opdivo combination fluoropyrimidine platinumcontaine chemotherapy firstline treatment adult september patient unresectable advanced recurrent metastatic esophageal squamous cell carcinoma fda assign pdufa goal date sbla submission base phase iii checkmate trial ono alliance partner opdivo japan announce company submit supplemental application japan opdivo combination yervoy opdivo combination chemotherapy september firstline treatment unresectable advanced recurrent esophageal cancer partial change esophageal approve item manufacturing marketing approval japan application base result phase iii checkmate trial opdivo yervoy announce ema validate maa opdivo combination yervoy opdivo combination fluoropyrimidine platinumcontaine chemotherapy firstline treatment adult august patient unresectable advanced recurrent metastatic esophageal squamous cell carcinoma validation application confirm submission complete begin emas centralized review process application base result pivotal phase iii checkmate trial announce threeyear datum checkmate trial demonstrate durable survival benefit september firstline treatment opdivo plus yervoy compare platinumbase standardofcare chemotherapy patient unresectable malignant pleural mesothelioma regardless histology announce approval opdivo plus yervoy line treatment adult unresectable malignant pleural june malignant pleural mesothelioma approval base result phase iii checkmate trial mesothelioma ono alliance partner opdivo japan announce company receive approval combination therapy opdivo yervoy japan firstline treatment unresectable advanced recurrent malignant pleural mesothelioma partial change approve item manufacture marketing approval approval base result phase iii checkmate trial product indication date development announce opdivo plus yervoy continue demonstrate durable longterm survival phase iii checkmate trial fiveyear survival rate patient previously untreate advanced rcc september metastatic rcc median followup month opdivo plus yervoy maintain superior overall survival response benefit versus sunitinib patient intermediate poorrisk prognostic factor primary endpoint population randomize patient announce phase iii checkmate trial continue demonstrate longterm survival benefit firstline treatment opdivo plus yervoy compare chemotherapy patient advance nsclc regardless pdl expression level histology minimum followup year opdivo yervoy nsclc announce opdivo plus yervoy cycle chemotherapy show durable survival benefit compare cycle chemotherapy year followup previously untreated patient advance nsclc phase iii checkmatela trial announce update phase iii checkmate trial compare opdivo plus yervoy extreme regiman cetuximab cisplatincarboplatin fluorouracil firstline treatment platinumeligible patient scchn july recurrent metastatic scchn opdivo plus yervoy show clear positive trend overall survival patient tumor express pdl combine positive score study meet primary endpoint announce fda approval orencia prevention agvhd combination calcineurin inhibitor methotrexate adult pediatric patient year age old undergo hematopoietic orencia agvhd december stem cell transplantation match allelemismatche unrelated donor approval base result phase aba trial announce fda accept priority review sbla reblozyl treatment anemia december adult nontransfusion dependent beta thalassemia fda set pdufa goal date march sbla base result phase trial announce ema validate maa reblozyl treatment anemia adult non transfusion dependent beta thalassemia validation application confirm submission reblozyl beta thalassemia december complete begin emas centralized review process application base result pivotal phase trial announce acceleron phase study evaluate reblozyl plus well supportive care adult patient nontransfusion dependent beta thalassemia demonstrate patient treat june reblozyl achieve hemoglobin increase gramdeciliter compare patient placebo arm announce approval zeposia treatment adult moderately severely active november inadequate response lose response intolerant conventional therapy biologic agent approval base datum pivotal phase iii true north trial announce fda approval zeposia treatment adult moderately severely active approval base datum pivotal phase iii true north trial zeposia announce interim result phase iii openlabel extension trial daybreak demonstrate long term efficacy safety profile zeposia patient relapse form daybreak extension study safety consistent prior finding new safety signal emerge report october period longterm use zeposia treatment zeposia demonstrate low annualize relapse rate month participant relapsefree month confirm disability progression observe participant trial respectively announce approval inrebic treatment diseaserelate splenomegaly enlarge spleen inrebic myelofibrosis february symptom adult patient primary myelofibrosis postpolycythaemia vera myelofibrosis post essential thrombocythaemia myelofibrosis jak inhibitor nave treat ruxolitinib announce approval onureg maintenance therapy adult patient aml achieve complete remission complete remission incomplete blood count recovery follow induction therapy onureg aml june consolidation treatment candidate include choose proceed hematopoietic stem cell transplantation approval base datum phase iii quazar aml study product indication date development receive positive chmp opinion breyanzi treatment adult patient relapse refractory diffuse large bcell lymphoma primary mediastinal large bcell lymphoma follicular lymphoma grade january line systemic therapy opinion base datum transcend nhl trial announce positive topline result phase iii transform trial evaluate breyanzi second line treatment adult relapse refractory large bcell lymphoma compare salvage therapy follow highdose chemotherapy hematopoietic stem cell transplant result prespecifie june interim analysis conduct independent review committee show study meet primary endpoint demonstrate clinically meaningful highly statistically significant improvement eventfree survival breyanzi lymphoma key secondary endpoint complete response rate progressionfree survival compare standard care announce japans ministry health labour welfare approval breyanzi treatment march patient relapse refractory large bcell lymphoma relapse refractory follicular lymphoma announce fda approval breyanzi treatment adult patient relapse refractory large cell lymphoma line systemic therapy include diffuse large bcell lymphoma february specify include dlbcl arise indolent lymphoma highgrade bcell lymphoma primary mediastinal large bcell lymphoma follicular lymphoma grade announce japan ministry health labour welfare approval abecma treatment adult patient relapse refractory multiple myeloma receive prior therapy include january immunomodulatory agent proteasome inhibitor anticd antibody experienced disease progression therapy relapse therapy approval base result phase bbmm phase crb trial announce approval abecma treatment adult patient relapse refractory multiple abecma multiple myeloma august myeloma receive prior therapy include immunomodulatory agent proteasome inhibitor anticd antibody demonstrate disease progression therapy approval base result pivotal karmma study announce bluebird fda approval abecma idecabtagene vicleucel idecel treatment adult patient relapse refractory multiple myeloma prior line therapy include march immunomodulatory agent proteasome inhibitor anticd monoclonal antibody approval base result pivotal phase karmma study announce phase latticeuc study evaluating deucravacitinib compare placebo moderate severe meet primary efficacy endpoint clinical remission week secondary efficacy endpoint safety profile deucravacitinib consistent previously report study october psoriasis psoriatic arthritis new safety signal observe potential deucravacitinib continue evaluate second phase trial include high dose announce fda accept nda deucravacitinib treatment adult november moderate severe plaque psoriasis fda set pdufa goal date september nda base result phase iii poetyk pso poetyk pso trial announce ema validate maa deucravacitinib treatment adult moderate severe plaque psoriasis validation application confirm submission deucravacitinib november complete begin emas centralized review process application base result phase iii poetyk pso poetyk pso trial plaque psoriasis announce japan ministry health labour welfare accept nda deucravacitinib treatment adult moderate severe plaque psoriasis pustular psoriasis erythrodermic november psoriasis application base result phase iii poetyk pso poetyk pso trial announce positive result poetyk pso second pivotal phase iii trial evaluate deucravacitinib tyrosine kinase inhibitor treatment patient moderate severe plaque psoriasis poetyk pso meet coprimary endpoint versus placebo significantly february patient achieve psoriasis area severity index pasi define percent improvement baseline pasi static physician global assessment spga score clear clear spga week treatment product indication date development announce fda extended review nda mavacamten treatment november patient symptomatic obstructive hypertrophic cardiomyopathy april allow sufficient time review information pertaining update propose rem announce ema validate maa mavacamten treatment patient october obstructive hcm validation application confirm submission complete begin emas centralized review process application base result pivotal phase iii explorerhcm trial mavacamten obstructive hcm announce new analysis datum phase iii explorerhcm study evaluating mavacamten investigational firstinclass cardiac myosin inhibitor patient ohcm week change kansas city cardiomyopathy questionnaire overall summary score kccq oss great mavacamten patient placebo similar benefit kccq subscale announce fda accept nda mavacamten investigational novel oral allosteric march modulator cardiac myosin patient symptomatic obstructive hypertrophic cardiomyopathy fda assign pdufa goal date january announce ema validate maa relatlimab nivolumab fixeddose combination october line treatment adult pediatric patient advance unresectable metastatic melanoma validation application confirm submission complete begin emas centralized review process application base result pivotal phase iiiii relativity trial announce fda accept priority review bla fix dose combination relatlimab nivolumab treatment adult pediatric patient unresectable metastatic september melanoma fda assign pdufa goal date march bla submission base relatlimab melanoma phase iiiii relativity trial announce primary result phase iiiii relativity trial evaluate fix dose combination relatlimab antilag antibody opdivo versus opdivo patient previously untreate metastatic unresectable melanoma trial meet primary endpoint march progressionfree survival follow overall survival secondary endpoint ongoing fixeddose combination welltolerate new safety signal report relatlimab opdivo combination arm opdivo arm special note forwardlooke statement include document incorporate reference write oral statement time time contain certain forward look statement meaning section security act section exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base current expectation projection future financial result goal plan objective involve inherent risk assumption uncertainty include internal external factor delay divert change year cause future financial result goal plan objective differ materially express imply statement statement likely relate thing goal plan objective financial position result operation cash flow market position product development product approval sale effort expense performance result current anticipate product business development strategy relation ability realize project benefit acquisition celgene myokardia impact covid pandemic operation development commercialization product potential law regulation low drug price market action take private government payer manage drug utilization contain cost expiration patent datum protection certain product include assumption ability retain marketing exclusivity certain product outcome contingency legal proceeding financial result forwardlooke statement guarantee include important factor cautionary statement include particularly item risk factor believe cause actual result differ materially forwardlooke statement believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date additional risk currently deem immaterial presently know cause forwardlooke event discuss occur require federal security law undertake obligation release publicly update revision forwardlooke statement result new information future event change circumstance date item quantitative qualitative disclosure market risk expose market risk result change currency exchange rate interest rate certain derivative financial instrument available costeffective basis hedge underlie economic exposure financial instrument include derivative subject counterparty credit risk consider overall fair value measurement derivative financial instrument trading purpose foreign exchange risk significant amount revenue earning cash flow expose change foreign currency rate primary net foreign currency translation exposure euro japanese yen foreign currency forward contract manage risk primarily arise certain intercompany sale purchase transaction expose foreign exchange transaction risk arise nonfunctional currency denominate asset liability earning denominate nonus dollar currency foreign currency forward contract offset exposure designate hedge estimate appreciation underlie currency hedge level dollar variable hold constant decrease fair value foreign exchange forward contract million million december december respectively reduce earning remain life contract expose translation risk nonus dollardenominate net asset nonus dollar borrowing hedge foreign currency exposure net investment certain international affiliate designate hedge net investment effective portion foreign exchange gain loss hedge include foreign currency translation component accumulate comprehensive loss net investment decrease equivalent value nonus debt borrowing change remeasurement basis debt subject recognition income change occur additional information refer item financial statement supplementary datanote financial instrument fair value measurement interest rate risk use fixedtofloate interest rate swap contract designate fair value hedge provide appropriate balance fix float rate debt use cross currency interest rate swap contract designate hedge company net investment japan subsidiary fair value contract marketable debt security analyze yearend determine sensitivity interest rate change sensitivity analysis basis point increase shortterm longterm interest rate december december expect adverse impact earning material estimate increase basis point longterm interest rate december december decrease fair value longterm debt billion billion respectively credit risk monitor investment counterpartie objective minimize concentration credit risk investment policy invest institution meet high credit quality standard establish limit time maturity investment individual counterparty policy require investment enter corporate financial institution meet high credit quality standard use derivative instrument expose credit risk counterparty fails perform fair value derivative instrument contract positive counterparty fails perform collateral require party derivative asset liability position policy diversify derivative counterpartie mitigate overall risk counterparty default additional information refer item financial statement supplementary datanote financial instrument fair value measurement item financial statement supplementary datum bristolmyer squibb company consolidate statement earning dollar million share datum year end december earning net product sale alliance revenue total revenue cost product solda marketing sell administrative research development iprd charge myokardia acquisition amortization acquire intangible asset incomeexpense net total expense earningsloss income taxis provision income taxis net earningsloss noncontrolle interest net earningsloss attributable bms earningsloss common share basic dilute exclude amortization acquire intangible asset consolidate statement comprehensive incomeloss dollar millions year end december comprehensive incomeloss net earningsloss comprehensive incomeloss net taxis reclassification earning derivative qualify cash flow hedge pension postretirement benefit marketable debt security foreign currency translation total comprehensive incomeloss comprehensive incomeloss comprehensive income attributable noncontrolle interest comprehensive incomeloss attributable bms accompany note integral consolidated financial statement bristolmyers squibb company consolidated balance sheet dollar million share share datum december asset current asset cash cash equivalent marketable debt security receivables inventory current asset total current asset property plant equipment goodwill intangible asset defer income taxis marketable debt security noncurrent asset total asset liability current liability shortterm debt obligation account payable current liability total current liability defer income taxis longterm debt noncurrent liability total liability commitment contingency equity bristolmyers squibb company shareholder equity prefer stock convertible series par value share authorize million share issue outstanding liquidation value share common stock par value share authorize billion share billion issue capital excess par value stock accumulate comprehensive loss retain earning cost treasury stock million common share million common share total bristolmyer squibb company shareholder equity noncontrolle interest total equity total liability equity accompany note integral consolidated financial statement bristolmyers squibb company consolidate statement cash flow dollar million year end december cash flow operating activity net earningsloss adjustment reconcile net earningsloss net cash provide operating activity depreciation amortization net defer income taxis stockbase compensation impairment charge pension settlement amortization divestiture gain royalty iprd charge myokardia acquisition asset acquisition charge equity investment gain net contingent consideration fair value adjustment adjustment change operate asset liability receivable inventory account payable rebate discount income taxis payable net cash provide operating activity cash flow invest activity sale maturity marketable debt security purchase marketable debt security proceed sale equity investment security capital expenditure divestiture proceed acquisition payment net cash acquire net cash investing activity cash flow financing activity shortterm debt obligation net issuance longterm debt repayment longterm debt repurchase common stock dividend net cash inprovided financing activity effect exchange rate cash cash equivalent restrict cash increase cash cash equivalent restrict cash cash cash equivalent restrict cash beginning year cash cash equivalent restrict cash end year accompany note integral consolidated financial statement note accounting policy recently issue accounting standard basis consolidation consolidate financial statement prepare conformity gaap include account bristolmyer squibb company control majorityowned subsidiary certain variable interest entity intercompany balance transaction eliminate material subsequent event evaluate disclose report issuance date refer summary abbreviate term end term document alliance license arrangement assess determine term provide economic control entity require consolidation entity entity control mean majority voting interest refer variable interest entity consolidate bms power direct activity variable interest entity significantly impact economic performance obligation absorb loss right receive benefit potentially significant entity business segment information bms operate single segment engage discovery development licensing manufacturing marketing distribution sale innovative medicine help patient prevail disease global research development organization supply chain organization responsible discovery development manufacturing supply product regional commercial organization market distribute sell product business support global corporate staff function consistent bmss operational structure chief executive officer ceo chief operating decision maker manage allocate resource global corporate level manage allocate resource global corporate level enable ceo assess overall level resource available well deploy resource function therapeutic area regional commercial organization research development project line overarch longterm corporatewide strategic goal product franchise basis determination single segment consistent financial information regularly review ceo purpose evaluate performance allocate resource set incentive compensation target planning forecast future period information product regional revenue note revenue use estimate judgment preparation financial statement require use management estimate judgment assumption significant assumption estimate determine accounting acquisition impairment goodwill intangible asset chargeback cash discount sale rebate return adjustment legal contingency income taxis actual result differ estimate reclassification certain reclassification conform prior period consolidated financial statement current period presentation proceed receive sale equity investment security previously present divestiture proceed consolidated statement cash flow present separately proceed sale equity investment security additionally rebate discount previously present change operate asset liability consolidated statement cash flow present separately rebate discount cash cash equivalent cash cash equivalent include bank deposit time deposit commercial paper money market fund cash equivalent consist highly liquid investment original maturity month time purchase recognize cost approximate fair value marketable debt security marketable debt security classify availableforsale date purchase report fair value fair value determine base observable market quote valuation model assessment counterparty credit worthiness credit default risk underlie security overall capital market liquidity marketable debt security review impairment assess decline market value investment carry value temporary consider intent ability retain investment period time sufficient allow anticipated recovery market value duration extent market value cost investee financial condition investment equity security investments equity security readily determinable fair value record fair value change fair value record incomeexpense net investment equity security readily determinable fair value record cost minus impairment plus minus change estimate fair value result observable price change orderly transaction identical similar investment issuer change estimate fair value investment equity security readily determinable fair value record incomeexpense net investment own company account equity method accounting ability exercise significant influence operate financial decision investee maintain proportional share investee net income loss equity investment account equity method include incomeexpense net investment equity security readily determinable fair value investment equity account equity method assess potential impairment quarterly basis base qualitative factor inventory valuation inventory state low average cost net realizable value property plant equipment depreciation expenditure addition renewal improvement capitalize cost depreciation compute straightline method base estimate useful life relate asset range year building year machinery equipment fixture current fact circumstance periodically evaluate determine carry value depreciable asset hold recoverable circumstance exist estimate undiscounted future cash flow generate longlived asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique unobservable fair value input discount value estimate future cash flow capitalize software eligible cost obtain internal use software capitalize amortize estimate useful life software range year acquisition business acquire consolidate obtain control fair value asset acquire liability assume recognize date acquisition excess purchase price estimate fair value net asset acquire recognize goodwill business acquisition cost expense incur contingent consideration potential development regulatory approval salesbase milestone salesbase royalty include purchase price business combination exclude asset acquisition certain transaction account asset acquisition determine business term define asc primarily significant process acquire substantially relative fair value allocate single asset amount allocate investigational compound asset acquisition expense date acquisition goodwill acquire inprocess research development intangible asset fair value acquire intangible asset determine incomebased approach refer excess earning method utilize level fair value input market participant valuation assume global view consider potential jurisdiction indication base discount aftertax cash flow projection risk adjust estimate probability technical regulatory success finitelive intangible asset include license market product right iprd project reach commercialization amortize straightline basis estimate useful life estimate useful life determine consider period asset expect contribute future cash flow finitelive intangible asset test impairment fact circumstance suggest carry value asset recoverable carrying value exceed project undiscounted pretax cash flow intangible asset impairment loss equal excess carrying value estimate fair value discount aftertax cash flow recognize goodwill tested annually impairment assess qualitative factor determine likely fair value net asset carry amount example qualitative factor assess include bmss share price financial performance compare budget longterm financial plan macroeconomic industry market condition substantial excess fair value carry value net asset annual impairment test perform prior year relevant factor assess individually aggregate iprd test impairment annually frequently event occur circumstance change indicate potential reduction fair value asset carry value impairment charge recognize extent carry value iprd determine exceed fair value restructure restructuring charge recognize result action streamline operation realize synergy acquisition reduce number facility estimate impact restructuring plan include future termination benefit integration expense exit cost require judgment actual result vary estimate restructure charge recognize meet certain criterion include finalization commit plan reliable estimate discussion local work council certain market contingency loss contingency legal proceeding claim occur government investigation shareholder lawsuit product environmental liability contractual claim tax matter accrual recognize probable liability incur loss reasonably estimate gain contingency include contingent proceed related divestiture recognize realize legal fee expense incur revenue recognition refer note revenue detailed discussion accounting policy relate revenue recognition include defer revenue royalty refer note alliance detail alliance research development research development cost expense incur clinical study certain research cost recognize service period specify contract adjust necessary base ongoing review level effort cost actually incur research development cost present net reimbursement alliance partner upfront contingent development milestone payment connection acquisition licensing thirdparty intellectual property right include research development expense alternative future use advertising product promotion cost advertising product promotion cost expense incurred advertising product promotion cost include marketing sell administrative expense billion million million foreign currency translation foreign subsidiary earning translate dollar average exchange rate net asset foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate recognize comprehensive incomeloss income taxis provision income taxis include income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis asset liability adjust change tax rate tax law change enact valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment tax effect global intangible lowtaxed income certain foreign subsidiary recognize income tax provision period tax arise tax benefit recognize uncertain tax position likely tax position sustain examination tax authority base technical merit position tax benefit recognize financial statement particular tax position base large benefit likely realize settlement recently adopt accounting standard income taxis december fasb issue amend guidance accounting reporting income taxis guidance intend simplify accounting income taxis remove exception relate certain intraperiod tax allocation defer tax liability clarify guidance primarily related evaluate stepup tax basis goodwill business combination reflect enact change tax law rate annual effective tax rate bms adopt new guidance effective january amend guidance material impact bmss result operation recently issue accounting standard adopt business combination october fasb issue amend guidance accounting contract asset contract liability contract customer business combination guidance intend address inconsistency relate recognition acquire contract liability payment term effect subsequent revenue recognize acquisition date entity account relate revenue contract accordance exist revenue recognition guidance generally assess acquiree apply recognition measurement financial statement amend guidance effective january prospective approach early adoption permit note revenue follow table summarize disaggregation revenue nature year end december dollar million net product sale alliance revenues revenues total revenue net product sale represent total revenue period present product sell principally wholesaler distributor specialty pharmacy less extent directly retailer hospital clinic government agency customer order generally fulfil day receipt result minimal order backlog contractual performance obligation usually limit transfer control product customer transfer occur shipment receipt product consider customer obtain legal title product infusion cell therapie bms obtain right payment point customer able direct use obtain substantially remain benefit product gross revenue large pharmaceutical wholesaler percentage global gross revenue follow year end december mckesson corporation amerisourcebergen corporation cardinal health inc wholesaler initially invoice contractual list price payment term typically day base customary practice country revenue reduce wholesaler list price time recognition expect chargeback discount rebate sale allowance product return refer gtn adjustment reduction attribute commercial arrangement manage healthcare organization government program medicare medicaid drug pricing program contain pricing implication mandatory discount pricing protection wholesaler list price discount medicare beneficiarie coverage gap addition nonus government program include different pricing scheme cost cap volume discount outcomebase pricing pricing clawback determine sale individual company aggregation company participate specific market chargeback cash discount reflect reduction receivables settle issuance credit customer typically month rebate discount adjustment include medicaid medicare reflect liability settle cash payment customer typically time period range month year significant judgment require estimate gtn adjustment consider legal interpretation applicable law regulation historical experience payer channel mix current contract price applicable program unbilled claim processing time lag inventory level distribution channel follow table summarize gtn adjustment year end december dollar millions gross product sale gtn adjustmentsa chargeback cash discount medicaid medicare rebate rebate return discount adjustment total gtn adjustment net product sale include adjustment provision product sale prior period result change estimate million million million alliance revenue consist primarily amount relate collaboration outlicense arrangement arrangement evaluate represent contract scope revenue recognition guidance entirety contain aspect scope guidance directly reference base application guidance relate derecognition nonfinancial asset asc performance obligation identify separate party benefit directly right good service readily available resource right good service highly interdependent interrelate transaction price arrangement include fix upfront amount variable consideration contingent development regulatory milestone salesbase milestone royalty likely method estimate contingent development regulatory salesbase milestone ultimate outcome binary nature expect value method estimate royalty broad range potential outcome exist instance royalty relate license variable consideration include transaction price extent significant reversal cumulative revenue recognize probable occurring uncertainty associate variable consideration subsequently resolve significant judgment require estimating variable consideration recognize assess factor outside bmss influence likelihood regulatory success limited availability party information expect duration time resolution lack relevant past experience historical practice offering fee concession large number broad range possible amount extent arrangement include multiple performance obligation separable transaction price assign distinct performance obligation reflective relative standalone selling price recognize point time transfer control type outlicense arrangement typically utilize arrangement bms outlicense intellectual property party performance obligation arrangement include license additional performance obligation supply product request party iii collaboration arrangement include transfer license party jointly develop commercialize product outlicense arrangement consist single performance obligation satisfy execution agreement development commercialization right transfer party upfront fee recognize immediately include incomeexpense net contingent development regulatory milestone amount assess period likelihood achievement typically constrain recognize uncertainty subsequently resolve milestone include incomeexpense net salesbase milestone royalty recognize milestone achieve subsequent sale occur salesbased milestone include incomeexpense net royalty include alliance revenue certain outlicensing arrangement include contingent performance obligation supply commercial product party request license supply obligation account separate performance obligation consider distinct party benefit license supply resource readily available obligation separately identifiable obligation contract accordance revenue recognition guidance consider standalone selling price situation upfront fee contingent development regulatory milestone amount salesbase milestone royalty allocate license recognize manner describe consideration supply obligation usually base stipulate costplus margin contractual term represent standalone selling price supply consideration recognize point time transfer control product party include alliance revenues fee allocation license supply represent consideration expect entitle satisfaction separate performance obligation collaboration arrangement unique nature party active participant operating activity expose significant risk reward depend commercial success activity performance obligation inherent arrangement include transfer certain development commercialization right ongoing development commercialization service product supply obligation certain product supply obligation consider distinct account separate performance obligation similar manner discuss performance obligation consider distinct combine single performance obligation transfer right highly integrate interrelated obligation jointly develop commercialize product party result upfront fee recognize ratably time expect period collaboration activity include incomeexpense net license combine development commercialization obligation contingent development regulatory milestone long constrain recognize similar manner prospective basis royalty profit sharing recognize underlie sale profit occur include alliance revenue refer note alliance information follow table summarize disaggregation revenue product region year end december dollar million revlimid eliquis opdivo pomalystimnovid orencia sprycel yervoy abraxane reblozyl empliciti abecma zeposia breyanzi inrebic onureg mature brand total revenues united states europe rest world othera total revenue revenue include royalty alliancerelate revenue product sell bmss regional commercial organization contract asset primarily estimate future royalty termination fee eligible licensing exclusion recognize adoption asc asc contract asset reduce receivable increase period underlie sale occur cumulative catchup adjustment revenue affect contract asset contract liability material year end december revenue recognize performance obligation satisfy prior period million million consist primarily revise estimate gtn adjustment relate prior period sale royalty outlicense arrangement sale commission incremental cost obtain customer contract expense incur amortization period year note alliance bms enter collaboration arrangement party development commercialization certain product arrangement unique nature party active participant operating activity collaboration expose significant risk reward depend commercial success activity bms inlicense intellectual property own party outlicense intellectual property party arrangement typically include research development manufacturing andor commercial activity cover single investigational compound commercial product multiple compound andor product life cycle stage right obligation party global limited geographic region bms refer collaboration alliance partner alliance partner common activity bms alliance partner present result operation follow bms principal end customer sale product sale include net product sale bms alliance partner principal end customer sale bmss contractual share thirdparty sale andor royalty income include alliance revenues sale commercial product consider bmss ongoing major central operation refer note revenue information recognition criterion amount payable bms alliance partner principal end customer sale supply commercial product include alliance revenues sale commercial product consider bmss ongoing major central operation profit share royalty salesbase fee payable bms alliance partner include cost product sell incur cost reimbursement party recognize incur include cost product sell marketing sell administrative expense research development expense base underlying nature relate activity subject reimbursement upfront contingent development regulatory approval milestone payable bms alliance partner investigational compound commercial product defer amortize expect period bms development copromotion obligation market exclusivity period period relate compound product expect contribute future cash flow amortization present consistent nature payment arrangement example amount receive investigational compound present incomeexpense net activity perform time relate sale commercial product include bmss ongoing major central operation amount receive commercial product present alliance revenue sale commercial product consider bmss ongoing major central operation upfront contingent regulatory approval milestone payable bms alliance partner commercial product capitalize amortize short contractual term period relate product expect contribute future cash flow upfront contingent milestone payable bms alliance partner prior regulatory approval expense incur include research development expense royalty contingent consideration payable bms alliance partner relate divestiture business include incomeexpense net earn payment bms alliance partner present cash flow operating activity upfront milestone payment present cash flow investing activity select financial information pertain alliance follow include net product sale bms principal thirdparty customer sale product subject alliance expense summarize include amount attribute activity product alliance payment alliance partner relate amortization payment defer capitalize year end december dollar millions revenue alliance net product sale alliance revenue total revenue payment tofrom alliance partner cost product sell marketing sell administrative research development incomeexpense net select alliance balance sheet information december dollar million receivable alliance partner account payable alliance partner defer income alliancesa include unamortized upfront milestone payment specific information pertain significant alliance discuss include nature purpose significant right obligation party specific accounting policy election statement earning classification amount attributable payment party pfizer bms pfizer jointly develop commercialize eliquis anticoagulant discover bms pfizer fund development cost depend study profit loss share equally global basis certain country pfizer commercialize eliquis pay bms sale base fee coexclusive license right grant pfizer exchange upfront payment potential milestone payment party assume certain obligation actively participate joint executive committee operating committee joint responsibility research development distribution sale marketing activity alliance resource infrastructure bms pfizer manufacture product alliance bms principal end customer product sale significant country europe canada australia china japan south korea certain small country pfizer commercialization right bms supply product pfizer cost plus percentage net sale price endcustomer record transfer control product pfizer bms allocate consideration right transfer pfizer right sell separately bms party pfizer receive benefit deliver right fulfillment ongoing obligation bms alliance agreement global alliance treat single unit accounting upfront proceed subsequent contingent milestone proceed amortize expect period bmss copromotion obligation market exclusivity period bms receive million nonrefundable upfront milestone licensing payment amortize include incomeexpense net eliquis commercial product commencement alliance summarize financial information relate alliance follow year end december dollar millions revenue pfizer alliance net product sale alliance revenue total revenue payment tofrom pfizer cost product sell profit sharing incomeexpense net amortization defer income select alliance balance sheet information december dollar million receivables account payable deferred income ono bms ono jointly develop commercialize opdivo yervoy bms investigational compound japan south korea taiwan bms responsible supply product profit loss development cost share equally combination therapy involve compound party share activity involve party compound bms ono jointly develop commercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulation jointly promote party assign customer account bms responsible product supply copromotion fee pay sale partys assign customer ono exercise right accept nktr alliance bms completion phase clinical study opdivo nktr ono territory ono partially reimburse bms development cost incur study share certain future development cost contingent milestone payment profit loss collaboration nektar ono grant bms exclusive license development commercialization ono onos prostaglandin receptor antagonist right terminate party summarize financial information relate alliance follow year end december dollar millions revenue ono alliance net product sale alliance revenue total revenue bms principal end customer product sale exclusive right develop manufacture commercialize opdivo worldwide japan south korea taiwan ono entitle receive royalty north america territory exclude country list subject customary adjustment nektar bms nektar commence worldwide license collaboration development commercialization bempegaldesleukin nktr nektars investigational immunostimulatory therapy design selectively expand specific cancerfighting cell natural killer cell directly tumor micro environment january party amend collaboration agreement opdivo nktr combination therapy currently phase iii clinical study metastatic melanoma adjuvant melanoma muscleinvasive bladder cancer rcc joint development plan agree party original agreement update january amendment specify development certain indication tumor type party responsible supply product bmss share development cost associate therapy comprise bms medicine combination nktr subject certain cost cap nektar january amendment retain cost sharing percentage original agreement party jointly commercialize therapy subject regulatory approval bmss share global nktr profit loss subject certain annual loss cap nektar bm pay nektar billion right discuss million share nektar common stock represent ownership interest bmss equity ownership subject certain lockup standstill voting provision fiveyear period upfront payment allocate equity investment million consider nektar stock price date close current limitation trading security remain billion upfront payment allocate right discuss bms pay billion achievement contingent development regulatory salesbase milestone life alliance period research development cost reimbursement million million million seventy bio bluebird november bluebird complete taxfree spinoff oncology program portfolio seventy bio inc independent publiclytraded company party jointly develop commercialize novel diseasealtering gene therapy product candidate target bcma collaboration arrangement began include right bms license antibcma product result collaboration right seventy bio participate development commercialization license product result collaboration codevelopment profit share exchange reduction milestone payment iii salesbase milestone royalty payable seventy bio commercialization license product result collaboration seventy bio decline exercise codevelopment profit sharing right option license idecabtagene vicleucel idecel exercise respectively party elect pursue development profit loss relate develop commercialize manufacturing idecel share equally bms exclusively responsible development commercialization idecel outside term collaboration amend include certain manufacturing obligation party release future exclusivity relate bcmadirecte cell therapy bms pay million extinguish obligation future exus milestone royalty idecel include research development expense fda approve idecel abecma treatment relapse refractory multiple myeloma net product sale abecma alliance territory million relate profit sharing cost million cost reimbursement material eisai bms eisai commence exclusive global strategic collaboration codevelopment cocommercialization morab selective folate receptor alpha antibodydrug conjugate investigate endometrial ovarian lung breast cancer morab currently phase iii clinical trial solid tumor party jointly develop commercialize morab canada europe russia japan china certain country asiapacific region collaboration territory eisai responsible global manufacturing supply profit research development commercialization cost share collaboration territory bms responsible development commercialization outside collaboration territory pay royalty sale million upfront collaboration fee include research development expense bms obligate pay billion achievement contingent development regulatory salesbase milestone cost reimbursement material otsuka bms otsuka copromote sprycel bms responsible development manufacture product principal end customer product sale fee pay otsuka base net sale level oncology territory japan equate million billion annual net sale plus net sale excess billion effective january otsuka long copromote sprycel result arrangement long consider collaboration asc revenue earn fee pay otsuka oncology territory include select financial information table revenue earn otsuka alliance billion payment otsuka million record cost product sell note acquisition divestiture license arrangement acquisition business combination celgene november bms complete celgene acquisition acquisition expect position bms lead biopharmaceutical company sustain innovation longterm growth address need patient cancer inflammatory immunologic cardiovascular disease high value innovative medicine lead scientific capability share celgene common stock convert right receive share bms common stock cash celgene shareholder receive tradeable contingent value right cvr share celgene common stock represent right receive cash subject achievement future regulatory milestone aggregate cash pay connection celgene acquisition billion billion net cash acquire bms fund acquisition cash onhand debt proceed transaction account business combination require asset acquire liability assume recognize fair value acquisition date assessment fair value asset acquire liability assume finalized total consideration acquisition consist follow amount million share datum total consideration celgene share outstanding november cash share cash consideration outstanding share celgene share outstanding november closing price bms common stock november estimate fair value share consideration celgene share outstanding november close price cvra fair value cvrs fair value replacement option fair value replacement restrict share award fair value cvrs issue option share award holder fair value sharebase compensation award attributable precombination serviceb total consideration transfer closing price cvr base trade november fair value award attribute postcombination service billion include compensation cost refer note employee stock benefit plan information purchase price allocation result follow amount allocate asset acquire liability assume acquisition date base respective fair value summarize purchase price dollar million allocation cash cash equivalent receivables inventory property plant equipment intangible assetsa otezla asset heldforsaleb asset account payable income taxis payable deferred income tax liability debt liability identifiable net asset acquire goodwillc total consideration transfer intangible asset consist currently market product right approximately billion amortize year calculate weightedaverage useful life asset iprd approximately billion amortize value multiperiod excess earning method method starts forecast expect future net cash flow associate asset involve adjust forecast present value apply appropriate discount rate reflect risk factor associate cash flow stream include million inventory billion develop product right million accrue liability million noncurrent liability refer divestiture information goodwill represent goingconcern value associate future product discovery exist pipeline expect value synergy result cost saving avoidance attribute identifiable asset goodwill deductible tax purpose bmss consolidated statement earning year end december include billion revenue billion net loss associate result operation celgene acquisition date december acquisition expense million year end december include financial advisory legal proxy filing regulatory financing fee hedge cost follow unaudited pro forma information prepare celgene acquisition otezla divestiture occur january unaudited supplemental pro forma consolidated result purport reflect combine company result operation project future result operation combine company unaudite supplemental pro forma consolidated result reflect historical financial information bms celgene adjust effect celgene acquisition otezla divestiture occur january primarily follow adjustment amortization expense primarily relate fair value adjustment celgene intangible asset inventory debt nonrecurre acquisitionrelate cost directly attributable celgene acquisition tax expense directly attributable otezla divestiture interest expense include amortization defer financing fee attributable celgene acquisition financing elimination historical revenue expense relate otezla refer divestiture adjustment adjust applicable tax impact estimate weightedaverage statutory tax rate apply applicable pro forma adjustment year end december amount million total revenue net earning asset acquisition myokardia bms acquire myokardia clinicalstage biopharmaceutical company pioneer precision medicine approach discover develop commercialize target therapy treatment cardiovascular disease bms subsidiary complete tender offer acquire issue outstanding share myokardia common stock accept share validly tender withdraw expiration time tender offer share billion include cash settlement equity stock awards acquisition provide bms right myokardia lead asset mavacamten potential firstinclass cardiovascular medicine treatment obstructive hypertrophic cardiomyopathy bms fund transaction combination cash hand operation net proceed receive connection senior unsecured note offer consideration transfer allocate base relative fair value gross asset acquire transaction account asset acquisition mavacamten represent substantially fair value gross asset acquire exclude cash defer income taxis result billion iprd charge recognize fda accept nda mavacamten patient symptomatic obstructive hcm assign pdufa goal date january fda subsequently extend review nda mavacamten april follow summarizes total consideration transfer allocation consideration transfer asset acquire liability assume amount million amount cash consideration outstanding share cash consideration stock award consideration pay charge unvested stock awardsa transaction cost consideration allocate intangible assetsb cash cash equivalent defer income taxis asset liability total asset acquire net represent accelerate vest myokardia stock award include marketing sell administrative expense million research development expense million december include iprd billion billion related mavacamten license million forbius bm acquire outstanding share forbius privately hold clinicalstage protein engineering company design develop biotherapeutic treatment cancer fibrotic disease acquisition provide bms right forbiuss tgfbeta program include program lead investigational asset avid phase development bms account transaction asset acquisition avid represent substantially fair value gross asset acquire transaction price include upfront payment million contingent development regulatory salesbase milestone payment million upfront payment include research development expense million allocate defer tax asset research development expense include million result occurrence certain development event attribute cormorant asset acquisition complete divestiture follow table summarize financial impact divestiture include royalty include incomeexpense net revenue pretax earning relate divestiture material period present exclude divestiture gain loss proceedsa divestiture gainslosse royalty income dollar millions diabete business otezla upsa business mature brand total include royalty receive subsequent relate sale asset business diabete business february bms astrazeneca terminate diabetes business alliance agreement bms sell astrazeneca substantially diabete business comprise alliance consideration transaction include tiere royalty payment range base net sale royalty million million million september bm transfer percentage future royalty right amylin net product sale cppib transfer right represent approximately potential future royalty bms entitle exchange transfer bms receive additional tieredbase royalty amylin net product sale cppib cppib transfer future royalty right amylin net product sale ocm healthcare result transfer right royalty income amylin net product sale reduce million million million november bm transfer percentage future royalty right portion onglyza farxiga net product sale royalty pharma transfer right represent approximately potential future royalty bms entitle product result transfer right royalty income onglyza farxiga net product sale increase million reduce million million otezla order complete celgene acquisition bms require ftc div certain product bms complete divestiture otezla apremilast amgen billion cash transaction account asset divestiture otezla acquire celgene acquisition classify heldforsale time acquisition fair value otezla net asset consist billion develop product right million inventory upsa business bm sell upsa consumer health business include share upsa sas bmss asset liability relate upsa product portfolio transaction account sale business mature brand erbitux business bms commercialization agreement lilly lillys subsidiary imclone codevelopment promotion erbitux canada japan bms principal end customer product sale north america pay lilly distribution fee erbitux net sale north america plus share certain royalty pay lilly bm transfer cocommercialization right japan merck kgaa exchange salesbase royalty result adoption asc estimate future royalty result transfer right merck kgaa record cumulative effect adjustment retain earning royalty income increase million million result change estimate future royalty manufacturing operation bms sell manufacturing packaging facility anagni italy catalent inc transaction account sale business asset reduce relative fair value consider purchase price result impairment charge million include cost product sell product right mature brand sell result proceed million divestiture gain million licensing arrangement follow table summarize financial impact keytruda royalty tecentriq royalty upfront licensing fee milestone product obtain commercial approval include incomeexpense net year end december dollar million keytruda royalty tecentriq royalty upfront licensing fee contingent milestone income amortization defer income royalty total tecentriq patent license bms ono enter global patent license agreement roche group relate tecentriq atezolizumab roche antipdl antibody agreement roche pay million include royalty month end september pay singledigit royalty worldwide net sale tecentriq december upfront payment royalty share bms ono consistent exist agreement bms record million incomeexpense net settlement million million royalty respectively inlicense arrangement immatic bm enter global exclusive license immatic tcr bispecific program studied oncology clinical trial application file german federal regulatory authority plan commence half bms immatic collaborate development bms responsible commercialization relate product worldwide include strategic decision regulatory responsibility funding manufacturing transaction include upfront payment million include research development expense immatic eligible receive contingent development regulatory salesbase milestone million royalty global net sale agreement close quarter agenu bm obtain global exclusive license agenu proprietary agen bispecific antibody program block tigit additional target agen study oncology phase clinical trial initiate october bms responsible development subsequent commercialization agen relate product worldwide include strategic decision regulatory responsibility funding manufacturing transaction include upfront payment million include research development expense agenu eligible receive contingent development regulatory salesbase milestone billion royalty global net sale dragonfly bms obtain global exclusive license dragonfly interleukin investigational immunotherapy program include extended halflife cytokine bms responsible development subsequent commercialization relate product worldwide include strategic decision regulatory responsibility funding manufacture dragonfly continue involve development current certain future phase iii clinical trial bms pay million dragonfly right include million follow commencement phase combination clinical study include research development expense dragonfly eligible receive additional contingent consideration comprise development regulatory salesbase milestone payment billion royalty global net sale note incomeexpense net year end december dollar million interest expense royalty license income equity investment gain integration expense contingent consideration loss debt redemption provision restructure litigation settlement transition service fee investment income pension postretirement divestiture gain reversion excise tax intangible asset impairment acquisition expense incomeexpense net note restructure celgene acquisition plan restructure integration plan implement initiative realize sustainable run rate synergy result cost saving avoidance celgene acquisition currently expect approximately billion synergy expect realize cost product sell marketing sell administrative expense research development expense charge approximately billion expect incur majority charge expect incur cumulative charge approximately billion recognize date include integration planning execution expense employee termination benefit cost accelerate stockbased compensation contract termination cost shutdown cost associate site exit cash outlay connection action expect approximately billion employee workforce reduction approximately myokardia acquisition plan restructure integration plan initiate realize expect cost synergy result cost saving avoidance myokardia acquisition charge approximately million expect incur consist integration planning execution expense employee termination benefit cost cost cumulative charge approximately million recognize action date company transformation restructuring plan announce evolve streamline bmss operating model cumulative charge approximately billion recognize action announcement action plan complete december follow provide charge relate restructuring initiative type cost year end december dollar million celgene acquisition plan myokardia acquisition plan company transformation total charge employee termination cost termination cost provision restructure integration expense accelerate depreciation asset impairment shutdown cost net total charge cost product sell marketing sell administrative research development incomeexpense net total charge follow summarize charge spend related restructuring plan activity year end december dollar million liability december ceaseuse liability reclassification liability january provision restructuringa foreign currency translation payment liability december include reduction liability result change estimate million million million exclude million million million accelerate stockbased compensation relate celgene acquisition plan note income taxis provisionbenefit income taxis consist year end december dollar millions current nonus total current defer nonus total defer total provision effective tax rate reconciliation effective tax rate statutory federal income tax rate follow earning income taxis dollar million earningsloss income taxis nonus total statutory rate global intangible low tax income gilti foreign tax effect certain operation ireland puerto rico switzerland internal transfer intangible asset federal state foreign contingent tax matter federal research base credit contingent value right nondeductible charge puerto rico excise tax state local taxis net valuation allowance foreign total gilti tax associate otezla divestiture million million bm long indefinitely reinveste respect undistribute earning foreign subsidiary provide defer tax liability foreign state income withholding tax apply bms remain indefinitely reinveste respect financial statement basis excess tax basis foreign subsidiary determination defer tax liability respect basis difference practicable bms operate favorable tax grant puerto rico schedule expire prior internal transfer certain intangible asset streamline legal entity structure subsequent celgene acquisition result tax benefit tax charge adjust defer taxis book revalue tax basis difference relate asset federal state foreign contingent tax matter include million tax benefit respect lapse statute fair value adjustment contingent value right taxable tax deductible nondeductible charge primarily result billion myokardia iprd charge puerto rico imposes excise tax gross company purchase price good sell bmss manufacturer puerto rico excise tax recognize cost product sell intraentity sale occur income tax purpose excise tax deductible result foreign tax credit generally recognize bmss provision income taxis excise tax incur defer taxis valuation allowance component current noncurrent defer income tax assetsliabilitie follow december dollar millions defer tax asset foreign net operating loss carryforward state net operating loss credit carryforward federal net operating loss credit carryforward milestone payment license fee foreign defer tax asset sharebase compensation total defer tax asset valuation allowance defer tax asset net valuation allowance defer tax liability acquire intangible asset goodwill total defer tax liability defer tax liability net recognize deferred income taxis asset noncurrent defer income taxis liability noncurrent total federal net operating loss carryforward million december carryforward acquire result certain acquisition subject limitation section internal revenue code net operating loss carryforward expire vary amount begin foreign state net operating loss carryforward expire vary amount begin certain amount unlimited life december valuation allowance billion exist follow item million primarily foreign net operating loss tax credit carryforward million state defer tax asset include net operating loss tax credit carryforward million federal defer tax asset include equity fair value adjustment federal net operating loss carryforward change valuation allowance follow year end december dollar million balance begin year provision utilization foreign currency translation acquisitionsdispositionsliquidation net non rate change balance end year certain foreign net operating loss relate valuation allowance utilize eliminate result internal legal entity restructuring income tax payment billion billion billion connection enactment tcja require pay onetime transition tax elect pay period year permit tcja remain amount payable year follow million million million billion million business conduct country world subject tax numerous jurisdiction significant number tax return file subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report require year resolve liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense deem repatriation transition tax liability represent reasonable provision taxis ultimately expect pay need adjusted time information know effect change estimate related contingent tax liability include effective tax rate reconciliation reconciliation begin end gross unrecognized tax benefit follows exclude interest penalty year end december dollar million balance begin year gross addition tax position relate current year gross addition tax position relate prior year gross addition tax position assume acquisition gross reduction tax position relate prior year settlement reduction tax position relate lapse statute cumulative translation adjustment balance end year additional information unrecognized tax benefit follow year end december dollar millions unrecognized tax benefit recognize impact effective tax rate accrue interest accrue penalty accrue interest penalty payable unrecognized tax benefit include current noncurrent income taxis payable interest penalty relate unrecognized tax benefit include income tax expense bms currently examination number tax authority propose consider propose material adjustment tax position issue transfer price certain tax credit deductibility certain expense previously disclose bms receive notice propose adjustment irs relate transfer pricing tax position tax year bms disagree irss position continue work cooperatively irs resolve open tax audits reasonably possible new issue raise tax authority increase unrecognized tax benefit estimate increase reasonably time bms believe adequately provide open tax year tax jurisdiction reasonably possible total unrecognized tax benefit december decrease range approximately million million month result settlement certain tax audits event expect change unrecognized tax benefit result payment additional taxis adjustment certain defer taxis andor recognition tax benefit follow summary major tax jurisdiction tax authority assert additional taxis base tax year currently audit subsequent year likely audit canada france germany italy japan note earningsloss share year end december amount million share datum net earningsloss attributable bms basic diluted eps calculation weightedaverage common share outstanding basic incremental share attributable sharebased compensation plan weightedaverage common share outstanding dilute earningsloss common share basic diluted total number potential share common stock exclude diluted earningsloss share computation antidilutive impact million material note financial instrument fair value measurement financial instrument include cash cash equivalent marketable security account receivable payable debt instrument derivative change exchange rate interest rate create exposure market risk certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument qualify cash flow net investment fair value hedge meet certain criterion include effectiveness offset hedge exposure change fair value derivative qualify hedge accounting recognize earning occur derivative financial instrument trading purpose financial instrument subject counterparty credit risk consider overall fair value measurement counterparty credit risk monitor ongoing basis mitigate limiting amount outstanding individual counterparty utilize conventional derivative financial instrument enter agreement counterpartie meet high credit quality standard consolidate financial statement materially impact counterparty fail perform accord term agreement collateral require party derivative asset liability position term agreement fair value measurement fair value financial instrument classify follow category level input utilize unadjusted quote price active market accessible measurement date identical asset liability fair value hierarchy provide high priority level input level input utilize observable price similar instrument quote price identical similar instrument nonactive market additionally certain corporate debt security utilize thirdparty matrix pricing model significant input corroborate market datum substantially term asset equity fix income fund primarily invest publicly trade security value respective nav underlie investment level derivative instrument value libor yield curve credit valuation adjustment observable forward foreign exchange rate report date valuation derivative contract fluctuate considerably volatility underlie foreign currency underlie interest rate drive market condition duration contract level unobservable input little market datum available level financial liability consist acquisition relate contingent consideration success payment relate undeveloped product right result celgene acquisition transfer level year end december financial asset liability measure fair value recur basis summarize december december dollar million level level level level level level cash cash equivalent money market security marketable debt security certificate deposit commercial paper corporate debt security derivative asset equity investment derivative liability contingent consideration liability contingent value right acquisition relate contingent consideration contingent consideration obligation record estimate fair value obligation revalue reporting period relate contingency resolve contingent value right adjust fair value trade price security end report period fair value measurement contingent consideration liability estimate probabilityweighte discount cash flow approach base significant unobservable input relate product candidate acquire business combination review quarterly input include applicable estimate probability time achieve specify development regulatory milestone discount rate calculate present value estimate future payment significant change increase decrease probability achieve relate development regulatory event shorten lengthen time require achieve event result correspond increase decrease fair value obligation marketable debt security follow table summarize marketable debt security december december gross unrealized gross unrealized amortize amortize dollar million cost gain loss fair value cost gain loss fair value certificate deposit commercial paper corporate debt security total marketable debt securitiesa marketable debt security mature year december equity investment follow summarize carry equity investment december dollar million equity investment readily determinable fair value equity investment readily determinable fair value limited partnership equity method investment total equity investment follow summarize activity relate equity investment equity investment gainsloss include incomeexpense net dollar million equity investment readily determine fair valuesa net lossgain recognize net lossgain recognize investment sell net unrealized lossgain recognize investment hold equity investment readily determinable fair value upward adjustment impairment downward adjustment cumulative upward adjustment cumulative impairment downward adjustment equity net incomeloss affiliatesb certain prior year amount reclassify conform current year presentation termination fee relate europe asia partnership sanofi million include qualifying hedge nonqualifye derivative cash flow hedge foreign currency forward contract hedge certain forecast intercompany inventory purchase sale transaction certain foreign currency transaction fair value contract designate cash flow hedge temporarily report accumulate comprehensive loss include earning hedge item affect earning net gain loss foreign currency forward contract expect reclassify net earning primarily include cost product sell incomeexpense net month notional outstanding foreign currency forward contract primarily attribute euro billion japanese yen billion december earning impact relate discontinued cash flow hedge hedge ineffectiveness material period present cash flow hedge accounting discontinue forecast transaction long probable occur day originally forecast date hedge long effective assessment determine derivative designate qualifying hedge highly effective offset change cash flow hedge item perform inception quarterly basis foreign currency forward contract designate hedge instrument offset exposure certain foreign currency denominate asset liability earning change fair value derivative recognize earning occur bms hedge portion future foreign currency exposure utilize strategy involve purchase local currency option write local currency option account hedge future sale denominate local currency specifically bms sell write local currency option purchase local currency option expiration date local currency notional amount different strike price premium collect sale option equal premium pay purchase option result net premium pay combination transaction generally refer zerocost collar expiration date notional amount correspond timing forecast foreign currency sale dollar weaken relative currency hedge anticipate sale purchase option value reduce zero bms benefit increase dollar equivalent value anticipate foreign currency cash flow benefit cap strike level write form upper end collar treasury lock hedge contract enter total notional value billion hedge future interest rate risk associate anticipate issuance longterm debt fund myokardia acquisition treasury lock contract terminate issuance unsecured senior note million proceed include comprehensive incomeloss net investment hedge nonus dollar borrowing million billion december designate net investment hedge hedge euro currency exposure net investment certain foreign affiliate recognize longterm debt effective portion foreign exchange gain remeasurement euro debt include foreign currency translation component accumulate comprehensive loss relate offset long term debt crosscurrency interest rate swap contract million december designate hedge japanese yen currency exposure bmss net investment japan subsidiary contract fair value change record foreign currency translation component accumulate comprehensive loss relate offset noncurrent asset noncurrent liability fair value hedge fix float interest rate swap contract designate fair value hedge interest rate risk management strategy create appropriate balance fix float rate debt contract underlie debt hedge benchmark risk record fair value effective interest rate contract onemonth libor december plus interest rate spread gain loss result change fair value underlie debt attributable hedge benchmark interest rate risk record interest expense associate offset carry value debt specific term notional swap intend align debt hedge change fair value swap record interest expense associate offset derivative asset liability consolidate balance sheet result net impact earning underlie swap terminate prior maturity fair value adjustment underlie debt amortize reduction interest expense remain term debt follow summarize fair value outstanding derivative december december asseta liabilityb asseta liabilityb dollar million notional fair value notional fair value notional fair value notional fair value derivative designate hedge instrument interest rate swap contract crosscurrency interest rate swap contract foreign currency forward contract derivative designate hedge instrument foreign currency forward contract include current asset noncurrent asset include current liability noncurrent liability follow table summarize financial statement classification gainloss recognize hedging instrument year end december cost incomeexpense cost incomeexpense cost incomeexpense dollar million product sell net product sell net product sell net interest rate swap contract crosscurrency interest rate swap contract foreign currency forward contract forward start interest rate swap option contract deal contingent forward start interest rate swap contract foreign currency zerocost collar contract follow table summarize effect derivative nonderivative instrument designate hedge instrument comprehensive incomeloss year end december dollar million derivative qualify cash flow hedge foreign currency forward contract gainloss recognize comprehensive incomelossa reclassify cost product sell treasury lock hedge contract gain recognize comprehensive incomeloss derivative qualify net investment hedge crosscurrency interest rate swap contract gainloss recognize comprehensive incomeloss nonderivative qualify net investment hedge non dollar borrowing gainloss recognize comprehensive incomeloss majority expect reclassify earning month debt obligation shortterm debt obligation include december dollar millions nonus shortterm borrowing current portion longterm debt total longterm debt current portion longterm debt include december dollar million principal value note note note float rate note note note note note note note note note note note note note note euro note note note note note note note note note note euro note note note note note note note note note note note note note note note note mature total december dollar million principal value adjustment principal value fair value interest rate swap contract unamortize basis adjustment swap termination unamortized bond discount issuance cost unamortized purchase price adjustment celgene debt total current portion longterm debt longterm debt total fair value longterm debt billion billion december respectively value level input base quote market price similar debt instrument fair value shortterm borrowing approximate carry value short maturity debt instrument bms issue aggregate principal approximately billion float rate fix rate unsecured senior note proceed net discount defer loan issuance cost billion note rank equally right payment bmss exist future senior unsecured indebtedness fix rate note redeemable time vary specify redemption price plus accrue unpaid interest connection celgene acquisition bm commence offer exchange outstanding note issue celgene approximately billion likeamount new note issue bms exchange offer exchange transaction account modification assume debt instrument follow settlement exchange offer bms issue approximately billion new note exchange celgene note tender exchange offer aggregate principal celgene note remain outstanding follow settlement exchange offer approximately billion bm enter billion term loan credit agreement consist billion day tranche billion threeyear tranche billion year tranche connection celgene acquisition term loan subject customary term condition financial covenant proceed term loan fund portion cash pay celgene acquisition payment relate fee expense subsequent completion acquisition bms repay term loan entirety cash proceed generate otezla divestiture bms issue aggregate principal billion fix rate unsecured senior note proceed net discount defer loan issuance cost billion note rank equally right payment bmss exist future senior unsecured indebtedness redeemable time vary specify redemption price plus accrue unpaid interest bms purchase aggregate principal billion certain debt security approximately billion cash series tender offer redemption connection transaction million loss debt redemption recognize base carry value debt include incomeexpense net repayment note maturity aggregate billion billion billion interest payment billion billion million aggregate maturity longterm debt interest year follow billion billion billion billion billion december bm separate revolve credit facility total billion consist day billion facility expire january threeyear billion facility expire january fiveyear billion facility extend september july respectively borrowing outstanding revolve credit facility december january bms enter fiveyear billion facility expire january extendable annually year consent lender facility provide customary term condition financial covenant provide backup liquidity bmss commercial paper borrowing concurrently entry facility commitment bmss exist fiveyear billion facility terminate available financial guarantee provide form bank overdraft facility standby letter credit performance bond approximately billion december standby letter credit guarantee issue financial institution support obligation include sale product hospital foreign ministry health bond custom duty value add tax note receivable december dollar million trade receivable chargeback cash discount allowance expect credit loss net trade receivables alliance royalty vat receivables nonus receivables sell nonrecourse basis billion billion million aggregate receivable pharmaceutical wholesaler represent approximately total trade receivables december respectively change allowance expect credit loss chargeback cash discount follow year end december dollar million balance begin year celgene acquisition provisiona utilization balance end year include provision expect credit loss million million million note inventory december dollar million finished good work process raw packaging material total inventory inventory noncurrent asset total inventory include fair value adjustment result celgene acquisition approximately million million december respectively recognize future period noncurrent asset include inventory expect remain hand month period note property plant equipment december dollar million land building machinery equipment fixture construction progress gross property plant equipment accumulate depreciation property plant equipment united states europe rest world total depreciation expense million million million note lease lease facility office research development storage distribution purpose comprise approximately total lease obligation lease term vary base nature operation market dynamic country lease facility classify operating lease remain lease term year year lease contain specific renewal option period range year year notice renew provide advance lease expiration automatic renewal advance notice require period cover option extend lease include noncancellable lease term exercise option determine reasonably certain certain lease contain termination option provide flexibility terminate lease ahead expiration sufficient advance notice period cover option terminate lease include non cancellable lease term exercise option determine reasonably certain judgment require assess renewal termination option reasonably certain exercise factor consider contractual term compare current market rate leasehold improvement expect significant value cost terminate lease importance facility operation cost determine variable base index rate include measurement real estate lease liability variable cost include real estate taxis insurance utility common area maintenance operating cost implicit rate lease readily determinable incremental borrowing rate apply portfolio approach discount real estate lease liability remain lease obligation comprise vehicle primarily salesforce research development facility operate party management direction vehicle lease term vary country term generally year year follow table summarize component lease expense year end december dollar million operating lease cost variable lease cost shortterm lease cost sublease income total operating lease expense operating lease rightofuse asset liability follow december dollar million noncurrent asset current liability noncurrent liability total liability future lease payment noncancellable operating lease december follow dollar million total future lease payment imputed interest total lease liability rightofuse asset obtain exchange new operating lease obligation million cash pay amount include measurement operating lease liability million million undiscounte lease obligation operating lease commence approximately million december obligation primarily relate research development facility construct lessor expect ready use rightofuse asset impairment charge million incur site vacancy partial sublease fair value rightofuse asset determine income approach incorporate potential future cash flow associate sublease build supplemental balance sheet information relate lease follow december weight average remain lease term year year weight average discount rate note goodwill intangible asset december estimate dollar million useful life goodwill intangible asset license year acquire market product right year capitalize software year iprd gross intangible asset accumulate amortization intangible asset billion iprd reclassify acquire market product right approval breyanzi abecma amortization expense intangible asset billion billion billion future annual amortization expense intangible asset expect approximately billion billion billion billion billion intangible asset impairment charge billion billion million million iprd impairment charge investigational compound record research development expense primarily result change clinical timeline expect launch date competitive landscape compound study potential treatment hematologic disease acquire acquisition celgene charge represent partial writedown carry value base estimate fair value determine discount cash flow projection additionally million iprd impairment charge record research development expense follow decision discontinue development investigational compound connection prioritization current pipeline opportunity compound study potential treatment fibrotic disease acquire acquisition celgene charge represent writedown base estimate fair value determine discount cash flow projection inrebic regulatory approval milestone million achieve result million increase acquire market product right intangible asset establish applicable defer tax liability impairment charge million recognize cost product sell carry value asset exceed project undiscounted cash flow asset charge equal excess asset carrying value estimate fair value discount cash flow projection million impairment charge record cost product sell result low cash flow projection reflect revise commercial forecast inrebic result impairment asset additionally million impairment charge record research development expense follow decision discontinue orvacel program development inrebic orvacel obtain connection acquisition celgene note supplemental financial information december dollar million income taxis research development contract asset equity investment restrict casha current asset december dollar million equity investment inventory operate lease pension postretirement research development restrict casha noncurrent asset restrict cash consist fund restrict annual company contribution define contribution plan escrow litigation settlement cash restrict withdrawal general use contractually legally restrict december dollar million rebate discount income taxis employee compensation benefit research development dividend interest royalty operating lease contingent value right current liability december dollar million income taxis payable pension postretirement operating lease defer income defer compensation noncurrent liability note equity accumulate capital excess common stock treasury stock par value comprehensive retain noncontrolle dollar share million share par value stock loss earning share cost interest balance january accounting change cumulative effecta adjust balance january net earnings comprehensive incomeloss celgene acquisition cash dividend declaredb share repurchase program stock compensation distribution balance december net loss comprehensive incomeloss cash dividend declaredb share repurchase program stock compensation distribution balance december net earning comprehensive incomeloss cash dividend declaredb share repurchase program stock compensation distribution balance december cumulative effect result adoption asu asu cash dividend declare common share bms share repurchase program authorize board director allow repurchase share effect open market privately negotiate transaction compliance rule exchange act include rule trading plan share repurchase program expiration date suspend discontinue time treasury stock recognize cost reacquire share share issue treasury recognize utilize firstin firstout method outstanding share repurchase authority authorization program billion december january december board director approve increase billion billion respectively share repurchase authorization bmss common stock bm repurchase approximately million share common stock billion remaining share repurchase capacity share repurchase program approximately billion december bm repurchase approximately million share common stock billion asr settle approximately million share common stock receive bms transfer treasury stock bms execute asr agreement repurchase aggregate billion common stock asr agreement fund cash onhand approximately million share common stock billion aggregate repurchase price receive bms include treasury stock addition approximately million share common stock repurchase million february bms execute asr agreement repurchase aggregate billion common stock asr agreement fund cash hand expect settle second quarter total number share repurchase asr agreement base volumeweighted average price bms common stock term asr transaction discount subject adjustment pursuant term condition asr agreement component comprehensive incomeloss follow year end december dollar million pretax tax tax pretax tax tax pretax tax tax derivative qualify cash flow hedge unrealize gainslosse reclassify net earningsa derivative qualify cash flow hedge pension postretirement benefit actuarial gainslosse amortizationb settlementsb pension postretirement benefit marketable debt security unrealize lossesgain realize gainslossesb marketable debt security foreign currency translation comprehensive incomeloss include cost product sell include incomeexpense net accumulate balance relate component comprehensive incomeloss net taxis follow december dollar million derivative qualify cash flow hedge pension postretirement benefit marketable debt security foreign currency translation accumulate comprehensive loss note retirement benefit bms sponsor define benefit pension plan define contribution plan termination indemnity plan regular fulltime employee principal define benefit pension plan bristol myers squibb retirement income plan plan cover employee future benefit relate service plan eliminate bms contribute minimum require erisa plan benefit base primarily participant year credit service final average compensation bms announce plan fully terminate plan pension obligation relate plan distribute combination lump sum payment eligible plan participant elect payment purchase group annuity contract wholly own insurance subsidiary athene holding ltd athene billion distribute plan participant elect lump sum payment election window group annuity contract purchase athene billion remain plan participant athene irrevocably assume pension obligation transaction fully terminate plan result billion noncash pretax pension settlement charge net periodic benefit cost define benefit pension plan include year end december dollar million service cost benefit earn year interest cost project benefit obligation expect return plan asset amortization prior service credit amortization net actuarial loss settlement curtailment net periodic pension benefit cost pension settlement charge recognize determine annual lump sum payment exceed annual interest service cost certain pension plan include primary pension plan change define benefit pension plan obligation asset fund status amount recognize consolidated balance sheet follow year end december dollar million benefit obligation begin year service costbenefit earn year interest cost settlement curtailment actuarial gainslosse benefit pay foreign currency benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution settlement benefit pay foreign currency fair value plan asset end year fund status assetsliabilitie recognize noncurrent asset current liability noncurrent liability fund status recognize accumulate comprehensive loss net actuarial loss prior service credit total accumulate benefit obligation define benefit pension plan billion billion december respectively additional information relate pension plan follow december dollar million pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset actuarial assumption weightedaverage assumption determine define benefit pension plan obligation follow december discount rate rate compensation increase interest credit rate weightedaverage actuarial assumption determine define benefit pension plan net periodic benefit cost follow year end december discount rate expect longterm return plan asset rate compensation increase interest credit rate yield high quality corporate bond match duration benefit obligation determine discount rate ftse pension discount curve develop discount rate plan expect return plan asset assumption plan base management expectation longterm average rate return achieve underlying investment portfolio factor consider develop expect return plan asset include longterm historical return input external advisor individual asset class return forecast develop base market condition example priceearning level yield longterm growth expectation expect longterm rate return weightedaverage target asset allocation individual asset class actuarial gain loss result change actuarial assumption change discount rate revise mortality rate difference assume actual experience difference actual expect return plan asset actuarial gain loss relate plan benefit obligation primarily result change discount rate postretirement benefit plan comprehensive medical group life benefit provide substantially bm retiree elect participate comprehensive medical group life plan less extent certain benefit nonus employee medical plan contributory contribution adjust periodically vary date retirement life insurance plan noncontributory postretirement benefit plan obligation million million december respectively weightedaverage discount rate determine benefit obligation december respectively net periodic benefit credit material result bristol myers squibb retirement income plan termination million asset hold separate account pension trust fund retiree medical plan payment revert company result excise tax million plan asset fair value pension postretirement plan asset asset category december follow december december dollar million level level level total level level level total plan asset equity security equity fund fix income fund corporate debt security treasury agency security insurance contract cash cash equivalent plan asset subject leveling plan asset measure nav practical expedient net plan asset investment valuation policy investment class follow level input utilize unadjusted quote price active market accessible measurement date identical asset liability fair value hierarchy provide high priority level input instrument include equity security equity fund fix income fund publicly trade national security exchange cash cash equivalent cash cash equivalent highly liquid investment original maturity month time purchase recognize cost approximate fair value pende trade sale purchase include cash cash equivalent final settlement level input utilize observable price similar instrument quote price identical similar instrument nonactive market observable input corroborate market datum substantially term asset liabilitie equity fund fix income fund classify level fair value hierarchy value nav share hold year end represent fair value corporate debt security treasury agency security classify level fair value hierarchy value utilize observable price similar instrument quote price identical similar instrument market active level unobservable input little market datum available insurance contract hold certain foreign pension plan carry contract value approximate estimate fair value base fair value underlie investment insurance company investment practical expedient consist primarily multiasset fund redeemable daily weekly monthly basis investment strategy maximize return maintain appropriate level risk provide sufficient liquidity benefit obligation plan expense individual plan investment allocation determine local fiduciary committee composition total asset pension plan december broadly characterize allocation equity security debt security investment contribution estimate future benefit payment contribution pension plan million million million expect material estimate annual future benefit payment include lump sum payment approximately million approximately million year subsequent year period saving plan principal define contribution plan bristolmyer squibb saving investment program contribution base employee contribution level company match define contribution plan expense approximately million million million note employee stock benefit plan shareholder approve stock award incentive plan plan plan replace plan authorization grant award set expire plan replace equity incentive plan plan stock incentive plan plan originate plan celgene corporation assume amend rename acquire celgene plan authorize award form incentive stock option nonqualifie stock option stock appreciation right restrict unrestricted stock stock unit dividend equivalent performance share unit market share unit stockbase award december plan plan authorize grant equity award plan provide million share authorize grant plus share recapture forfeiture termination award plan plan plan subject adjustment accordance term plan december million share available award share generally issue treasury stock satisfy bmss obligation plan prior plan celgene acquisition bms assume plan plan plan provide grant option restrict stock unit rsus performance share unit psus sharebase performancebase award celgene employee officer nonemployee director additionally term plan provide accelerate vest award change control follow involuntary termination cause outstanding celgene equity award assume bms convert bms equity award acquisition replacement bms award generally term condition include vest celgene award exchange cvrs issue holder vest unexercised money celgene option outstanding acquisition date celgene rsu holder unveste money option outstanding acquisition date award vest prior march eligible receive cvrs celgene rsu holder unveste money option outstanding acquisition date award vest march eligible receive cash value preconverte celgene rsu money option cvr milestone achieve contractual obligation pay contingent value right terminate january fda approve lisocel jcar december plan executive officer employee grant option purchase common stock market price date option grant option generally exercisable ratably year maximum term year plan provide grant stock appreciation right grantee surrender exercisable right receive common stock andor cash measure excess market price common stock award exercise price rsus grant executive officer employee subject restriction continuous employment generally vest occur ratably fouryear period grant date stock unit right receive stock end specify vest andor deferral period stock unit vote right market share unit msus grant executive vest condition continuous employment vest date payout factor grantdate share price give measurement date attainment high payout factor share price measurement date divide share price award date result high percentage payout msus maximum target number msus share price payout factor calculate average closing price grant measurement date trading day immediately precede grant measurement date vest occur ratably year psus grant executive threeyear performance cycle grant target number unit subject adjustment number share issue psus vest determine base achievement specify performance goal base bmss threeyear total shareholder return relative peer group company vest condition continuous employment occur anniversary grant date stockbase compensation expense award ultimately expect vest recognize vest period forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate stockbase compensation expense follow year end december dollar million cost product sell marketing sell administrative research development incomeexpense net total stockbase compensation expense income tax benefita income tax benefit exclude excess tax benefit sharebase compensation award vest exercise million million million total stockbase compensation expense year end december include million million million respectively relate celgene postcombination service period million million million respectively accelerate vest award relate celgene acquisition refer note acquisition divestiture license arrangement information relate celgene acquisition replacement stock option grant celgene option holder acquisition issue consistent vest condition replace award replacement stock option contractual term year initial grant date celgene majority stock option outstanding vest onefourth increment fouryear period certain award cliff vest long short service period celgene option holder elect exercise option time option term share purchase vested date exercise shall subject forfeiture lapse accordance establish vest time period fair value acquisition date attributable postcombination service adjust estimate forfeiture recognize expense straightline basis remain vest period bms estimate fair value replacement option black schole option pricing model follow assumption year end december weight average riskfree interest rate expect volatility weight average expect term year expect dividend yield riskfree interest rate base rate available federal reserve treasury constant maturity remain term equal option expect life time replacement award expect volatility replacement stock option award estimate base blend imply volatility year historical volatility bmss publicly trade stock expect term employee stock option period time option expect outstanding base historical forecast exercise behavior dividend yield estimate base bms annual dividend rate time award replacement follow table summarize stock compensation activity year end december stock optionsa restrict stock unit market share unit performance share unit weighted weight weight weight average number average number average number average number exercise price nonveste grantdate nonveste grantdate nonveste grantdate share million option share award fair value award fair value award fair value balance january grant releasedexercised adjustment actual payout forfeitedcancele balance december expect vest december substantially million unvested stock option weightedaverage exercise price expect vest restrict performance share dollar million stock option stock unit market share unit unit unrecognize compensation cost expect weightedaverage period year compensation cost recognize amount million share datum weightedaverage grant date fair value share stock option replacement award restrict stock unit replacement award restrict stock unit market share unit performance share unit fair value award vest restricted stock unit replacement award restrict stock unit market share unit performance share unit total intrinsic value stock option exercise fair value rsus approximate closing trading price bmss common stock grant date adjust unit eligible accrue dividend fair value msus estimate grant date monte carlo simulation fair value psus estimate monte carlo simulation portion relate relative total shareholder return measure consider probability satisfy payout factor adjust unit eligible accrue dividend relative remain portion psus fair value replacement rsus approximate closing trading price bmss common stock date acquisition adjust unit eligible accrue dividend fair value acquisition date attributable postcombination service adjust estimate forfeiture recognize expense straightline basis remain vest period follow table summarize significant outstanding exercisable option december number option weightedaverage remain weightedaverage aggregate intrinsic value range exercise price million contractual life year exercise price share million outstanding exercisable aggregate intrinsic value precede table represent total pretax intrinsic value base close stock price december note legal proceeding contingency bms certain subsidiary involve lawsuit claim government investigation legal proceeding arise ordinary course business claim proceeding involve type party include government competitor customer supplier service provider licensee employee shareholder matter involve patent infringement antitrust security pricing sale marketing practice environmental commercial contractual right licensing obligation health safety matter consumer fraud employment matter product liability insurance coverage resolution matter develop long period time expectation change result new finding ruling appeal settlement arrangement legal proceeding significant bms believe significant material describe bms believe matter specifically note material adverse effect financial position liquidity bms believe substantial defense matter outcomes bmss legal proceeding contingency inherently unpredictable subject significant uncertainty assurance increase scope pende matter future lawsuit claim government investigation legal proceeding material bmss financial position result operation cash flow particular period furthermore failure enforce bmss patent right likely result substantial decrease respective product revenue generic competition note bms unable assess outcome respective matter able estimate possible loss range loss potentially result matter contingency accrual recognize probable liability incur relate loss reasonably estimate development legal proceeding matter cause change amount previously accrue evaluated reporting period discussion bmss tax contingency note income taxis intellectual property antipd antibody litigation september danafarber cancer institute danafarber file complaint district court district massachusetts seek correct inventorship relate patent direct method treat cancer pdl antibodie specifically danafarber seeking add scientist inventor patent october pfizer allow intervene case allege scientist identify danafarber employ company eventually acquire pfizer relevant period february bms settle lawsuit pfizer bench trial lawsuit danafarber take place february district court issue opinion rule scientist add inventor patent affirm appeal supreme court decline consider case june danafarber file new lawsuit district massachusetts bms seek damage result district court decision add scientist inventor february bms file motion dismiss complaint august court deny motion dismiss rule danafarber claim damage date district court rule danafarber coinventor patentsare preempt federal patent law trial date schedule car october juno sloan kettering institute cancer research ski file complaint patent infringement kite pharma inc kite district court central district california complaint allege kite yescarta product infringe certain claim patent patent concern car cell technology kite file answer counterclaim assert noninfringement invalidity patent december follow eightday trial jury reject kite defense find kite willfully infringe patent award juno ski reasonable royalty consist million upfront payment run royalty kite sale yescarta expiration patent august january kite renew previous motion judgment matter law move new trial juno file motion seek enhanced damage supplemental damage ongoing royalty prejudgment interest march court deny kite motion entirety april court grant juno motion enter final judgment award juno ski approximately billion royalty interest enhance damage run royalty kite sale yescarta december expiration patent august april kite appeal final judgment court appeal federal circuit court hold oral hearing july august federal circuit panel reverse jury verdict district court decision find patent invalid october juno ski file petition federal circuit panel banc rehear federal circuit deny january company intend file petition writ certiorari supreme court eliquis bms receive notice letter twentyfive generic company notify bms file anda contain paragraph certification seek approval generic version eliquis result eliquis patent list fda orange book challenge composition matter patent claim apixaban specifically formulation patent response bms partner pfizer initiate patent infringement action hatchwaxman act generic filer district court district delaware april august patent trademark office grant patent term restoration composition matter patent november restore term eliquis composition matter patent bmss basis project minimum market exclusivity date bms settle number anda filer settlement affect bmss project minimum market exclusivity date eliquis trial remain anda filer take place late august district court issue decision find remain anda filer product infringe eliquis composition matter formulation patent eliquis patent invalid september federal circuit affirm low court decision time remain anda filer seek review federal circuit decision lapse decision final eliquis europe november january sandoz limited sandoz teva pharmaceutical industries ltd teva limited respectively file lawsuit united kingdom seek revocation apixaban composition matter patent relate supplementary protection certificate bms subsequently file counterclaim infringement action trial schedule begin early similar lawsuit file france italy netherlands portugal republic ireland sweden seek revocation composition matter patent relate eliquis additional infringement invalidity action involve eliquis patent file country europe come month onureg november bms receive notice letter accord notify bm file anda contain paragraph certification seek approval generic version onureg challenge fda orange bookliste formulation patent expiring response bms file patent infringement action accord district court district delaware trial date schedule plavix australia sanofi notify august genrx proprietary limited genrx obtain regulatory approval application clopidogrel bisulfate tablets australia genrx subsidiary apotex inc subsequently change apotex genrxapotex august genrxapotex file application federal court australia seek revocation sanofis australian patent case nsd sanofi file counterclaims infringement seek injunction september federal court australia grant sanofis injunction subsidiary bms subsequently add party proceeding february second company spirit pharmaceuticals pty ltd file revocation suit patent case consolidated genrxapotex case august federal court australia hold claim patent cover clopidogrel bisulfate hydrochloride hydrobromide taurocholate salt valid federal court hold process claim pharmaceutical composition claim claim direct clopidogrel pharmaceutically acceptable salt invalid bms sanofi file notice appeal court federal court australia court appeal hold invalidity claim cover clopidogrel pharmaceutically acceptable salt process claim pharmaceutical composition claim genrxapotex appeal hold validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claim september court hold claim patent invalid march high court australia deny request bms sanofi hear appeal court decision case remand federal court proceeding relate damage seek genrx apotex bms genrxapotex settle genrxapotex case dismiss australian government intervene matter seek maximum damage million aud million plus interest split bms sanofi allege loss experience pay high price brand plavix period injunction place bms sanofi dispute australian government entitle damage trial conclude september april federal court issue decision dismiss australian government claim damage australian government appeal federal court decision appeal hearing conclude february pomalyst begin celgene receive notice letter behalf settle previous reporting period mylan pharmaceuticals inc mylan notify celgene file anda contain paragraph certification seek approval market generic version pomalyst response celgene file patent infringement action mylan district court district new jersey assert certain fda orange bookliste patent february celgene file additional patent infringement action district court district new jersey mylan assert certain patent list fda orange book cover polymorphic form pomalidomide march celgene subsequently file additional patent infringement action district court district new jersey mylan assert newlyissue patent list fda orange book cover formulation comprise pomalidomide mylan respond move dismiss improper venue lack jurisdiction november celgene enter confidential settlement agreement mylan settle outstanding claim litigation mylan june celgene receive notice letter reddys laboratories ltd reddys laboratories inc drl notifying celgene file anda contain paragraph certification seek approval market generic version pomalyst response celgene initiate patent infringement action drl district court district new jersey assert certain fda orange bookliste patent march celgene file additional patent infringement action district court district new jersey drl assert newlyissue patent list fda orange book cover formulation comprise pomalidomide consolidate drl case february celgene file additional patent infringement action district court district new jersey drl assert certain patent list fda orange book cover polymorphic form pomalidomide drl file answer counterclaim allege assert patent invalid andor infringe january celgene enter confidential settlement agreement drl settle outstanding claim litigation drl revlimid celgene receive notice letter behalf settle previous reporting period lupin limited lupin hikma pharmaceuticals usa inc hikma alembic pharmaceutical limit alembic global hold alembic pharmaceuticals inc alembic notifying celgene file anda contain paragraph certification seek approval market generic version revlimid response celgene file patent infringement action company district court district new jersey assert certain fda orange bookliste patent certain defendant file answer andor counterclaim allege assert patent invalid andor infringe trial date schedule action december january celgene enter confidential settlement agreement lupin hikma respectively settle outstanding claim litigation lupin hikma sprycel august bm receive notice letter alembic notifying bm file anda contain paragraph certification seek approval generic version sprycel challenge fda orange bookliste monohydrate form patent expire response bms file patent infringement action alembic district court district new jersey october bms receive notice letter eugia pharma specialties ltd eugia notifying bm file anda contain paragraph certification seek approval generic version sprycel challenge fda orange bookliste monohydrate form patent expire response bms file patent infringement action eugia district court district new jersey december january bms enter confidential settlement agreement alembic eugia respectively settle outstanding claim litigation zeposia october actelion pharmaceuticals ltd actelion pharmaceutical inc actelion file complaint patent infringement united states district court district new jersey bms celgene allege infringement patent patent complaint allege sale zeposia infringe certain claim patent actelion seek damage injunctive relief trial date schedule pricing sale promotional practice litigation plavix state attorney general lawsuit bms certain sanofi entity defendant consumer protection action bring attorney general hawaii new mexico relate label sale andor promotion plavix trial hawaii matter occur february court issue decision sanofi bms impose penalty total million million attribute bms sanofi bms disagree decision appeal bms remain confident merit case likelihood success appeal bms believe establish reserve warrant matter trial new mexico matter set court april trial docket product liability litigation bms party product liability lawsuit plaintiff case seek damage relief ground allege personal injury economic loss previously disclose addition lawsuit bms face unfiled claim involve product abilify bms otsuka codefendant product liability litigation relate abilify plaintiff allege abilify cause engage compulsive gambling impulse control disorder case file state federal court additional case pende canada judicial panel multidistrict litigation consolidated federal court case pretrial purpose district court northern district florida february bms otsuka enter master settlement agreement establish propose settlement program resolve abilify compulsivity claim file january mdl state court include california new jersey date approximately case comprise approximately plaintiff dismiss base participation settlement program failure comply settlement relate court order case remain mdl case remain pende state court new jersey massachusetts case pende canada class action seven individual injury claim case active class action quebec ontario class action certify proceed separately subject pende appeal ontario class certification decision byetta amylin subsidiary bms lilly codefendant product liability litigation relate byetta litigation involve lawsuit behalf plaintiff include injury plaintiff claim spouse andor beneficiary court majority case bring individual allege personal injury sustain byetta primarily pancreatic cancer case claim alleged wrongful death majority case pende federal court san diego mdl coordinated proceeding california superior court los angeles jccp april defendant file motion summary judgment base federal preemption motion summary judgment base absence general causation evidence mdl jccp motion grant march april respectively order result dismissal claim allege injury pancreatic cancer mdl jccp plaintiff initially appeal mdl order subsequently file motion dismiss appeal amylin lilly motion dismiss grant october make mdl decision final amylin lilly plaintiff seek appeal jccp december plaintiffs counsel submit dismissal prejudice exchange waiver cost behalf nearly plaintiff jccp include injury plaintiff spousebeneficiary plaintiff allege claim amylin lilly additional dismissal anticipate bms sell byetta astrazeneca february bmss global diabetes business divestiture additional liability amylin respect byetta expect share astrazeneca onglyza bms astrazeneca codefendant product liability litigation relate onglyza plaintiff assert claim include claim wrongful death result heart failure cardiovascular injury allege cause use onglyza june claim pende state federal court behalf approximately individual allege ingest product suffer injury february judicial panel multidistrict litigation order federal case transfer mdl district court eastern district kentucky significant majority claim pende mdl pende coordinated proceed california superior court san francisco jccp august mdl jccp court jointly hear evidence party motion exclude general causation expert september jccp court grant defendant motion exclude plaintiff general causation expert largely deny plaintiff motion exclude defendant general causation expert january mdl court likewise grant defendant motion exclude plaintiff expert deny entirely plaintiff motion bmss global diabete business divestiture bms sell onglyza astrazeneca february potential liability respect onglyza expect share astrazeneca security litigation bms security class action february separate putative class action complaint file district northern district california district court southern district new york bms bmss chief executive officer giovanni caforio bmss chief financial officer time charle bancroft certain current executive bms case california voluntarily dismiss remain complaint allege violation security law bmss disclosure relate checkmate clinical trial lung cancer september court grant bmss motion dismiss allow plaintiff leave file amend complaint october plaintiff file amend complaint september court grant bmss motion dismiss amend complaint prejudice plaintiff appeal court decision october october oral argument appeal hold court appeal second circuit celgene security litigation begin march putative class action file celgene certain officer district court district new jersey celgene security class action complaint allege defendant violate federal security law make misstatement andor omission concern trial ge celgene outlook project sale otezla new drug application zeposia court consolidate action appoint lead plaintiff lead counsel coliaison counsel putative class february defendant file motion dismiss plaintiff amend complaint december court deny motion dismiss grant motion dismiss include claim arise allege misstatement ge court give plaintiff leave replead dismiss claim elect dismiss claim dismiss prejudice november court grant class certification respect remain claim december defendant seek leave appeal court class certification decision deny prejudice march april certain schwab management investment company behalf certain schwab fund file individual action district court district new jersey assert largely allegation celgene security class action remain defendant action schwab action july defendant file motion dismiss plaintiff complaint march court grant deny defendant motion dismiss consistent decision celgene security class action california public employees retirement system april calper action dfa investment dimensions group inc behalf certain fund american century mutual fund inc behalf certain fund july respectively dfa action american century action gic private limited september gic action file separate individual action district court district new jersey assert largely allegation celgene security class action schwab individual action remain defendant action october action consolidate pretrial proceeding schwab action court consolidate future direct action raise common question law fact schwab action trial date schedule celgene security litigation contingent value right litigation june action file bms district court southern district new york assert claim allege breach contingent value right agreement cvr agreement enter connection closing bmss acquisition celgene corporation november successor trustee cvr agreement allege bms breach cvr agreement allegedly fail use diligent effort obtain fda approval lisocel breyanzi contractual milestone date avoid billion potential obligation holder contingent value right govern cvr agreement allegedly fail permit inspection record response request successor trustee successor trustee seek damage determine trial relief include interest attorney fee bms dispute successor trustee allegation file motion dismiss july discovery stay decision motion dismiss october allege celgene stockholder file complaint district court southern district new york assert claim behalf putative class celgene stockholder violation section securities exchange act complaint allege joint proxy statement date february seek stockholder approval propose merger transaction celgene bms materially false misleading fail disclose allegedly bms intention time obtain fda approval lisocel contractual milestone date condition payment holder cvrs issue bms connection celgene transaction complaint assert claim bms member board director time joint proxy statement different allege celgene stockholder purchaser cvrs separately file complaint december district court southern district new york assert claim behalf separate putative class celgene stockholder purchaser cvrs violation section security act section securities exchange act complaint allege registration statement file connection propose merger transaction celgene bms materially false misleading fail disclose allegedly bms intention time obtain fda approval lisocel contractual milestone date complaint allege joint proxy statement date february seek stockholder approval propose merger transaction celgene bm certain statement bmss periodic sec filing certain press release earning call presentation materially false misleading substantially reason complaint assert claim bms member board director time registration statement joint proxy statement certain bms officer sign bmss periodic sec filing statement press release earning call presentation action consolidated action previously file october november allege purchaser cvrs file complaint supreme court state new york new york county assert claim behalf putative class cvr acquirer violation section securities act complaint allege registration statement file connection propose merger transaction celgene bms materially false misleading fail disclose allegedly bms intention time obtain fda approval lisocel contractual milestone date complaint assert claim bms member board director time joint proxy statement certain bms officer sign registration statement bms remove action district court southern district new york plaintiff file motion remand action state court november allege celgene stockholder file complaint superior court new jersey union county assert claim behalf separate putative class acquirer cvr acquirer bms common stock violation section securities act complaint allege registration statement file connection propose merger transaction celgene bms materially false misleading fail disclose allegedly bms intention time obtain fda approval lisocel contractual milestone date complaint assert claim bms member board director time joint proxy statement certain bms officer sign registration statement celgene chairman chief executive officer bms remove action district court district new jersey file motion transfer action district court southern district new york plaintiff file motion remand action state court trial date schedule cvr litigation litigation hiv medication antitrust litigation bms manufacturer hiv medication defendant relate lawsuit pende northern district california lawsuit allege defendant agreement develop sell fixeddose combination product treatment hiv include atripla evotaz violate antitrust law currently pende action assert behalf indirect purchaser initiate northern district california southern district florida florida matter transfer northern district california july court grant defendant motion dismiss include dismiss prejudice plaintiff claim overarch conspiracy plaintiff theory base alleged payment royalty patent expiration claim remain september october purport class action file assert similar claim behalf direct purchaser march court dismiss direct purchaser case limit claim remain direct purchaser case arise later court give plaintiff leave amend complaint plaintiff file amend complaint march september additional nonclass action direct purchaser complaint file number retail pharmacy grocery store chain bms manufacturer hiv medication complaint allegation similar raise federal court case new mexico state court case describe october bms enter settlement agreement putative class indirect purchaser october bms reach agreement principle settle claim file putative class direct purchaser settlement subject court approval january bms reach agreement settle case file retail pharmacy grocery store chain february bms manufacturer hiv medication sue state court new mexico attorney general state new mexico case allege defendant agreement develop sell fixeddose combination product treatment hiv include atripla agreement settle certain patent litigation violate antitrust law state new mexico trial date schedule december additional nonclassaction indirect purchaser case file northern district california additional nonclassaction indirect purchaser case file california state court naming bms manufacturer defendant complaint allegation similar federal court case trial date schedule case nimbus august complaint file nimbus therapeutic llc nimbus lakshmi inc collectively nimbus district court southern district new york celgene bms complaint relate warrant agreement tyrosine kinase tyk product celgene nimbus lakshmi inc nimbuss complaint allege breach contract violation federal antitrust law stem bmss acquisition celgene action take celgene exercise assign right agreement addition damage nimbus seek declaratory judgment day file complaint nimbus send celgene bms letter purport terminate relevant warrant agreement theory set forth complaint bms dispute nimbuss allegation validity attempt terminate warrant agreement september celgene bms file counterclaim nimbus allege breach contract tortious interference claim base nimbuss effort prevent celgene act right warrant agreement similarly seek damage declaratory judgment october court grant celgene bmss motion preliminarily enjoin nimbus selling transferring encumber dispose tyk product final judgment merit party finalize settlement action claim voluntarily dismiss prejudice january thalomid revlimid litigation begin november certain putative class action lawsuit file celgene district court district new jersey allege celgene violate antitrust consumer protection unfair competition law allegedly secure exclusive supply contract allege purpose prevent generic manufacturer secure supply thalidomide active pharmaceutical ingredient allegedly refuse sell sample thalomid revlimid brand drug generic manufacturer allege purpose bioequivalence test necessary anda submit fda approval market generic version product allegedly bring unjustified patent infringement lawsuit order allegedly delay approval propose generic version thalomid revlimid andor allegedly enter settlement patent infringement lawsuit certain generic manufacturer allegedly anticompetitive effect plaintiff behalf putative class thirdparty payer seek injunctive relief damage lawsuit consolidate master action purpose march celgene reach settlement class plaintiff october court enter final order approve settlement dismiss matter settlement resolve claim certain entity opt settlement humana inc humana file lawsuit celgene pike county circuit court commonwealth kentucky humanas complaint allege celgene engage unlawful offlabel marketing connection sale thalomid revlimid assert claim celgene fraud breach contract negligent misrepresentation unjust enrichment violation new jersey racketeer influence corrupt organization act complaint seek thing treble punitive damage injunctive relief attorney fee cost trial schedule january march humana file lawsuit celgene district court district new jersey humanas complaint make largely claim allegation class action litigation complaint purport assert claim behalf humana subsidiary capacity include direct purchaser indirect purchaser seek thing treble punitive damage injunctive relief attorney fee cost celgene file motion dismiss humanas complaint court stay discovery pende adjudication motion trial date schedule march united healthcare services inc uhs affiliate opt settlement thalomid revlimid antitrust class action litigation file lawsuit celgene district court district minnesota uhss complaint make largely claim allegation class action litigation addition certain claim donation direct copay assistance complaint purport assert claim behalf uhs subsidiary capacity include direct purchaser indirect purchaser seek thing treble punitive damage injunctive relief attorney fee cost december celgene motion transfer action district new jersey grant case pende court january celgene file motion dismiss uhss complaint court administratively terminate june pende decision celgene pende motion dismiss humanas complaint trial date schedule celgene file suit humana pharmacy inc hpi humana subsidiary delaware superior court celgene complaint allege hpi breach contractual obligation celgene assign claims humana humana asserting complaint seek damage hpis breach declaratory judgment trial schedule march july blue cross blue shield association bcbsa sue celgene bms behalf federal employee program district court district columbia bcbsas complaint make largely claim allegation class action litigation april party joint motion transfer action district new jersey grant case pende court trial date schedule august bcbsm inc health care service corporation hcsc blue cross blue shield florida inc molina healthcare inc molina sue celgene bms minnesota state court complaint make largely claim allegation class action litigation add allegation behalf hcsc allege offlabel market thalomid revlimid september celgene bms remove action district court district minnesota march court deny plaintiff motion remand action state court dismiss molina lack personal jurisdiction grant defendant motion transfer action district new jersey case pende district new jersey trial date schedule january cigna corporation cigna sue celgene bms district court eastern district pennsylvania cignas complaint make largely claim allegation class action litigation cigna complaint purport assert claim behalf cigna subsidiary capacity include direct purchaser indirect purchaser party joint motion transfer action district new jersey grant case pende court trial date schedule molina sue celgene bms san francisco superior court molinas complaint make largely claim allegation class action litigation july celgene bms remove action district court northern district california january court grant molinas motion remand san francisco superior court trial date schedule december group plaintiffsmsp recovery claim series llc mspa claims llc maomso recovery llc series pmpi segregate series maomso recovery llc msp recovery claim series llc msp recovery claim prov series llc msp recovery claim caid series llc mspsue celgene bms district court district new jersey msps complaint make largely claim allegation class action litigation msp purport pursue assignment certain name unnamed entity allegedly purchase provide reimbursement thalomid andor revlimid purport bring direct indirect purchaser claim trial date schedule government investigation like pharmaceutical company bms certain subsidiary subject extensive regulation national state local authority country bms operate result bms time time subject governmental regulatory inquiry investigation threaten legal action proceeding possible criminal charge substantial fine andor civil penalty result government regulatory investigation environmental proceeding previously report bms party environmental proceeding matter responsible state federal foreign law include cercla certain cost investigate andor remediate contamination result past industrial activity bmss current site waste disposal reprocess facility operate party cercla matter respect cercla matter bms responsible state federal international law bm typically estimate potential cost base information obtain environmental protection agency counterpart state foreign agency andor study prepare independent consultant include total estimate cost site expect costshare potentially responsible party bms accrue liability probable reasonably estimable bms estimate share future cost site million december represent sum good estimate good estimate reasonably estimate minimal probable range cost take account potential recovery party include estimate cost additional probable loss associate previously disclose north brunswick township high school remediation site report independent register public accounting firm shareholder board director bristolmyers squibb company opinion financial statement audit accompany consolidated balance sheet bristolmyer squibb company company december relate consolidated statement earning comprehensive incomeloss cash flow year period end december relate note collectively refer financial statement opinion financial statement present fairly material respect financial position company december result operation cash flow year period end december conformity accounting principle generally accept united states america audit accordance standard public company accounting oversight board united states pcaob company internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion company internal control financial reporting basis opinion financial statement responsibility company management responsibility express opinion company financial statement base audits public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audit obtain reasonable assurance financial statement free material misstatement error fraud audits include perform procedure assess risk material misstatement financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation financial statement believe audits provide reasonable basis opinion critical audit matter critical audit matter communicate matter arise currentperiod audit financial statement communicate require communicate audit committee relate account disclosure material financial statement involve especially challenge subjective complex judgment communication critical audit matter alter way opinion financial statement take communicate critical audit matter provide separate opinion critical audit matter account disclosure relate grosstonet rebate accrual medicaid medicare manage healthcare refer note revenue financial statement critical audit matter description fully disclose note financial statement company reduce gross product sale list price time revenue recognize expect chargeback discount rebate sale allowance product return refer grosstonet gtn adjustment reduction attribute commercial arrangement manage healthcare organization government program mandate reduction list price chargeback cash discount reflect reduction receivables settle issuance credit customer rebate discount adjustment reflect liability settle cash payment certain gtn liability relate medicaid medicare manage healthcare organization rebate program gtn rebate accrual involve use significant assumption judgment calculation significant assumption judgment include consideration legal interpretation applicable law regulation historical claim experience payer channel mix current contract price unbilled claim claim submission time lag inventory level distribution channel give complexity involve determine significant assumption calculate certain gtn rebate accrual auditing estimate involve especially subjective judgment critical audit matter address audit audit procedure relate gtn rebate accrual include follow evaluate appropriateness consistency company method assumption calculate gtn rebate accrual test effectiveness internal control review company estimation model include underlying assumption key input company process calculate gtn rebate accrual test mathematical accuracy gtn rebate accrual test significant assumption key input calculate gtn rebate accrual evaluate company ability estimate gtn rebate accrual accurately compare actual amount incur gtn rebate accrual historical estimate test overall reasonableness gtn rebate accrual record period end develop expectation comparison actual record balance involve audit professional industry quantitative analytic experience assist perform auditing procedure taxis unrecognize tax benefit liabilitie transfer pricing refer note income taxis financial statement critical audit matter description fully disclose note financial statement company recognize certain income tax benefit associate transaction operate company relate foreign affiliate income tax benefit estimate base transfer pricing agreement thirdparty transfer pricing study company judgment morelikelythannot benefit realize tax benefit ultimately realize company determine judgment accrue unrecognized tax benefit liability amount recognize unrecognized tax benefit liability relate transfer pricing significantly affect subsequent period factor change tax law identification additional relevant fact change company judgment measurement tax benefit ultimate settlement tax authority give complexity associate significant assumption judgment calculate unrecognized tax benefit liability relate transfer pricing auditing estimate involve especially subjective judgment critical audit matter address audit audit procedure relate unrecognized tax benefit liability relate transfer pricing include follow evaluate appropriateness consistency company method assumption identification recognition measurement disclosure unrecognized tax benefit liability test effectiveness internal control review underlie assumption key input company process calculate unrecognized tax benefit liability obtain understand company relate party transaction transfer pricing policy test mathematical accuracy unrecognized tax benefit liability test completeness unrecognized tax benefit liability test reasonableness underlie tax position amount accrue selection unrecognized tax benefit liability review company evaluation relevant fact tax law associate tax position test significant assumption input calculate unrecognized tax benefit liability reference party datum information produce entity understand transfer pricing principle tax law inquire management evaluate company appropriately consider new information significantly change recognition measurement disclosure unrecognized tax benefit liability involve income tax specialist audit professional industry experience assist perform auditing procedure deloitte touche llp parsippany new jersey february serve company auditor item change disagreement accountant account financial disclosure item control procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure control procedure define exchange act rule end period cover base evaluation management conclude december disclosure control procedure effective management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting define exchange act rule supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include report form issue report effectiveness company internal control financial reporting december include change internal control financial reporting change companys internal control financial reporting quarter end december materially affect reasonably likely materially affect company internal control financial reporting item information item disclosure foreign jurisdiction prevent inspection applicable report independent register public accounting firm shareholder board director bristolmyers squibb company opinion internal control financial reporting audit internal control financial reporting bristolmyer squibb company company december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue coso audit accordance standard public company accounting oversight board united states pcaob consolidate financial statement year end december company report date february express unqualified opinion consolidated financial statement basis opinion company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audit accordance standard pcaob standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp parsippany new jersey february iii item director executive officer corporate governance reference proxy statement respect director incorporate reference hereof response information require item information require item respect executive officer include reliance general instruction instruction item regulation incorporate reference hereof response information require item item executive compensation reference proxy statement respect executive compensation incorporate reference hereof response information require item item security ownership certain beneficial owner management relate stockholder matter reference proxy statement respect security ownership certain beneficial owner management incorporate reference hereof response information require item item certain relationship relate transaction reference proxy statement respect certain relationship relate transaction incorporate reference hereof response information require item item principal accountant fee service reference proxy statement respect aggregate fee bill principal accountant deloitte touche llp pcaob incorporate reference hereof response information require item item